{
    "questions": [
        {
            "id": "5a6f960fb750ff445500005c",
            "body": "Centor criteria are used for which disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23613571",
                "http://www.ncbi.nlm.nih.gov/pubmed/15231926",
                "http://www.ncbi.nlm.nih.gov/pubmed/22432746"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571",
                    "text": "CONCLUSIONS Our results confirm the ineffectiveness of Centor criteria as a predicting factor for finding GABHS in a throat swab culture in children.",
                    "offsetInBeginSection": 1763,
                    "offsetInEndSection": 1912,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571",
                    "text": "INTRODUCTION Centor criteria (fever >38.5\u00b0C, swollen, tender anterior cervical lymph nodes, tonsillar exudate and absence of cough) are an algorithm to assess the probability of group A \u03b2 haemolytic Streptococcus (GABHS) as the origin of sore throat, developed for adults.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 274,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15231926",
                    "text": "BACKGROUND Rapid antigen detection testing (RADT) is often performed for diagnosis of group A beta-hemolytic streptococcal (GABHS) pharyngitis among children.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 158,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22432746",
                    "text": "0-2 Centor criteria to relieve symptoms.",
                    "offsetInBeginSection": 1068,
                    "offsetInEndSection": 1108,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22432746",
                    "text": "In diagnosis, Centor clinical scoring system or rapid antigen test can be helpful in targeting antibiotic use.",
                    "offsetInBeginSection": 200,
                    "offsetInEndSection": 310,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22432746",
                    "text": "In patients with high likelihood of streptococcal infections (e.g.",
                    "offsetInBeginSection": 436,
                    "offsetInEndSection": 502,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15231926",
                    "text": "However, even among pediatric patients with > or =3 Centor criteria for GABHS pharyngitis, the sensitivity of RADT is still too low to support the use of RADT without culture confirmation of negative results.",
                    "offsetInBeginSection": 2052,
                    "offsetInEndSection": 2260,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22432746",
                    "text": "3-4 Centor criteria) physicians can consider the use of rapid antigen test (RAT).",
                    "offsetInBeginSection": 503,
                    "offsetInEndSection": 584,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15231926",
                    "text": "Spectrum bias was present, inasmuch as RADT sensitivity increased with Centor scores, ie, 47% sensitivity among children with 0 Centor criteria, 65% among those with 1 criterion, 82% among those with 2 criteria, and 90% among those with 3 or 4 criteria.",
                    "offsetInBeginSection": 1676,
                    "offsetInEndSection": 1929,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15231926",
                    "text": "Patients were stratified according to the number of clinical features present by using modified Centor criteria, ie, history of fever, absence of cough, presence of pharyngeal exudates, and cervical lymphadenopathy.",
                    "offsetInBeginSection": 800,
                    "offsetInEndSection": 1015,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a86ebf2faa1ab7d2e000038",
            "body": "Which are the main transcriptional activators of circadian oscillations?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11517254",
                "http://www.ncbi.nlm.nih.gov/pubmed/19917250",
                "http://www.ncbi.nlm.nih.gov/pubmed/20967239",
                "http://www.ncbi.nlm.nih.gov/pubmed/18177499",
                "http://www.ncbi.nlm.nih.gov/pubmed/22217096",
                "http://www.ncbi.nlm.nih.gov/pubmed/9115195"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19917250",
                    "text": "Circadian rhythms in mammals are generated by a transcriptional negative feedback loop that is driven primarily by oscillations of PER and CRY, which inhibit their own transcriptional activators, CLOCK and BMAL1.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 212,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254",
                    "text": "In the model of the Neurospora oscillator, FRQ suppresses frq transcription by binding to a complex of the transcriptional activators WC-1 and WC-2, thus yielding negative feedback.",
                    "offsetInBeginSection": 341,
                    "offsetInEndSection": 522,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18177499",
                    "text": "Two basic helix-loop-helix (bHLH) PAS (for Period-Arnt-Sim) domain-containing transcriptional activators, CLOCK and BMAL1, are known to regulate gene expression by interacting with a promoter element termed the E-box (CACGTG).",
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 335,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9115195",
                    "text": "The white collar-1 and white collar-2 genes, both global regulators of photoresponses in Neurospora, encode DNA binding proteins that contain PAS domains and are believed to act as transcriptional activators.",
                    "offsetInBeginSection": 487,
                    "offsetInEndSection": 695,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20967239",
                    "text": "Bmal1 is an essential transcriptional activator within the mammalian circadian clock.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22217096",
                    "text": "Transcriptional oscillations of four clock genes, period, timeless, Par domain protein 1\u03f5, and vrille, were significantly reduced in heads, but not in bodies, of aging flies.",
                    "offsetInBeginSection": 784,
                    "offsetInEndSection": 959,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18177499",
                    "text": "BACKGROUND The circadian expression of the mammalian clock genes is based on transcriptional feedback loops.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20967239",
                    "text": "The emergence of stochastic circadian oscillations from the SCN network in the absence of cell-autonomous circadian oscillatory function highlights a previously unrecognized level of circadian organization.",
                    "offsetInBeginSection": 1010,
                    "offsetInEndSection": 1216,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20967239",
                    "text": "Propagation of this feed-forward signal between SCN neurons then promotes quasi-circadian oscillations that arise as an emergent property of the SCN network.",
                    "offsetInBeginSection": 636,
                    "offsetInEndSection": 793,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9115195",
                    "text": "Data shown here suggest that wc-1 is a clock-associated gene and wc-2 is a clock component; both play essential roles in the assembly or operation of the Neurospora circadian oscillator.",
                    "offsetInBeginSection": 696,
                    "offsetInEndSection": 882,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67c8c4b750ff4455000013",
            "body": "What is the link between TADs and GRBs?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28874668",
                "http://www.ncbi.nlm.nih.gov/pubmed/26150425",
                "http://www.ncbi.nlm.nih.gov/pubmed/28060840",
                "http://www.ncbi.nlm.nih.gov/pubmed/24727717",
                "http://www.ncbi.nlm.nih.gov/pubmed/26518482",
                "http://www.ncbi.nlm.nih.gov/pubmed/27167421",
                "http://www.ncbi.nlm.nih.gov/pubmed/27919068",
                "http://www.ncbi.nlm.nih.gov/pubmed/1448082",
                "http://www.ncbi.nlm.nih.gov/pubmed/16943830"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26518482",
                    "text": "Contrary to previous studies, we find that regions between TADs (i.e., the inter-TADs and TAD boundaries) in Drosophila are only weakly enriched with the insulator protein dCTCF, while another insulator protein Su(Hw) is preferentially present within TADs.",
                    "offsetInBeginSection": 625,
                    "offsetInEndSection": 881,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28060840",
                    "text": "This approach revealed that: 1) TADs and LADs correspond to isochores, i.e., isochores are the genomic units that underlie chromatin domains; 2) the conservation of TADs and LADs in mammalian genomes is explained by the evolutionary conservation of isochores; 3) chromatin domains corresponding to GC-poor isochores (e.g., LADs) show not only self-interactions but also intrachromosomal interactions with other domains also corresponding to GC-poor isochores even if located far away; in contrast, chromatin domains corresponding to GC-rich isochores (e.g., TADs) show more localized chromosomal interactions, many of which are inter-chromosomal.",
                    "offsetInBeginSection": 379,
                    "offsetInEndSection": 1025,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27919068",
                    "text": "C-walks that couple 2-4 TADs indicate stochastic associations between transcriptionally active, early replicating loci.",
                    "offsetInBeginSection": 874,
                    "offsetInEndSection": 993,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1448082",
                    "text": "Repression depends on the presence of the transactivation domains (TADs), suggesting that a limiting factor interacting with the TADs is essential to link Jun and the components of the transcriptional machinery.",
                    "offsetInBeginSection": 388,
                    "offsetInEndSection": 599,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26518482",
                    "text": "Collectively, our results suggest that TADs are condensed chromatin domains depleted in active chromatin marks, separated by regions of active chromatin.",
                    "offsetInBeginSection": 1275,
                    "offsetInEndSection": 1428,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874668",
                    "text": "The close correspondence between extreme noncoding conservation and TADs suggests that these TADs are ancient, revealing a regulatory architecture conserved over hundreds of millions of years.Metazoan genomes contain many clusters of conserved noncoding elements.",
                    "offsetInBeginSection": 902,
                    "offsetInEndSection": 1165,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16943830",
                    "text": "Although the link between long gamma-ray bursts (GRBs) and supernovae has been established, hitherto there have been no observations of the beginning of a supernova explosion and its intimate link to a GRB.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26518482",
                    "text": "However, Drosophila inter-TADs harbor active chromatin and constitutively transcribed (housekeeping) genes.",
                    "offsetInBeginSection": 882,
                    "offsetInEndSection": 989,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874668",
                    "text": "Clusters of CNEs define the span of regulatory inputs for many important developmental regulators and have been described previously as genomic regulatory blocks (GRBs).",
                    "offsetInBeginSection": 235,
                    "offsetInEndSection": 404,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26518482",
                    "text": "In particular, Hi-C revealed that chromosomes of animals are organized into topologically associating domains (TADs), evolutionary conserved compact chromatin domains that influence gene expression.",
                    "offsetInBeginSection": 162,
                    "offsetInEndSection": 360,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7600b983b0d9ea6600000c",
            "body": "Which clinical trials for psoriasis involved tofacitinib? (November 2017)",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28829236",
                "http://www.ncbi.nlm.nih.gov/pubmed/27267933",
                "http://www.ncbi.nlm.nih.gov/pubmed/26267722",
                "http://www.ncbi.nlm.nih.gov/pubmed/29134822",
                "http://www.ncbi.nlm.nih.gov/pubmed/28441904",
                "http://www.ncbi.nlm.nih.gov/pubmed/27692733",
                "http://www.ncbi.nlm.nih.gov/pubmed/24883332",
                "http://www.ncbi.nlm.nih.gov/pubmed/26889727",
                "http://www.ncbi.nlm.nih.gov/pubmed/27716172",
                "http://www.ncbi.nlm.nih.gov/pubmed/26889081"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26889727",
                    "text": "EVIDENCE SYNTHESIS Only randomized controlled trial results or trial results for registration purposes of etanercept, adalimumab, infliximab, ustekinumab, secukinumab, brodalumab, ixekizumab, guselkumab, tofacitinib, and apremilast are included.",
                    "offsetInBeginSection": 569,
                    "offsetInEndSection": 814,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24883332",
                    "text": "In phase III trials for rheumatoid arthritis, tofacitinib was efficacious in patients with inadequate responses to tumor necrosis factor inhibitors, methotrexate monotherapy, or disease-modifying antirheumatic drugs.",
                    "offsetInBeginSection": 684,
                    "offsetInEndSection": 900,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27692733",
                    "text": "BACKGROUND Tofacitinib is an oral Janus kinase inhibitor that improves clinical measures of psoriasis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24883332",
                    "text": "Tofacitinib, an oral or topically administered JAK1 and JAK3 inhibitor, and ruxolitinib, a topical JAK1 and JAK2 inhibitor, have been most extensively studied in psoriasis, and both improved clinical symptoms of psoriasis.",
                    "offsetInBeginSection": 388,
                    "offsetInEndSection": 610,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26889081",
                    "text": "Tofacitinib is an orally available compound belonging to a novel category of nonbiologic drugs, the \"JAK inhibitors\", which target JAKs.",
                    "offsetInBeginSection": 739,
                    "offsetInEndSection": 875,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722",
                    "text": "METHODS We reviewed phase III randomized, placebo-controlled clinical trial results for apremilast and tofacitinib for efficacy and safety in psoriasis.",
                    "offsetInBeginSection": 441,
                    "offsetInEndSection": 593,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27716172",
                    "text": "Tofacitinib is a small molecule Janus kinase inhibitor investigated for the topical treatment of psoriasis.",
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236",
                    "text": "Expert opinion: Although tofacitinib plus MTX is statistically more clinically effective, tofacitinib monotherapy is effective in many patients with RA.",
                    "offsetInBeginSection": 1043,
                    "offsetInEndSection": 1195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26267722",
                    "text": "CONCLUSION Both new oral medications, apremilast and tofacitinib, appear to be effective in treating psoriasis",
                    "offsetInBeginSection": 1042,
                    "offsetInEndSection": 1152,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236",
                    "text": "Tofacitinib is a pan JAK inhibitor with specificity for JAK3 over JAK1 over JAK2, which is approved in many countries for the treatment of rheumatoid arthritis (RA), including the United States and the European Union, either as monotherapy or in combination with conventional synthetic disease modifying anti-arthritis drugs (csDMARDs).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 336,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a551a8fb750ff4455000002",
            "body": "What is a potential side effect for Tymlos?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17650055",
                "http://www.ncbi.nlm.nih.gov/pubmed/16370982",
                "http://www.ncbi.nlm.nih.gov/pubmed/27924737",
                "http://www.ncbi.nlm.nih.gov/pubmed/21385029",
                "http://www.ncbi.nlm.nih.gov/pubmed/25119580",
                "http://www.ncbi.nlm.nih.gov/pubmed/6131489",
                "http://www.ncbi.nlm.nih.gov/pubmed/2183167",
                "http://www.ncbi.nlm.nih.gov/pubmed/27836000",
                "http://www.ncbi.nlm.nih.gov/pubmed/24261314",
                "http://www.ncbi.nlm.nih.gov/pubmed/7021123"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27836000",
                    "text": "This case highlights the potential side effect of lipodystrophy secondary to leuprolide acetate injections.",
                    "offsetInBeginSection": 481,
                    "offsetInEndSection": 588,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2183167",
                    "text": "A potential side effect of paracetamol is its hepatotoxicity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 61,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924737",
                    "text": "However, there is increasing awareness of potential side effects associated with the intra- and peri-articular use of both glucocorticoids and topical analgesics.- In this review we will discuss the effects and side effects of intra-articular glucocorticoid injections in the context of non-rheumatic knee and shoulder conditions.",
                    "offsetInBeginSection": 65,
                    "offsetInEndSection": 395,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17650055",
                    "text": "The authors review changing from one antipsychotic to another (\"switching\") as a potential treatment strategy for reducing the overall side effect burden of antipsychotic therapy.",
                    "offsetInBeginSection": 429,
                    "offsetInEndSection": 608,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27836000",
                    "text": "The implication of this potential side effect poses difficult management strategies for such patients, and second-line alternatives such as chemotherapy may need to be considered.",
                    "offsetInBeginSection": 1778,
                    "offsetInEndSection": 1957,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17650055",
                    "text": "Because of the differences in side effect profiles between the newer and older antipsychotic medications, and distinct differences among the newer agents themselves, the spectrum of side effects associated with antipsychotic therapy has changed tremendously.",
                    "offsetInBeginSection": 170,
                    "offsetInEndSection": 428,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27836000",
                    "text": "Leuprolide acetate in commonly used as one of the gonadotrophin-releasing hormone agonists and thus we should be mindful of the potential effect of producing lipodystrophy, especially in patients with cirrhosis, and to watch for any signs and symptoms as appropriate.",
                    "offsetInBeginSection": 1510,
                    "offsetInEndSection": 1777,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27924737",
                    "text": "In view of the potential (harmful) side effects, it is advisable to use the lowest possible effective dose.",
                    "offsetInBeginSection": 838,
                    "offsetInEndSection": 945,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24261314",
                    "text": "We hope this case may encourage clinicians to inquire about headache as a potential side effect of indomethacin.",
                    "offsetInBeginSection": 1150,
                    "offsetInEndSection": 1262,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21385029",
                    "text": "Our method thus represents a promising step toward shortcutting the process and reducing the cost of side effect elucidation.",
                    "offsetInBeginSection": 1175,
                    "offsetInEndSection": 1300,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a87f44061bb38fb2400000f",
            "body": "Which disorder has been approved for treatment with Alk inhibitors?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23201355",
                "http://www.ncbi.nlm.nih.gov/pubmed/28182271",
                "http://www.ncbi.nlm.nih.gov/pubmed/28979145",
                "http://www.ncbi.nlm.nih.gov/pubmed/26294238",
                "http://www.ncbi.nlm.nih.gov/pubmed/24166094",
                "http://www.ncbi.nlm.nih.gov/pubmed/27468827",
                "http://www.ncbi.nlm.nih.gov/pubmed/26992917",
                "http://www.ncbi.nlm.nih.gov/pubmed/28536155",
                "http://www.ncbi.nlm.nih.gov/pubmed/28065466",
                "http://www.ncbi.nlm.nih.gov/pubmed/27122312"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28065466",
                    "text": "BACKGROUND Second-generation anaplastic lymphoma kinase (ALK) inhibitors, such as alectinib and ceritinib, have recently been approved for treatment of ALK-rearranged non-small-cell lung cancer (NSCLC).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26294238",
                    "text": "Crizotinib is an oral tyrosine kinase inhibitor approved in 2011 as a first-line therapy for patients with metastatic ALK mutation-driven NSCLC.",
                    "offsetInBeginSection": 440,
                    "offsetInEndSection": 584,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28979145",
                    "text": "Alectinib, a second-generation ALK inhibitor, has recently been approved for ALK-rearranged NSCLC after patients progressed on crizotinib.",
                    "offsetInBeginSection": 527,
                    "offsetInEndSection": 665,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24166094",
                    "text": "Most recently, pediatric phase I testing has been completed for the first approved ALK inhibitor, Crizotinib, showing very encouraging antitumoral results in neuroblastoma patients.",
                    "offsetInBeginSection": 742,
                    "offsetInEndSection": 923,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26294238",
                    "text": "CONCLUSION The tyrosine kinase inhibitors crizotinib and ceritinib provide an effective treatment approach for patients with ALK-mutated NSCLC.",
                    "offsetInBeginSection": 1442,
                    "offsetInEndSection": 1585,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26992917",
                    "text": "Crizotinib is the first anaplastic lymphoma kinase (ALK) inhibitor to have been approved for the treatment of non-small cell lung cancer (NSCLC) harboring an ALK fusion gene, but it has been found that, in the clinic, patients develop resistance to it.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 252,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26992917",
                    "text": "Alectinib and ceritinib are second-generation ALK inhibitors which show remarkable clinical responses in both crizotinib-naive and crizotinib-resistant NSCLC patients harboring an ALK fusion gene.",
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 449,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468827",
                    "text": "Crizotinib is approved for the treatment of advanced ALK-positive non-small cell lung cancer (NSCLC).",
                    "offsetInBeginSection": 283,
                    "offsetInEndSection": 384,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28182271",
                    "text": "This review article provides an overview of currently approved ALK inhibitors, other ALK inhibitors in development, and commonly described mechanisms of resistance to ALK inhibitors.",
                    "offsetInBeginSection": 264,
                    "offsetInEndSection": 446,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27122312",
                    "text": "AREAS COVERED Three drugs have been approved for clinical use in ALK-positive patients - crizotinib, ceritinib and alectinib.",
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 388,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a723edd2dc08e987e00000c",
            "body": "Is Tofacitinib effective for Ulcerative Colitis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                "http://www.ncbi.nlm.nih.gov/pubmed/22894574"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "text": "BACKGROUND Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "text": "CONCLUSIONS In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.",
                    "offsetInBeginSection": 2249,
                    "offsetInEndSection": 2409,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                    "text": "BACKGROUND Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "text": "METHODS We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis.",
                    "offsetInBeginSection": 262,
                    "offsetInEndSection": 407,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                    "text": "CONCLUSIONS Patients with moderately to severely active ulcerative colitis treated with tofacitinib were more likely to have clinical response and remission than those receiving placebo.",
                    "offsetInBeginSection": 2066,
                    "offsetInEndSection": 2252,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                    "text": "One additional treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2, which is expected to block signaling involving gamma chain-containing cytokines including interleukins 2, 4, 7, 9, 15, and 21.",
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 440,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                    "text": "METHODS In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of tofacitinib in 194 adults with moderately to severely active ulcerative colitis.",
                    "offsetInBeginSection": 527,
                    "offsetInEndSection": 698,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "text": "RESULTS In the OCTAVE Induction 1 trial, remission at 8 weeks occurred in 18.5% of the patients in the tofacitinib group versus 8.2% in the placebo group (P=0.007); in the OCTAVE Induction 2 trial, remission occurred in 16.6% versus 3.6% (P<0.001).",
                    "offsetInBeginSection": 1064,
                    "offsetInEndSection": 1312,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "text": "In the OCTAVE Induction 1 and 2 trials, 598 and 541 patients, respectively, who had moderately to severely active ulcerative colitis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were randomly assigned to receive induction therapy with tofacitinib (10 mg twice daily) or placebo for 8 weeks.",
                    "offsetInBeginSection": 408,
                    "offsetInEndSection": 742,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "text": "In the OCTAVE Sustain trial, remission at 52 weeks occurred in 34.3% of the patients in the 5-mg tofacitinib group and 40.6% in the 10-mg tofacitinib group versus 11.1% in the placebo group (P<0.001 for both comparisons with placebo).",
                    "offsetInBeginSection": 1313,
                    "offsetInEndSection": 1547,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a85a0f1faa1ab7d2e000032",
            "body": "What is the definition of General Regulatory Factors (GRFs)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12200417",
                "http://www.ncbi.nlm.nih.gov/pubmed/28448767",
                "http://www.ncbi.nlm.nih.gov/pubmed/28158860",
                "http://www.ncbi.nlm.nih.gov/pubmed/17158163",
                "http://www.ncbi.nlm.nih.gov/pubmed/27014338",
                "http://www.ncbi.nlm.nih.gov/pubmed/27540088",
                "http://www.ncbi.nlm.nih.gov/pubmed/25620770",
                "http://www.ncbi.nlm.nih.gov/pubmed/21914852",
                "http://www.ncbi.nlm.nih.gov/pubmed/25215414",
                "http://www.ncbi.nlm.nih.gov/pubmed/20371324"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27540088",
                    "text": "We found that nucleosomes and specific DNA-binding proteins, including the general regulatory factors (GRFs) Reb1p, Rap1p, and Abf1p, and Pol III transcription factors enhance the efficiency of NNS termination by physically blocking Pol II progression.",
                    "offsetInBeginSection": 328,
                    "offsetInEndSection": 580,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417",
                    "text": "Together with Reb1p and Tbf1p, previously involved in the activity of Saccharomyces cerevisiae subtelomeric insulators, insulating potential emerges as a supplementary common property of General Regulatory Factors (GRFs).",
                    "offsetInBeginSection": 658,
                    "offsetInEndSection": 879,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17158163",
                    "text": "Abf1 and Rap1 are general regulatory factors (GRFs) that contribute to transcriptional activation of a large number of genes, as well as to replication, silencing and telomere structure in yeast.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158860",
                    "text": "Here, we show that most Ribi gene promoters also contain binding sites for one or more General Regulatory Factors (GRFs), most frequently Abf1 and Reb1, and that these factors are enriched in vivo at Ribi promoters.",
                    "offsetInBeginSection": 304,
                    "offsetInEndSection": 519,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28448767",
                    "text": "This regulon has recently been shown to rely on a small set of transcriptional regulators (mainly Abf1, but also Reb1, Tbf1 and Rap1) previously referred to as general regulatory factors (GRFs) because of their widespread binding and action at many promoters and other specialized genomic regions.",
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 419,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25215414",
                    "text": "Here, we will focus on the roles of gene regulatory factors (GRFs), in particular transcription factors (TFs) and long non-coding RNAs (lncRNAs) during human evolution.",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 298,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25620770",
                    "text": "The expression of several GRFs is controlled by microRNA miR396, and the GRF-miRNA396 regulatory module appears to be central to several of these processes.",
                    "offsetInBeginSection": 390,
                    "offsetInEndSection": 546,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20371324",
                    "text": "Gene-regulation functions (GRF) provide a unique characteristic of a cis-regulatory module (CRM), relating the concentrations of transcription factors (input) to the promoter activities (output).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158860",
                    "text": "Our observations point to GRFs as new multifaceted players in Ribi gene regulation both during exponential growth and under repressive conditions.",
                    "offsetInBeginSection": 1159,
                    "offsetInEndSection": 1305,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25620770",
                    "text": "Growth-regulating factors (GRFs) are plant-specific transcription factors that were originally identified for their roles in stem and leaf development, but recent studies highlight them to be similarly important for other central developmental processes including flower and seed formation, root development, and the coordination of growth processes under adverse environmental conditions.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 389,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68a463b750ff4455000014",
            "body": "Do chromatin features predict genes associated with eQTLs?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23275551"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551",
                    "text": "Here, we integrate genome-wide data on TF-binding sites, chromatin markers and functional annotations to predict genes associated with human eQTLs.",
                    "offsetInBeginSection": 382,
                    "offsetInEndSection": 529,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551",
                    "text": "Using the random forest classifier, we found that genomic proximity plus five TF and chromatin features are able to predict >90% of target genes within 1 megabase of eQTLs.",
                    "offsetInBeginSection": 530,
                    "offsetInEndSection": 702,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551",
                    "text": "Mapping studies for expression quantitative trait loci (eQTLs), transcription factors (TFs) and chromatin markers have become widely used tools for identifying gene regulatory elements, but prediction of target genes remains a major challenge.",
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 381,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551",
                    "text": "Despite being regularly used to map target genes, proximity is not a good indicator of eQTL targets for genes   150 kilobases away, but insulators, TF co-occurrence, open chromatin and functional similarities between TFs and genes are better indicators.",
                    "offsetInBeginSection": 703,
                    "offsetInEndSection": 956,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551",
                    "text": "Cell type-specific gene expression in humans involves complex interactions between regulatory factors and DNA at enhancers and promoters.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551",
                    "text": "We hope this study will not only provide validation of eQTL-mapping studies, but also provide insight into the molecular mechanisms explaining how genetic variation can influence gene expression.",
                    "offsetInBeginSection": 1137,
                    "offsetInEndSection": 1332,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551",
                    "text": "Using all six features in the classifier achieved an area under the specificity and sensitivity curve of 0.91, much better compared with at most 0.75 for using any single feature.",
                    "offsetInBeginSection": 957,
                    "offsetInEndSection": 1136,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a760a4183b0d9ea66000016",
            "body": "What is filgotinib?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27988142",
                "http://www.ncbi.nlm.nih.gov/pubmed/25681059",
                "http://www.ncbi.nlm.nih.gov/pubmed/27993829",
                "http://www.ncbi.nlm.nih.gov/pubmed/27993828",
                "http://www.ncbi.nlm.nih.gov/pubmed/28838249",
                "http://www.ncbi.nlm.nih.gov/pubmed/26693854",
                "http://www.ncbi.nlm.nih.gov/pubmed/28645489",
                "http://www.ncbi.nlm.nih.gov/pubmed/24818516",
                "http://www.ncbi.nlm.nih.gov/pubmed/28622463",
                "http://www.ncbi.nlm.nih.gov/pubmed/28765121"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28765121",
                    "text": "We summarise the development and recent application of Janus kinase (JAK) inhibitors in the treatment of IMIDs, including first-generation pan-JAK inhibitors (tofacitinib, baricitinib, ruxolitinib, peficitinib) and second-generation selective JAK inhibitors (decernotinib, filgotinib, upadacitinib).",
                    "offsetInBeginSection": 1255,
                    "offsetInEndSection": 1554,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818516",
                    "text": "Phase II data for four JAK inhibitors (baricitinib, decernotinib, filgotinib and INCB-039110) are contrasted with that reported for the recently approved JAK inhibitor tofacitinib.",
                    "offsetInBeginSection": 556,
                    "offsetInEndSection": 736,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27988142",
                    "text": "BACKGROUND Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25681059",
                    "text": "BACKGROUND AND OBJECTIVES Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24818516",
                    "text": "JAK inhibitors differ in isoform specificity profiles, with good efficacy achievable by selective inhibition of either JAK1 (filgotinib or INCB-039110) or JAK3 (decernotinib).",
                    "offsetInBeginSection": 1176,
                    "offsetInEndSection": 1351,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28765121",
                    "text": "Emerging strategies to interfere with cellular adhesion processes involved in lymphocyte recruitment are discussed, including both integrin blockade (natalizumab, vedolizumab, etrolizumab) and sphingosine-1-phosphate receptor inhibition (fingolimod, ozanimod).",
                    "offsetInBeginSection": 994,
                    "offsetInEndSection": 1254,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993828",
                    "text": "OBJECTIVES To evaluate the efficacy and safety of different doses of filgotinib, an oral Janus kinase 1 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) and previous inadequate response to methotrexate (MTX).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 235,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26693854",
                    "text": "OBJECTIVE The selective Janus kinase 1 inhibitor filgotinib (GLPG0634), which is currently in clinical development for the treatment of rheumatoid arthritis (RA) and Crohn's disease, demonstrated encouraging safety and efficacy profiles in RA patients after 4 weeks of daily dosing.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 282,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28838249",
                    "text": "The first oral targeted small molecules approved for RA are competitive inhibitors of the Janus kinase (JAK) enzyme family which mediate signalling for a cytokine subset important in RA pathogenesis.",
                    "offsetInBeginSection": 168,
                    "offsetInEndSection": 367,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993829",
                    "text": "OBJECTIVES To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 251,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a74d9980384be9551000008",
            "body": "What is LHON, also known as Lebers syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27843288",
                "http://www.ncbi.nlm.nih.gov/pubmed/9147893",
                "http://www.ncbi.nlm.nih.gov/pubmed/25566062",
                "http://www.ncbi.nlm.nih.gov/pubmed/9309689",
                "http://www.ncbi.nlm.nih.gov/pubmed/11329546",
                "http://www.ncbi.nlm.nih.gov/pubmed/16523300",
                "http://www.ncbi.nlm.nih.gov/pubmed/7916404",
                "http://www.ncbi.nlm.nih.gov/pubmed/10993496",
                "http://www.ncbi.nlm.nih.gov/pubmed/27756254",
                "http://www.ncbi.nlm.nih.gov/pubmed/8240101"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843288",
                    "text": "Leber's hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial disorder with bilateral loss of central vision primarily due to mitochondrial DNA (mtDNA) mutations in subunits of complex I in the respiratory chain (primary LHON mutations), while other mtDNA mutations can also be causative.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 309,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11329546",
                    "text": "Wolff-Parkinson-White syndrome, myocardial thickening and ILVAT may be rare manifestations of LHON.",
                    "offsetInBeginSection": 839,
                    "offsetInEndSection": 938,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9309689",
                    "text": "The phenotypic characteristics of the syndrome resemble those found in other mitochondrial (mt)DNA mediated disorders such as Leber's hereditary optic neuropathy (LHON) or maternally inherited diabetes and deafness (MIDD).",
                    "offsetInBeginSection": 286,
                    "offsetInEndSection": 508,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9309689",
                    "text": "Wolfram or DIDMOAD (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and Deafness) syndrome, which has long been known as an autosomal-recessive disorder, has recently been proposed to be a mitochondrial-mediated disease with either a nuclear or a mitochondrial genetic background.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 285,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16523300",
                    "text": "BACKGROUND Leber's hereditary optic neuropathy (LHON) is a maternally inherited optic neuropathy caused by mutations in mitochondrial DNA (mtDNA).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9147893",
                    "text": "The pre-excitation syndrome Wolff-Parkinson-White syndrome or Lown-Ganong-Levine syndrome, is reportedly common in Finns with LHON, being seen in 14 (9%) of the 163 individuals with mitochondrial DNA (mtDNA) mutations.",
                    "offsetInBeginSection": 113,
                    "offsetInEndSection": 331,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7916404",
                    "text": "Mitochondrial DNA causal for LHON may contribute to pre-excitation syndrome.",
                    "offsetInBeginSection": 552,
                    "offsetInEndSection": 628,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7916404",
                    "text": "Pre-excitation syndrome is common in families with Leber's hereditary optic neuropathy (LHON).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843288",
                    "text": "Since the first description, it is known that LHON is not restricted to the eyes but is a multisystem disorder additionally involving the central nervous system, ears, endocrinological organs, heart, bone marrow, arteries, kidneys, or the peripheral nervous system.",
                    "offsetInBeginSection": 310,
                    "offsetInEndSection": 575,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27756254",
                    "text": "BACKGROUND Leber's hereditary optic neuropathy (LHON) co-occuring with multiple sclerosis-like disease (LHON-MS) is suggested to be a separate disease entity denoted Harding's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8842a261bb38fb24000015",
            "body": "List proteins that are targeted by \"immune checkpoints inhibitors\".",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26282545",
                "http://www.ncbi.nlm.nih.gov/pubmed/27770382",
                "http://www.ncbi.nlm.nih.gov/pubmed/27683114",
                "http://www.ncbi.nlm.nih.gov/pubmed/26183909",
                "http://www.ncbi.nlm.nih.gov/pubmed/26765776",
                "http://www.ncbi.nlm.nih.gov/pubmed/27068940",
                "http://www.ncbi.nlm.nih.gov/pubmed/26680224",
                "http://www.ncbi.nlm.nih.gov/pubmed/23691926",
                "http://www.ncbi.nlm.nih.gov/pubmed/27664133",
                "http://www.ncbi.nlm.nih.gov/pubmed/26860624"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27664133",
                    "text": "Cytotoxic-T-lymphocyte antigen (CTLA-4) and programmed cell death protein 1 (PD-1) are the two most commonly targeted immune checkpoint molecules.",
                    "offsetInBeginSection": 164,
                    "offsetInEndSection": 310,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26183909",
                    "text": "Most promising therapeutic approaches to activating antitumor immunity include immune checkpoint inhibitors.",
                    "offsetInBeginSection": 147,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26680224",
                    "text": "Strategies that hold promise include dual immune checkpoint blockade, as well as the combination of immune checkpoint blockade with costimulatory receptor agonists, enhancers of innate immunity, inhibition of indoleamine 2,3-dioxygenase, adoptive T-cell transfer/T-cell engineering, therapeutic vaccines, small-molecule inhibitors, and radiation therapy.",
                    "offsetInBeginSection": 711,
                    "offsetInEndSection": 1065,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27683114",
                    "text": "Since alterations in DNA repair genes have been connected to the efficacy of checkpoint inhibitors, we investigated associations between methylation of DNA repair genes and CTLA4 and CD274 (PD-L1) expression.A list of DNA repair genes (179 genes) was selected from the literature, methylation status and expression of inflammation-associated genes (The Cancer Genome Atlas data) was correlated in head and neck squamous cell carcinoma (HNSCC), cervical and lung squamous cell carcinoma.A significant positive correlation of the methylation status of 15, 3 and 2 genes with checkpoint expression was identified, respectively.",
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 746,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26183909",
                    "text": "Immune checkpoints are numerous inhibitory pathways hardwired in the immune system.",
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 339,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27068940",
                    "text": "Combinatorial studies using both anti-CTLA-4 and anti-PD-1 demonstrate synergistic effects of targeting multiple checkpoints, paving the way for other immune checkpoints to be targeted.",
                    "offsetInBeginSection": 477,
                    "offsetInEndSection": 662,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26765776",
                    "text": "Combinations of PD-1 inhibitors with novel immune checkpoints or with molecularly targeted therapies are under investigation and may improve on the considerable progress made.",
                    "offsetInBeginSection": 504,
                    "offsetInEndSection": 679,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26860624",
                    "text": "Antibodies that block inhibitory checkpoints, such as anti-CTLA-4, anti-PD1 and anti-PD-L1 antibodies have demonstrated delayed tumor growth and increased survival.",
                    "offsetInBeginSection": 564,
                    "offsetInEndSection": 728,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27683114",
                    "text": "Methylation of the candidate genes was also associated with expression of other checkpoints, ligands, MHC- and T-cell associated genes as well as an interferon-inflammatory immune gene signature, predictive for the efficacy of PD-1 inhibition in HNSCC.Homologous recombination deficiency might therefore be mediated by DNA repair gene hypermethylation and linked to an immune-evasive phenotype in SCC.",
                    "offsetInBeginSection": 904,
                    "offsetInEndSection": 1305,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26765776",
                    "text": "Melanoma is at the forefront of development of systemic therapeutics with both molecular targeted therapies and immune checkpoint inhibitors as cornerstones of treatment.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 170,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a736efc3b9d13c708000006",
            "body": "Which chromosomes are implicated in the Emanuel syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19606488",
                "http://www.ncbi.nlm.nih.gov/pubmed/22434056",
                "http://www.ncbi.nlm.nih.gov/pubmed/22876593",
                "http://www.ncbi.nlm.nih.gov/pubmed/27973931",
                "http://www.ncbi.nlm.nih.gov/pubmed/18286821",
                "http://www.ncbi.nlm.nih.gov/pubmed/24171835",
                "http://www.ncbi.nlm.nih.gov/pubmed/28981939",
                "http://www.ncbi.nlm.nih.gov/pubmed/27785401",
                "http://www.ncbi.nlm.nih.gov/pubmed/27617132"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18286821",
                    "text": "Emanuel syndrome results from +der(22)t(11q23;22q11).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 53,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22876593",
                    "text": "Emanuel syndrome is an inherited chromosomal abnormality resulting from 3:1 meiotic segregation from parental balanced translocation carrier t(11;22)(q23;q11), mostly of maternal origin.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27617132",
                    "text": "Complex sSMCs consist of chromosomal material derived from more than one chromosome, for example, the derivative der(22)t(11;22)(q23;q11.2) in Emanuel syndrome.",
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 288,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27785401",
                    "text": "Emanuel syndrome (ES) is a rare chromosomal disorder that is characterized by multiple congenital anomalies and developmental disabilities.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27973931",
                    "text": "Emanuel syndrome is associated with supernumerary chromosome, which consists of the extra genetic material from chromosome 11 and 22.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488",
                    "text": "Emanuel syndrome is characterized by multiple congenital anomalies and developmental disability.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22876593",
                    "text": "Here in, we describe a female patient with supernumerary der(22) syndrome (Emanuel syndrome) due to balanced translocation carrier father t(11;22) (q23;q11).",
                    "offsetInBeginSection": 436,
                    "offsetInEndSection": 593,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24171835",
                    "text": "Complex sSMC consist of chromosomal material derived from more than one chromosome; the best known representative of this group is the derivative chromosome 22 {der(22)t(11;22)} or Emanuel syndrome.",
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 324,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28981939",
                    "text": "CONCLUSION A fetal case of Emanuel syndrome has been identified.",
                    "offsetInBeginSection": 904,
                    "offsetInEndSection": 968,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27617132",
                    "text": "Complex small supernumerary marker chromosomes (sSMCs) constitute one of the smallest subsets within the patients with an sSMC.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a86c938faa1ab7d2e000034",
            "body": "Which genes belong to the AUX/IAA family of transcription repressors in plants?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28111153",
                "http://www.ncbi.nlm.nih.gov/pubmed/27247276",
                "http://www.ncbi.nlm.nih.gov/pubmed/17077182",
                "http://www.ncbi.nlm.nih.gov/pubmed/17919906",
                "http://www.ncbi.nlm.nih.gov/pubmed/22368074",
                "http://www.ncbi.nlm.nih.gov/pubmed/27049520",
                "http://www.ncbi.nlm.nih.gov/pubmed/16478940",
                "http://www.ncbi.nlm.nih.gov/pubmed/22409484",
                "http://www.ncbi.nlm.nih.gov/pubmed/16284307",
                "http://www.ncbi.nlm.nih.gov/pubmed/17430601"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17430601",
                    "text": "The Arabidopsis gene AXR3/IAA17 encodes a member of the Aux/IAA family of auxin responsive transcriptional repressors.",
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27247276",
                    "text": "The coordinated action of the auxin-sensitive Aux/IAA transcriptional repressors and ARF transcription factors produces complex gene-regulatory networks in plants.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16478940",
                    "text": "In the presence of a low concentration of auxin in the nucleus, members of the Aux/IAA family of transcriptional repressors bind to ARF proteins and inhibit the transcription of specific auxin response genes.",
                    "offsetInBeginSection": 337,
                    "offsetInEndSection": 545,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22409484",
                    "text": "Functional characterization of SlIAA15, a member of the tomato (Solanum lycopersicum) Aux/IAA family, shows that the encoded protein acts as a strong repressor of auxin-dependent transcription.",
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27049520",
                    "text": "Auxin/Indole-3-Acetic Acid (Aux/IAA) are early auxin response genes noted as transcriptional repressors in plant auxin signaling.",
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 260,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16284307",
                    "text": "The AUXIN/INDOLE-3-ACETIC ACID (Aux/IAA) genes encode short-lived transcriptional repressors that are targeted by the TRANSPORT INHIBITOR RESPONSE1/AUXIN RECEPTOR F-BOX proteins.",
                    "offsetInBeginSection": 65,
                    "offsetInEndSection": 243,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22409484",
                    "text": "The Aux/IAA genes encode a large family of short-lived proteins known to regulate auxin signalling in plants.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17919906",
                    "text": "At the molecular level, auxin induces gene expression through direct physical interaction with the TIR1-like F box proteins, which in turn remove the Aux/IAA family of transcriptional repressors [1-4].",
                    "offsetInBeginSection": 75,
                    "offsetInEndSection": 276,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17077182",
                    "text": "The Aux/IAA genes are best characterized among the early auxin-responsive genes, which encode short-lived transcriptional repressors.",
                    "offsetInBeginSection": 173,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22368074",
                    "text": "Functional characterization using a dedicated single cell system revealed that tomato Aux/IAA proteins function as active repressors of auxin-dependent gene transcription, with, however, different Aux/IAA members displaying varying levels of repression.",
                    "offsetInBeginSection": 543,
                    "offsetInEndSection": 796,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a2bbcb750ff4455000022",
            "body": "What is Cellbase?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22693220",
                "http://www.ncbi.nlm.nih.gov/pubmed/28535294"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28535294",
                    "text": "HGVA calculates population frequencies for these projects and enriches their data with variant annotation provided by CellBase, a rich and fast annotation solution.",
                    "offsetInBeginSection": 771,
                    "offsetInEndSection": 935,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220",
                    "text": "CellBase implements a set of RESTful web services that query a centralized database containing the most relevant biological data sources.",
                    "offsetInBeginSection": 998,
                    "offsetInEndSection": 1135,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220",
                    "text": "CellBase documentation can be found at http://docs.bioinfo.cipf.es/projects/cellbase.",
                    "offsetInBeginSection": 1200,
                    "offsetInEndSection": 1285,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220",
                    "text": "CellBase provides a solution to the growing necessity of integration by easing the access to biological data.",
                    "offsetInBeginSection": 888,
                    "offsetInEndSection": 997,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28535294",
                    "text": "HGVA provides an efficient and intuitive web-interface for easy data mining, a comprehensive RESTful API and client libraries in Python, Java and JavaScript for fast programmatic access to its knowledge base.",
                    "offsetInBeginSection": 562,
                    "offsetInEndSection": 770,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28535294",
                    "text": "High-profile genomic variation projects like the 1000 Genomes project or the Exome Aggregation Consortium, are generating a wealth of human genomic variation knowledge which can be used as an essential reference for identifying disease-causing genotypes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 254,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28535294",
                    "text": "The Human Genome Variation Archive (HGVA) tackles these challenges and facilitates access to genomic data for key reference projects in a clean, fast and integrated fashion.",
                    "offsetInBeginSection": 388,
                    "offsetInEndSection": 561,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220",
                    "text": "Some of the most common problems are that the information is spread out in many small databases; frequently there are different standards among repositories and some databases are no longer supported or they contain too specific and unconnected information.",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 600,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28535294",
                    "text": "HGVA serves as a proof-of-concept of the genome analysis developments being carried out by the University of Cambridge together with UK's 100 000 genomes project and the National Institute for Health Research BioResource Rare-Diseases, in particular, deploying open-source for Computational Biology (OpenCB) software platform for storing and analyzing massive genomic datasets.",
                    "offsetInBeginSection": 936,
                    "offsetInEndSection": 1313,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220",
                    "text": "Today, there is more biological information than ever but, unfortunately, the current status of many of these repositories is far from being optimal.",
                    "offsetInBeginSection": 193,
                    "offsetInEndSection": 342,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76155c83b0d9ea6600001e",
            "body": "Which phase III clinical trials for rheumatoid arthritis involve baricitinib? (November 2017)",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27910962",
                "http://www.ncbi.nlm.nih.gov/pubmed/28255337",
                "http://www.ncbi.nlm.nih.gov/pubmed/27799159",
                "http://www.ncbi.nlm.nih.gov/pubmed/28923098",
                "http://www.ncbi.nlm.nih.gov/pubmed/27689735",
                "http://www.ncbi.nlm.nih.gov/pubmed/28290136",
                "http://www.ncbi.nlm.nih.gov/pubmed/28405473",
                "http://www.ncbi.nlm.nih.gov/pubmed/27577235"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27577235",
                    "text": "Results of phase III clinical trials using a JAK1/2 inhibitor, baricitinib, have shown feasible efficacy and tolerable safety.",
                    "offsetInBeginSection": 973,
                    "offsetInEndSection": 1099,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27910962",
                    "text": "Baricitinib (LY-3009104, INCB-028050), a new potent and selective tyrosine-protein kinase JAK1/JAK2 inhibitor, has shown clinical efficacy in patients with RA refractory to aggressive standard-of-care treatment (with both conventional DMARDs and bDMARDs) when administered orally at 4 mg q.d.",
                    "offsetInBeginSection": 535,
                    "offsetInEndSection": 827,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27910962",
                    "text": "in pivotal phase III clinical trials.",
                    "offsetInBeginSection": 828,
                    "offsetInEndSection": 865,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28923098",
                    "text": "BACKGROUND This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and na\u00efve to biological DMARDs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 343,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28290136",
                    "text": "Baricitinib (Olumiant\u2122) is an orally-administered, small-molecule, janus-associated kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritis (RA), atopic dermatitis and systemic lupus erythematosus.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 254,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27577235",
                    "text": "In addition, clinical phase III trials using filgotinib and ABT-494, specific JAK1 inhibitors, are currently underway.",
                    "offsetInBeginSection": 1218,
                    "offsetInEndSection": 1336,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28290136",
                    "text": "In February 2017, baricitinib was approved in the EU, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).",
                    "offsetInBeginSection": 491,
                    "offsetInEndSection": 804,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255337",
                    "text": "Biologics have changed expectation and outcomes for rheumatoid arthritis (RA).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27689735",
                    "text": "METHODS In this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-na\u00efve patients with rheumatoid arthritis and inadequate response or intolerance to \u22651 conventional synthetic DMARDs were randomly assigned 1:1:1 to placebo or baricitinib (2 or 4\u2005mg) once daily, stratified by region and the presence of joint erosions.",
                    "offsetInBeginSection": 91,
                    "offsetInEndSection": 460,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27689735",
                    "text": "CONCLUSIONS In patients with rheumatoid arthritis and an inadequate response or intolerance to conventional synthetic DMARDs, baricitinib was associated with clinical improvement and inhibition of progression of radiographic joint damage.",
                    "offsetInBeginSection": 1666,
                    "offsetInEndSection": 1904,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a87124561bb38fb24000001",
            "body": "What is cebocephaly",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23072180",
                "http://www.ncbi.nlm.nih.gov/pubmed/19673365",
                "http://www.ncbi.nlm.nih.gov/pubmed/16061113",
                "http://www.ncbi.nlm.nih.gov/pubmed/957381",
                "http://www.ncbi.nlm.nih.gov/pubmed/9132501",
                "http://www.ncbi.nlm.nih.gov/pubmed/2255999",
                "http://www.ncbi.nlm.nih.gov/pubmed/828460",
                "http://www.ncbi.nlm.nih.gov/pubmed/411936",
                "http://www.ncbi.nlm.nih.gov/pubmed/23599105",
                "http://www.ncbi.nlm.nih.gov/pubmed/115387"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16061113",
                    "text": "Here we report on first case of cebocephaly with semilobar holoprosencephaly, hypotelorism, and a single nostril due to intrauterine TORCH infection (Toxoplasmosis, other [syphilis, varicella-zoster, parvovirus B19], Rubella, Cytomegalovirus [CMV], and Herpes infections) in the English language literature.",
                    "offsetInBeginSection": 116,
                    "offsetInEndSection": 423,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23072180",
                    "text": "Cebocephaly is a very rare congenital anomaly combining with semilobar holoprosencephaly.",
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23599105",
                    "text": "We report a case of alobar holoprosencephaly (HPE) and cebocephaly associated with uncontrolled maternal type 1 (insulin-dependent) diabetes mellitus.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9132501",
                    "text": "We report on a female still-birth with cebocephaly, alobar holoprosencephaly, cleft palate, lumbar spina bifida, sirenomelia, a single umbilical artery, and a 46,XX karyotype, but without maternal diabetes mellitus.",
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 386,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16061113",
                    "text": "Cebocephaly is a very rare congenital anomaly combining a severe midline facial malformation and holoprosencephaly.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19673365",
                    "text": "We report here a case of alobar holoprosencephaly with cebocephaly and craniosynostosis.",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 275,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23072180",
                    "text": "Herein we present the first case of cebocephaly with severe semilobar holoprosencephaly and lissencephaly.",
                    "offsetInBeginSection": 383,
                    "offsetInEndSection": 489,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2255999",
                    "text": "Cebocephaly (hypotelorism, single-nostril nose) and ethmocephaly (hypotelorism, interorbital proboscis) lie in the middle of the spectrum of craniofacial changes associated with holoprosencephaly.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19673365",
                    "text": "Cebocephaly is a very rare congenital midline facial anomaly characterized by a blind-ended single nostril and ocular hypotelorism, and is usually combined with alobar holoprosencephaly.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9132501",
                    "text": "Cebocephaly and sirenomelia are uncommon birth defects.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 55,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8881118cb19eca6b000006",
            "body": "Has the proteome of mice hippocampus been analysed?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18283665",
                "http://www.ncbi.nlm.nih.gov/pubmed/15863242",
                "http://www.ncbi.nlm.nih.gov/pubmed/27062398",
                "http://www.ncbi.nlm.nih.gov/pubmed/17663576",
                "http://www.ncbi.nlm.nih.gov/pubmed/28449397"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17663576",
                    "text": "2D-gel electrophoresis and mass spectrometry were applied to study the proteome difference in denervated hippocampus in wildtype mice and mice lacking intermediate filament proteins glial fibrillary acidic protein (GFAP) and vimentin (GFAP-/-Vim-/-) that show attenuated reactive gliosis and enhanced posttraumatic regeneration.",
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 494,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15863242",
                    "text": "It was shown recently that Tg-hSOD1 mice develop a characteristic set of neurodegenerative changes in hippocampus and we therefore decided to study differential protein expression patterns, constructing a mouse hippocampal proteome map using two-dimensional electrophoresis (2-DE) with in-gel digestion of spots followed by matrix-assisted laser desorption/ionisation-time of flight (MALDI-TOF) identification and quantitatively compared protein profiles between non-transgenic mice, hemizygous and homozygous Tg-hSOD1 mice.",
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 814,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283665",
                    "text": "We find that transcriptome and proteome levels of function as well as the topological organization of synaptic protein clusters, detected by toponomics at physiological sites of hippocampus CA3 region, are all largely conserved between different mice.",
                    "offsetInBeginSection": 218,
                    "offsetInEndSection": 469,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17663576",
                    "text": "Culture-derived isotope tags (CDIT) and mass spectrometry demonstrated that 14-3-3 epsilon was the major isoform upregulated in denervated hippocampus and that its upregulation was attenuated in GFAP-/-Vim-/- mice and thus most likely connected to reactive gliosis.",
                    "offsetInBeginSection": 700,
                    "offsetInEndSection": 965,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27062398",
                    "text": "We unravel discrete proteome changes in mouse auditory cortex, frontal cortex, hippocampus, and striatum functionally implicated in the learning process.",
                    "offsetInBeginSection": 1635,
                    "offsetInEndSection": 1788,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283665",
                    "text": "We have correlated transcriptomics, proteomics and toponomics analyses of hippocampus tissue of inbred C57BL/6 mice to analyse the interrelationship of expressed genes and proteins at different levels of organization.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 217,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449397",
                    "text": "This study of proteome profiling in the hippocampus could provide conceptual insights into the molecular mechanisms involved in amnesia.",
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 389,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449397",
                    "text": "Therefore, we silenced Vdac1 in the hippocampus of normal young mice and found similar impairment in recognition memory of Vdac1 silenced and scopolamine-treated mice.",
                    "offsetInBeginSection": 1420,
                    "offsetInEndSection": 1587,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28449397",
                    "text": "Using two-dimensional gel electrophoresis coupled with MALDI-MS/MS, we have analyzed the hippocampal proteome and identified 18 proteins which were differentially expressed.",
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 702,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283665",
                    "text": "The findings provide insight in the systems biology of gene expression on transcriptome, proteome and toponome levels of function in the same brain subregion.",
                    "offsetInBeginSection": 719,
                    "offsetInEndSection": 877,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a742d620384be9551000002",
            "body": "Which disease risk can be estimated with the Stop-Bang questionnaire?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27610133",
                "http://www.ncbi.nlm.nih.gov/pubmed/27898430",
                "http://www.ncbi.nlm.nih.gov/pubmed/25837173",
                "http://www.ncbi.nlm.nih.gov/pubmed/22270686",
                "http://www.ncbi.nlm.nih.gov/pubmed/25758298",
                "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
                "http://www.ncbi.nlm.nih.gov/pubmed/26961117",
                "http://www.ncbi.nlm.nih.gov/pubmed/26378880",
                "http://www.ncbi.nlm.nih.gov/pubmed/27938922",
                "http://www.ncbi.nlm.nih.gov/pubmed/26557740"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22270686",
                    "text": "The STOP-BANG questionnaire offers clinicians an efficient and objective tool for improving detection of OSA risk in MS patients.",
                    "offsetInBeginSection": 1295,
                    "offsetInEndSection": 1424,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27938922",
                    "text": "OBJECTIVE The STOP-Bang questionnaire was developed as a quick and simple screening tool for obstructive sleep apnea (OSA) in preoperative clinics.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22270686",
                    "text": "PURPOSE This study aims: (1) to identify patients with multiple sclerosis (MS) who are at high risk for obstructive sleep apnea (OSA) by utilizing the STOP-BANG questionnaire and (2) to evaluate the relationship between OSA risk as determined by the STOP-BANG questionnaire and self-reported sleepiness and fatigue using the Epworth Sleepiness Scale (ESS) and the Fatigue Severity Scale (FSS), respectively.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 407,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25758298",
                    "text": "This study aimed to evaluate and validate the Arabic version of Stop-Bang questionnaire as a screening tool for patients with OSA symptoms referred to a sleep clinic.",
                    "offsetInBeginSection": 319,
                    "offsetInEndSection": 485,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25010615",
                    "text": "RESULTS Eighty-three out of 200 patients had a high risk of OSA based on the STOP-Bang questionnaire.",
                    "offsetInBeginSection": 798,
                    "offsetInEndSection": 899,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25758298",
                    "text": "CONCLUSION The Arabic version of STOP-Bang questionnaire is an easy-to-use tool that can be implemented as a reliable, quick screening tool for OSA in patients referred to sleep clinic.",
                    "offsetInBeginSection": 1550,
                    "offsetInEndSection": 1735,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430",
                    "text": "RECENT FINDINGS The STOP-Bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (OSA).",
                    "offsetInBeginSection": 186,
                    "offsetInEndSection": 359,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22270686",
                    "text": "CONCLUSIONS Over 40% of MS patients were identified as high risk for OSA based on the STOP-BANG questionnaire.",
                    "offsetInBeginSection": 1184,
                    "offsetInEndSection": 1294,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27938922",
                    "text": "We aimed to evaluate the validity of the STOP-Bang questionnaire to predict moderate-to-severe and severe OSA in the general population.",
                    "offsetInBeginSection": 148,
                    "offsetInEndSection": 284,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27938922",
                    "text": "CONCLUSION The STOP-Bang questionnaire can be used as a screening tool in the general population in view of its moderate sensitivity and high negative predictive value for subjects with moderate-to-severe and severe OSA.",
                    "offsetInBeginSection": 1341,
                    "offsetInEndSection": 1561,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a86ea05faa1ab7d2e000037",
            "body": "How is CTCF activated post-translationally?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21465478",
                "http://www.ncbi.nlm.nih.gov/pubmed/19170077",
                "http://www.ncbi.nlm.nih.gov/pubmed/21912613",
                "http://www.ncbi.nlm.nih.gov/pubmed/15361875",
                "http://www.ncbi.nlm.nih.gov/pubmed/24362533",
                "http://www.ncbi.nlm.nih.gov/pubmed/25183525",
                "http://www.ncbi.nlm.nih.gov/pubmed/20110362",
                "http://www.ncbi.nlm.nih.gov/pubmed/23843455",
                "http://www.ncbi.nlm.nih.gov/pubmed/29077515",
                "http://www.ncbi.nlm.nih.gov/pubmed/26657029"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25183525",
                    "text": "Functionally, we show that CTCF interacts with TET methylcytosine dioxygenase (TET) enzymes and promotes adipogenic transcriptional enhancer DNA hydroxymethylation.",
                    "offsetInBeginSection": 1100,
                    "offsetInEndSection": 1264,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21912613",
                    "text": "The Bcl-3/p50 complex suppressed CTCF promoter activity to down-regulate CTCF transcription.",
                    "offsetInBeginSection": 818,
                    "offsetInEndSection": 910,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24362533",
                    "text": "CTCF binding, which was found in BCL6-expressing cell lines, correlated with the presence of histone variant H2A.Z and active histone marks, suggesting that CTCF induces chromatin modification at a transcriptionally active BCL6 locus.",
                    "offsetInBeginSection": 972,
                    "offsetInEndSection": 1206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15361875",
                    "text": "We show that the chromatin insulator protein CTCF carries a post-translational modification: poly(ADP-ribosyl)ation.",
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 252,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20110362",
                    "text": "CCCTC binding factor (CTCF) controls DNA imprinting, insulates important gene expression, and mediates growth factor- and stress-induced cell fate.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19170077",
                    "text": "CCCTC-binding factor (CTCF) is a ubiquitous Zn-finger-containing protein with numerous recognized functions, including, but not limited to, gene activation and repression, enhancer-blocking, X-chromosome inactivation, and gene imprinting.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 238,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29077515",
                    "text": "CCCTC-binding factor (CTCF) is a conserved, essential regulator of chromatin architecture containing a unique array of 11 zinc fingers (ZFs).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24362533",
                    "text": "CCCTC-binding factor (CTCF) is a multi-functional chromatin regulator, which has recently been shown to bind in a methylation-sensitive manner to sites within the BCL6 first intron.",
                    "offsetInBeginSection": 629,
                    "offsetInEndSection": 810,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24362533",
                    "text": "This work demonstrates that, in contexts in which BCL6 is expressed, CTCF binding to BCL6 exon1A associates with epigenetic modifications indicative of transcriptionally open chromatin.",
                    "offsetInBeginSection": 1617,
                    "offsetInEndSection": 1802,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29077515",
                    "text": "Gene duplication and sequence divergence during early amniote evolution generated the CTCF paralog Brother Of the Regulator of Imprinted Sites (BORIS), which has a DNA binding specificity identical to that of CTCF but divergent N- and C-termini.",
                    "offsetInBeginSection": 142,
                    "offsetInEndSection": 387,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a2f88b750ff4455000024",
            "body": "What is Target Explorer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12824372"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372",
                    "text": "Target Explorer is available at http://trantor.bioc.columbia.edu/Target_Explorer/",
                    "offsetInBeginSection": 820,
                    "offsetInEndSection": 901,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372",
                    "text": "Target Explorer automates the entire process from the creation of a customized library of binding sites for known transcription factors through the prediction and annotation of putative target genes that are potentially regulated by these factors.",
                    "offsetInBeginSection": 417,
                    "offsetInEndSection": 664,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372",
                    "text": "With the increasing number of eukaryotic genomes available, high-throughput automated tools for identification of regulatory DNA sequences are becoming increasingly feasible.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372",
                    "text": "It was specifically designed for the well-annotated Drosophila melanogaster genome, but most options can be used for sequences from other genomes as well.",
                    "offsetInBeginSection": 665,
                    "offsetInEndSection": 819,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372",
                    "text": "Here we combine the prediction of clusters of binding sites for transcription factors with context information taken from genome annotations.",
                    "offsetInBeginSection": 275,
                    "offsetInEndSection": 416,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372",
                    "text": "Several computational approaches for the prediction of regulatory elements were recently developed.",
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 274,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a772e9dfaa1ab7d2e000001",
            "body": "Was saracatinib being considered as a treatment for Alzheimer's disease in November 2017?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26062928",
                "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                "http://www.ncbi.nlm.nih.gov/pubmed/29112196",
                "http://www.ncbi.nlm.nih.gov/pubmed/11802333",
                "http://www.ncbi.nlm.nih.gov/pubmed/26271177",
                "http://www.ncbi.nlm.nih.gov/pubmed/28828744",
                "http://www.ncbi.nlm.nih.gov/pubmed/11763163",
                "http://www.ncbi.nlm.nih.gov/pubmed/28817221",
                "http://www.ncbi.nlm.nih.gov/pubmed/22299278",
                "http://www.ncbi.nlm.nih.gov/pubmed/21977379"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928",
                    "text": "CONCLUSION Saracatinib is a novel oral Src kinase inhibitor that was well tolerated but failed to meet its primary endpoint of improvement in 4 month progression-free survival as a single agent in previously treated metastatic colorectal cancer patients.",
                    "offsetInBeginSection": 1396,
                    "offsetInEndSection": 1650,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928",
                    "text": "Saracatinib (AZD0530) is a novel selective oral Src kinase inhibitor.",
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 312,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26271177",
                    "text": "On the basis of the re-analysis it was concluded that solanezumab does show disease-modifying activity and should be considered a promising candidate for treatment of Alzheimer's disease in the near future.",
                    "offsetInBeginSection": 576,
                    "offsetInEndSection": 782,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                    "text": "Targeting Fyn kinase may be a promising therapeutic approach in AD, and a larger Phase IIa clinical trial of AZD0530 for the treatment of patients with AD has recently launched.",
                    "offsetInBeginSection": 2493,
                    "offsetInEndSection": 2670,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21977379",
                    "text": "OBJECTIVE The cholinesterase inhibitor rivastigmine is approved for the treatment of mild to moderate Alzheimer's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29112196",
                    "text": "A more flexible theoretical framework capable of accommodating the complexity of the APP proteolytic system is required to integrate available evidence.Molecular Psychiatry advance online publication, 7 November 2017; doi:10.1038/mp.2017.218.",
                    "offsetInBeginSection": 1474,
                    "offsetInEndSection": 1716,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                    "text": "Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.",
                    "offsetInBeginSection": 598,
                    "offsetInEndSection": 800,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11763163",
                    "text": "TAK-147 is a CNS-specific acetylcholinesterase inhibitor under development by Takeda as a potential treatment for Alzheimer's disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11802333",
                    "text": "METHOD Data were collected from patients with Alzheimer's disease who were treated with rivastigmine between 1 October 1998-30 November 1999 at the Memory Disorders Outpatients Clinic at the Academic Medical Centre or the Slotervaart Hospital, both in Amsterdam, the Netherlands.",
                    "offsetInBeginSection": 116,
                    "offsetInEndSection": 395,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26271177",
                    "text": "A more definite positioning of solanezumab will not be possible until data from the ongoing Expedition III study becomes available in 2017 at the earliest.",
                    "offsetInBeginSection": 865,
                    "offsetInEndSection": 1020,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a897729fcd1d6a10c000009",
            "body": "What is the asosciation between the  eustachian tube and the uvula?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/6586052",
                "http://www.ncbi.nlm.nih.gov/pubmed/18695625",
                "http://www.ncbi.nlm.nih.gov/pubmed/17049625",
                "http://www.ncbi.nlm.nih.gov/pubmed/19644792",
                "http://www.ncbi.nlm.nih.gov/pubmed/21112097",
                "http://www.ncbi.nlm.nih.gov/pubmed/7401840"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21112097",
                    "text": "CONCLUSION SMCP is often diagnosed very late, though symptoms of velopharyngeal insufficiency (hyper nasal speech, Eustachian tube dysfunction) and bifid uvula are present.",
                    "offsetInBeginSection": 795,
                    "offsetInEndSection": 967,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19644792",
                    "text": "CONCLUSIONS SMCP is often diagnosed very late, though symptoms of velopharyngeal insufficiency such as open nasal speech, Eustachian tube dysfunction and reduced contraction of the palate with bifid uvula are present.",
                    "offsetInBeginSection": 1222,
                    "offsetInEndSection": 1439,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17049625",
                    "text": "A bifid uvula may be considered the earliest form of a cleft palate, and more importantly, it has been shown in the literature to be associated with other anomalies as submucosal cleft, hyoplastic eustachian tube orifice, and absence of the salpingopharyngeal folds.",
                    "offsetInBeginSection": 766,
                    "offsetInEndSection": 1032,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052",
                    "text": "Cleft palate, even in the microform of cleft uvula, was an indicator of large eustachian tube (p less than 0.001).",
                    "offsetInBeginSection": 220,
                    "offsetInEndSection": 334,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19644792",
                    "text": "BACKGROUND Submucous cleft palate (SMCP) is often diagnosed very late and can cause velopharyngeal insufficiency with open nasal speech and Eustachian tube dysfunction.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052",
                    "text": "Clinical data supported the hypothesis that most otitis media requiring surgery is part of a life-long bilateral process that correlates with small mastoid air system, and with a bougie-assessable large eustachian tube.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 219,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17049625",
                    "text": "A bifid uvula, midline diastasis of the palatal muscles, and notching of the posterior hard palate have classically formed a triad diagnosing submucosal clefts.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19644792",
                    "text": "Main symptoms were Eustachian tube dysfunctions (61.3%) and hypernasal speech (48.1%).",
                    "offsetInBeginSection": 677,
                    "offsetInEndSection": 763,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7401840",
                    "text": "Middle ear diseases attributable to Eustachian tube dysfunction, with or without infection, was found in the majority of the children with underdeveloped palate.",
                    "offsetInBeginSection": 494,
                    "offsetInEndSection": 655,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21112097",
                    "text": "Typical findings of the palate were a lack of posterior nasal spine (68%) and bifid uvula (59%).",
                    "offsetInBeginSection": 575,
                    "offsetInEndSection": 671,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a888b56d543831129000002",
            "body": "What induces Arabidopsis ROF1 expression?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19366428",
                "http://www.ncbi.nlm.nih.gov/pubmed/17080288"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428",
                    "text": "Arabidopsis ROF1 (AtFKBP62) is a peptidyl prolyl cis/trans isomerase and a member of the FKBP (FK506 binding protein) family.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17080288",
                    "text": "We report the characterization of the Arabidopsis large FKBPs ROF1 (AtFKBP62) and ROF2 (AtFKBP65) expression and protein accumulation patterns.",
                    "offsetInBeginSection": 174,
                    "offsetInEndSection": 317,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428",
                    "text": "Exposure to heat stress induces nuclear localization of the ROF1-HSP90.1 complex, which is dependent upon the presence of the transcription factor HsfA2, which interacts with HSP90.1 but not with ROF1.",
                    "offsetInBeginSection": 363,
                    "offsetInEndSection": 564,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17080288",
                    "text": "The plant co-chaperones FK506-binding proteins (FKBPs) are peptidyl prolyl cis-trans isomerases that function in protein folding, signal transduction and chaperone activity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 173,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428",
                    "text": "ROF1 expression is induced by heat stress and developmentally regulated.",
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 198,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17080288",
                    "text": "The five amino acids identified as essential for recognition and interaction between the mammalian chaperones and HSP90 are conserved in the plant ROF1-HSP90.",
                    "offsetInBeginSection": 1220,
                    "offsetInEndSection": 1378,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428",
                    "text": "Nuclear localization of ROF1 was not detected in Arabidopsis HSP90.1 and HsfA2 knockout mutants.",
                    "offsetInBeginSection": 565,
                    "offsetInEndSection": 661,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17080288",
                    "text": "The tissue specificity and temporal expression of ROF1 and ROF2 show that they are developmentally regulated.",
                    "offsetInBeginSection": 573,
                    "offsetInEndSection": 682,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17080288",
                    "text": "Transgenic plants expressing ROF1 promoter fused to GUS reporter gene reveal that ROF1 expression is organ specific.",
                    "offsetInBeginSection": 318,
                    "offsetInEndSection": 434,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428",
                    "text": "In this study, we show that ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain, and localizes in the cytoplasm under normal conditions.",
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 362,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67a207b750ff4455000008",
            "body": "List indications for palivizumab for treatment of RSV-induced bronchiolitis. ",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21077358",
                "http://www.ncbi.nlm.nih.gov/pubmed/12171262",
                "http://www.ncbi.nlm.nih.gov/pubmed/28807039",
                "http://www.ncbi.nlm.nih.gov/pubmed/20705882",
                "http://www.ncbi.nlm.nih.gov/pubmed/20695756",
                "http://www.ncbi.nlm.nih.gov/pubmed/28987219",
                "http://www.ncbi.nlm.nih.gov/pubmed/26636747",
                "http://www.ncbi.nlm.nih.gov/pubmed/19811111",
                "http://www.ncbi.nlm.nih.gov/pubmed/20457017",
                "http://www.ncbi.nlm.nih.gov/pubmed/16236360"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20695756",
                    "text": "Prevention of RSV infection includes palivizumab, which is proven to be effective in reducing the overall hospitalization rate for RSV-induced bronchiolitis in preterm neonates.",
                    "offsetInBeginSection": 564,
                    "offsetInEndSection": 741,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20705882",
                    "text": "ANSWER Most infants should not be considered for RSV prophylaxis with palivizumab.",
                    "offsetInBeginSection": 254,
                    "offsetInEndSection": 336,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19811111",
                    "text": "CONCLUSION Palivizumab provides cost-effective prophylaxis against RSV in high-risk infants.",
                    "offsetInBeginSection": 2044,
                    "offsetInEndSection": 2136,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19811111",
                    "text": "OBJECTIVE To assess the cost effectiveness of palivizumab, a humanised monoclonal antibody, used as prevention against severe respiratory syncytial virus (RSV) infection requiring hospitalisation, in the indication of preterm infants and infants with preterm/bronchopulmonary dysplasia and in the second indication of children with congenital heart disease in the Dutch healthcare setting.",
                    "offsetInBeginSection": 380,
                    "offsetInEndSection": 769,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28987219",
                    "text": "There is definitive evidence that RSV-induced bronchiolitis can damage the airways to promote airway obstruction and recurrent wheezing.",
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 738,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28987219",
                    "text": "Treatments that inhibit inflammation have efficacy for RV-induced wheezing, whereas the anti-RSV mAb palivizumab decreases the risk of severe RSV-induced illness and subsequent recurrent wheeze.",
                    "offsetInBeginSection": 1225,
                    "offsetInEndSection": 1419,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20705882",
                    "text": "QUESTION Palivizumab, a specific monoclonal antibody for respiratory syncytial virus (RSV), is available for prevention of pediatric respiratory tract infections.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171262",
                    "text": "The routine use of RSV monoclonal antibody, palivizumab, for RSV prophylaxis was reported by 49% (31/63) of paediatricians.",
                    "offsetInBeginSection": 1049,
                    "offsetInEndSection": 1172,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28987219",
                    "text": "Respiratory syncytial virus (RSV) is the main causative agent of bronchiolitis, whereas rhinovirus (RV) is most commonly detected in wheezing children thereafter.",
                    "offsetInBeginSection": 83,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21077358",
                    "text": "Although children with such disorders should be protected from RSV, they are currently excluded from the indication for palivizumab administration as passive immunization against RSV in Japan.",
                    "offsetInBeginSection": 995,
                    "offsetInEndSection": 1187,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a86f074faa1ab7d2e00003a",
            "body": "With which cancers has the loss of SMARCB1 been associated?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26941181",
                "http://www.ncbi.nlm.nih.gov/pubmed/23432645",
                "http://www.ncbi.nlm.nih.gov/pubmed/24853101",
                "http://www.ncbi.nlm.nih.gov/pubmed/28974397",
                "http://www.ncbi.nlm.nih.gov/pubmed/22797305",
                "http://www.ncbi.nlm.nih.gov/pubmed/23060122",
                "http://www.ncbi.nlm.nih.gov/pubmed/26743474",
                "http://www.ncbi.nlm.nih.gov/pubmed/23851500",
                "http://www.ncbi.nlm.nih.gov/pubmed/25490678",
                "http://www.ncbi.nlm.nih.gov/pubmed/23174932"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22797305",
                    "text": "Here we sequenced the exomes of 35 rhabdoid tumors, highly aggressive cancers of early childhood characterized by biallelic loss of SMARCB1, a subunit of the SWI/SNF chromatin remodeling complex.",
                    "offsetInBeginSection": 374,
                    "offsetInEndSection": 569,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25490678",
                    "text": "Differences in mutation profiles and patterns of gene gains/losses are seen between BRCA2 (associated with TP53/PTEN mutations, loss of RB1 and gain of HRAS, STK11 and SMARCB1) and BRCAX (associated with PIK3CA mutations) tumours, suggesting that BRCA2 and BRCAX MBCs may be distinct and arise from different tumour pathways.",
                    "offsetInBeginSection": 1194,
                    "offsetInEndSection": 1519,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26941181",
                    "text": "Since discovering genetic alterations of the SMARCB1 gene in malignant rhabdoid tumours, the family of tumours harbouring loss of SMARCB1 expression has been steadily expanding.",
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 335,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28974397",
                    "text": "In the course of clinical care, we encountered a patient with a complete loss of SMARCB1 (switch/sucrose nonfermentable-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1), which encodes INI-1 (integrase interactor 1), as the sole detected driver of their urinary tract tumor.",
                    "offsetInBeginSection": 93,
                    "offsetInEndSection": 404,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23851500",
                    "text": "SMARCB1 (Snf5/Ini1/Baf47) is a potent tumor suppressor, the loss of which serves as the diagnostic feature in malignant rhabdoid tumors (MRT) and atypical teratoid/rhabdoid tumors (AT/RT), two highly aggressive forms of pediatric neoplasms.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 240,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23851500",
                    "text": "SMARCB1 is a core subunit of Swi/Snf chromatin remodeling complexes, and loss of SMARCB1 or other subunits of these complexes has been observed in a variety of tumor types.",
                    "offsetInBeginSection": 241,
                    "offsetInEndSection": 413,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23174932",
                    "text": "About 10% of epithelioid sarcomas have biallelic mutation of the SMARCB1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1) gene resulting in a lack of this nuclear protein.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 222,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23432645",
                    "text": "SMARCB1 is a core subunit of the SWI/SNF chromatin remodeling complex, and the recent emergence of frequent mutations in genes that encode subunits of this complex across a wide variety of cancers suggests that perturbation of this chromatin remodeling complex constitutes a key driver of cancer formation.",
                    "offsetInBeginSection": 192,
                    "offsetInEndSection": 498,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26743474",
                    "text": "An expanded survey of other members of the SWI/SNF complex showed SMARCB1 loss in the undifferentiated component of two SMARCA4-intact tumors, and all SMARCA4- or SMARCB1-deficient tumors showed concomitant loss of expression of SMARCA2.",
                    "offsetInBeginSection": 653,
                    "offsetInEndSection": 890,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853101",
                    "text": "Consequently, investigation of the mechanisms by which SMARCB1 mutation causes cancer has relevance not only for rhabdoid tumors, but also potentially for the wide variety of SWI/SNF mutant cancers.",
                    "offsetInBeginSection": 669,
                    "offsetInEndSection": 867,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d022ab750ff445500002a",
            "body": "Is there any linear-time and linear-space algorithm for the computation of avoided words in biological sequences?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28293277"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277",
                    "text": "We present a linear-time and linear-space algorithm for the computation of avoided words of length k in a given sequence x.",
                    "offsetInBeginSection": 1647,
                    "offsetInEndSection": 1770,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277",
                    "text": "Hence, computing all such words na\u00efvely can be a very time-consuming procedure, in particular for large k.   RESULTS In this article, we propose an [Formula: see text]-time and [Formula: see text]-space algorithm to compute all [Formula: see text]-avoided words of length k in a given sequence of length n over a fixed-sized alphabet.",
                    "offsetInBeginSection": 608,
                    "offsetInEndSection": 943,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277",
                    "text": "We suggest a modification to this algorithm so that it computes all avoided words of x, irrespective of their length, within the same time complexity.",
                    "offsetInBeginSection": 1771,
                    "offsetInEndSection": 1921,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277",
                    "text": "We also present a time-optimal [Formula: see text]-time algorithm to compute all [Formula: see text]-avoided words (of any length) in a sequence of length n over an integer alphabet of size [Formula: see text].",
                    "offsetInBeginSection": 944,
                    "offsetInEndSection": 1154,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277",
                    "text": "CONCLUSIONS The systematic search for avoided words is particularly useful for biological sequence analysis.",
                    "offsetInBeginSection": 1538,
                    "offsetInEndSection": 1646,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277",
                    "text": "We also present combinatorial results with regards to avoided words and absent words.",
                    "offsetInBeginSection": 1922,
                    "offsetInEndSection": 2007,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277",
                    "text": "In addition, we provide a tight asymptotic upper bound for the number of [Formula: see text]-avoided words over an integer alphabet and the expected length of the longest one.",
                    "offsetInBeginSection": 1155,
                    "offsetInEndSection": 1330,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277",
                    "text": "Experimental results, using both real and synthetic data, show the efficiency and applicability of our implementation in biological sequence analysis.",
                    "offsetInBeginSection": 1385,
                    "offsetInEndSection": 1535,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277",
                    "text": "BACKGROUND The deviation of the observed frequency of a word w from its expected frequency in a given sequence x is used to determine whether or not the word is avoided.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277",
                    "text": "We make available an implementation of our algorithm.",
                    "offsetInBeginSection": 1331,
                    "offsetInEndSection": 1384,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a735b383b9d13c708000002",
            "body": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28893208",
                "http://www.ncbi.nlm.nih.gov/pubmed/27033334",
                "http://www.ncbi.nlm.nih.gov/pubmed/25003808",
                "http://www.ncbi.nlm.nih.gov/pubmed/23432579",
                "http://www.ncbi.nlm.nih.gov/pubmed/10137064",
                "http://www.ncbi.nlm.nih.gov/pubmed/10137850",
                "http://www.ncbi.nlm.nih.gov/pubmed/28389707"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208",
                    "text": "BACKGROUND Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25003808",
                    "text": "INTRODUCTION Transthyretin (TTR)-related hereditary amyloidosis is an adult-onset, dominantly inherited, systemic neurodegenerative disease endemic in some populations.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707",
                    "text": "p53, caspase 2, PKN3, \u03b22-adrenergic receptor, mutated KRAS, microRNAs); (ii) therapeutic conditions, including ophthalmic diseases, kidney injury, amyloidosis, pancreatic cancer, viral hepatitis; and (iii) routes of administration (ocular, intravenous, subcutaneous, intratumoral).",
                    "offsetInBeginSection": 1020,
                    "offsetInEndSection": 1302,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334",
                    "text": "RNA interference (RNAi) is a clinically validated technology that may be a promising approach to the treatment of ATTR amyloidosis.",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 246,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10137064",
                    "text": "The entries include generic/chemical name, investigational drug number, synonyms, trade names, manufacturers, clinical trial status, predicted approval year, indications or drug class, whether the drug has been developed through biotechnology, and references.",
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 502,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10137850",
                    "text": "The entries include generic/chemical name, investigational drug number, synonyms, trade names, manufacturers, clinical trial status, predicted approval year, indications or drug class, whether the drug has been developed through biotechnology, and references.",
                    "offsetInBeginSection": 320,
                    "offsetInEndSection": 579,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23432579",
                    "text": "RNAi products include short interference RNA (siRNA) but also short hairpin RNA (shRNA), bifunctional short hairpin RNA (bi-shRNA) and microRNA (miRNA).",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 339,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334",
                    "text": "ATTR amyloidosis is a systemic, debilitating and fatal disease caused by transthyretin (TTR) amyloid accumulation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10137064",
                    "text": "The author catalogs over 800 investigational drugs/biologicals currently in Phase I, II or III clinical trials or drugs/biologicals submitted to the FDA as new drug applications.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10137850",
                    "text": "The author catalogs over 800 investigational drugs/biologicals currently in Phase I, II or III clinical trials or drugs/biologicals submitted to the FDA as new drug applications.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67b48cb750ff4455000010",
            "body": "SGOT is an abbreviation for an enzyme other wise known as alanine amino transferase, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21375200",
                "http://www.ncbi.nlm.nih.gov/pubmed/1678364",
                "http://www.ncbi.nlm.nih.gov/pubmed/589307",
                "http://www.ncbi.nlm.nih.gov/pubmed/1681419",
                "http://www.ncbi.nlm.nih.gov/pubmed/17880731",
                "http://www.ncbi.nlm.nih.gov/pubmed/5349302",
                "http://www.ncbi.nlm.nih.gov/pubmed/17904308",
                "http://www.ncbi.nlm.nih.gov/pubmed/1355593",
                "http://www.ncbi.nlm.nih.gov/pubmed/5470040",
                "http://www.ncbi.nlm.nih.gov/pubmed/16877991"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/589307",
                    "text": "Mean values of glutamate dehydrogenase (GDH), serum aspartate and alanine transferase (SGOT and SGPT), ornithine carbamoyltransferase (OCT), and gamma-glutamyltranspeptidase (gamma-GTP) tended to rise with increasing liver cell necrosis, though values of SGOT, SGPT, OCT, and gamma-GTP showed considerable overlap between the 32 patients with histologically proved hepatitis and the 68 without.",
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 550,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17904308",
                    "text": "The ethanolic extract of C. inerme significantly (P<0.001) decreases the serum enzyme alanine amino transferase (ALT), asparate amino transferase (AST), alkaline phosphates (ALP), triglycerides (TGL), total cholesterol (TC) and significantly increased the glutathione level.",
                    "offsetInBeginSection": 195,
                    "offsetInEndSection": 469,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1678364",
                    "text": "DEC inhibited activities of monoamine oxidase, aspartate amino transferase and alanine amino transferase and enhanced those of cathepsin and glutamate dehydrogenase.",
                    "offsetInBeginSection": 419,
                    "offsetInEndSection": 584,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17880731",
                    "text": "Complete blood picture, differential leukocyte count, and serum levels of Estrogen, Alanine amino transferase (SGPT), Aspartate amino transferase (SGOT), total protein and albumin were estimated.",
                    "offsetInBeginSection": 293,
                    "offsetInEndSection": 488,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21375200",
                    "text": "The study excluded by screening for AntiHCV, HBsAg and patients with aspartate amino transferase (SGOT), alanine amino transferase (SGPT), GGT levels more than three times the normal and subject with a total leukocyte count more than 10,000/microl.",
                    "offsetInBeginSection": 379,
                    "offsetInEndSection": 627,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/5470040",
                    "text": "Serum aspartate aminotransferase (SGOT), alanine aminotransferase (SGPT), creatinine phosphokinase (CPK), and butyric acid dehydrogenase (BDH) were determined in 94 patients before, 1(1/2) hours, and 24 hours after cardioversion.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 229,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16877991",
                    "text": "An increase in alanine amino transferase (ALT) and ALT/aspartate aminotransferase ratio was associated with the mutation (F = 4.46, P = 0.016 and F = 5.92, P = 0.0049, respectively).",
                    "offsetInBeginSection": 938,
                    "offsetInEndSection": 1120,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/5349302",
                    "text": "When synthetic oestrogens were given, raised values of serum aspartate and alanine amino-transferase (S.G.O.T.",
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 228,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21375200",
                    "text": "Subjects were measured for waist/hip ratio, BMI and serum levels of ALT, AST, Alk phosphatase and glutamyl transferase (GGT).",
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 378,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1681419",
                    "text": "Glucagon increased alanine amino transferase (AAT) activity in perfused rat liver by about 90% over control.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a893da7bc7bade53a000001",
            "body": "Is CREB a key memory protein?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16266283",
                "http://www.ncbi.nlm.nih.gov/pubmed/9530494",
                "http://www.ncbi.nlm.nih.gov/pubmed/22267118",
                "http://www.ncbi.nlm.nih.gov/pubmed/21712073",
                "http://www.ncbi.nlm.nih.gov/pubmed/23504989",
                "http://www.ncbi.nlm.nih.gov/pubmed/12006982",
                "http://www.ncbi.nlm.nih.gov/pubmed/15988467",
                "http://www.ncbi.nlm.nih.gov/pubmed/28017136",
                "http://www.ncbi.nlm.nih.gov/pubmed/19110430",
                "http://www.ncbi.nlm.nih.gov/pubmed/21734652"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12006982",
                    "text": "The cyclic AMP responsive element binding protein (CREB) is a key transcription factor in synaptic plasticity and memory consolidation.",
                    "offsetInBeginSection": 112,
                    "offsetInEndSection": 247,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23504989",
                    "text": "The transcription factor cAMP response element binding protein (CREB) is a key protein implicated in memory, synaptic plasticity and structural plasticity in mammals.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22267118",
                    "text": "The transcription factor cyclic AMP-response element binding protein (CREB) is a key regulator of many neuronal processes, including brain development, circadian rhythm and long-term memory.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 190,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15988467",
                    "text": "Moreover, Rolipram treatments have been shown to increase expression and phosphorylation of a key factor for hippocampal memory consolidation, the cAMP-dependent response element-binding protein, CREB.",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 316,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21712073",
                    "text": "The transcription factor cAMP response element binding protein (CREB) is a key player in synaptic plasticity and learning.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19110430",
                    "text": "Mechanistically, DREAM functions as a negative regulator of the key memory factor CREB in a Ca(2+)-dependent manner, and loss of DREAM facilitates CREB-dependent transcription during learning.",
                    "offsetInBeginSection": 927,
                    "offsetInEndSection": 1119,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9530494",
                    "text": "The cAMP responsive element binding protein (CREB) is a nuclear protein that modulates the transcription of genes with cAMP responsive elements in their promoters.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283",
                    "text": "The cAMP responsive element binding protein (CREB) is a nuclear transcription factor that modulates transcription of genes containing cAMP responsive elements (CRE sites) in their promoters.",
                    "offsetInBeginSection": 233,
                    "offsetInEndSection": 423,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28017136",
                    "text": "Moreover, sumoylation, an important post-translational modification of protein, plays a key role in sustaining CREB activation in the rat hippocampus in order to enhance the long-term memory and other aspects.",
                    "offsetInBeginSection": 319,
                    "offsetInEndSection": 528,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21734652",
                    "text": "As the transcription factor CREB (cAMP/Ca(2+) responsive element-binding protein) is critical for memory formation across species, we investigated the role of CREB in a mouse model of AD.",
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 268,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67ade5b750ff445500000c",
            "body": "Does erythromycin increase risk of hypertrophic pyloric stenosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12693559",
                "http://www.ncbi.nlm.nih.gov/pubmed/12090829",
                "http://www.ncbi.nlm.nih.gov/pubmed/10609814",
                "http://www.ncbi.nlm.nih.gov/pubmed/11562617",
                "http://www.ncbi.nlm.nih.gov/pubmed/27655365",
                "http://www.ncbi.nlm.nih.gov/pubmed/12100810",
                "http://www.ncbi.nlm.nih.gov/pubmed/25687145",
                "http://www.ncbi.nlm.nih.gov/pubmed/18358279",
                "http://www.ncbi.nlm.nih.gov/pubmed/12381214"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18358279",
                    "text": "BACKGROUND Erythromycin treatment before 2 weeks of age has been shown to increase the risk of infantile hypertrophic pyloric stenosis (IHPS) up to 10 times.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27655365",
                    "text": "PURPOSE Macrolide antibiotics, erythromycin, in particular, have been linked to the development of infantile hypertrophic pyloric stenosis (IHPS).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559",
                    "text": "A case report has suggested that exposure to erythromycin through breast milk might cause infantile hypertrophic pyloric stenosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11562617",
                    "text": "OBJECTIVES To evaluate the risk for infantile hypertrophic pyloric stenosis (IHPS) among infants prescribed systemic erythromycin, infants prescribed a course of erythromycin ophthalmic ointment, and infants whose mothers were prescribed a macrolide antibiotic during pregnancy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 278,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25687145",
                    "text": "BACKGROUND AND OBJECTIVE Use of oral erythromycin in infants is associated with infantile hypertrophic pyloric stenosis (IHPS).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559",
                    "text": "The use of macrolides during breast-feeding increases the risk of infantile hypertrophic pyloric stenosis.",
                    "offsetInBeginSection": 895,
                    "offsetInEndSection": 1001,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12381214",
                    "text": "One of the more serious of these is infantile hypertrophic pyloric stenosis (IHPS).",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 198,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12100810",
                    "text": "Causal inference from the association between prenatal nonerythromycin macrolides and infantile hypertrophic pyloric stenosis is limited by the small number of affected children and the evidence of other differences between users of nonerythromycin macrolides and controls.",
                    "offsetInBeginSection": 1442,
                    "offsetInEndSection": 1715,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559",
                    "text": "This study therefore examined whether macrolides, transmitted via breast milk, increase the risk of infantile hypertrophic pyloric stenosis in neonates.",
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 283,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12090829",
                    "text": "CONCLUSIONS The significant increase in pyloric stenosis in children with very early exposure to erythromycin is consistent with reports of other investigators.",
                    "offsetInBeginSection": 1236,
                    "offsetInEndSection": 1396,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a870b7bfaa1ab7d2e00003d",
            "body": "What is the function of STAR elements in yeast telomeres?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10228166",
                "http://www.ncbi.nlm.nih.gov/pubmed/21351687",
                "http://www.ncbi.nlm.nih.gov/pubmed/21949764",
                "http://www.ncbi.nlm.nih.gov/pubmed/8720065",
                "http://www.ncbi.nlm.nih.gov/pubmed/16228207",
                "http://www.ncbi.nlm.nih.gov/pubmed/16132818",
                "http://www.ncbi.nlm.nih.gov/pubmed/10517334",
                "http://www.ncbi.nlm.nih.gov/pubmed/12498682",
                "http://www.ncbi.nlm.nih.gov/pubmed/7991584",
                "http://www.ncbi.nlm.nih.gov/pubmed/9188726"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21351687",
                    "text": "The fragments have a 1.18-kb region homologous with the type X regions at yeast telomeres that contain ARS elements that allow the autonomous replication of plasmids in yeast.",
                    "offsetInBeginSection": 227,
                    "offsetInEndSection": 402,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16132818",
                    "text": "Telomeres are multifunctional genetic elements that cap chromosome ends, playing essential roles in genome stability, chromosome higher-order organization and proliferation control.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21949764",
                    "text": "Thus the STAR and TEF2-UASrpg boundary elements inhibit chromatin silencing through an antisilencing activity independently of their position or orientation in S. cerevisiae minichromosomes rather than by creating a position-specific barrier as seen in the genome.",
                    "offsetInBeginSection": 1122,
                    "offsetInEndSection": 1386,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21949764",
                    "text": "We found that both HML-E and HML-I silencers can efficiently repress the URA3 reporter on a multi-copy yeast minichromosome and we further showed that two distinct heterochromatin boundary elements STAR and TEF2-UASrpg are able to limit the heterochromatin spreading in circular minichromosomes.",
                    "offsetInBeginSection": 519,
                    "offsetInEndSection": 814,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8720065",
                    "text": "Most of the 'core' X elements also contain an Abf1p binding site and a URS1-like element, which may have consequences for the chromatin structure, nuclear architecture and transcription of native telomeres.",
                    "offsetInBeginSection": 1409,
                    "offsetInEndSection": 1615,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21351687",
                    "text": "DNA fragments isolated from the left end of chromosome III in the yeast Saccharomyces cerevisiae are recognized as telomeres in yeast, since plasmids constructed with such fragments are replicated as linear molecules in yeast.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166",
                    "text": "Overall, our results suggest that the silencing emanating from telomeres can be propagated in a discontinuous manner via a series of subtelomeric relay elements.",
                    "offsetInBeginSection": 1098,
                    "offsetInEndSection": 1259,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7991584",
                    "text": "Telomeres are required for the stable maintenance of chromosomes in the yeast Saccharomyces cerevisiae.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9188726",
                    "text": "The two proximal SF-1 response elements were shown to be critical for StAR promoter function in human granulosalutein cells, which express SF-1 and respond to cAMP with increased transcription of the StAR gene.",
                    "offsetInBeginSection": 872,
                    "offsetInEndSection": 1082,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166",
                    "text": "In budding yeast, the telomeric DNA is flanked by a combination of two subtelomeric repetitive sequences, the X and Y' elements.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6d13fbb750ff445500002f",
            "body": "What is MINDY (motif interacting with Ub-containing novel DUB family)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27292798"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798",
                    "text": "Here we report the discovery of a new family of DUBs, which we have named MINDY (motif interacting with Ub-containing novel DUB family).",
                    "offsetInBeginSection": 139,
                    "offsetInEndSection": 275,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798",
                    "text": "Found in all eukaryotes, MINDY-family DUBs are highly selective at cleaving K48-linked polyUb, a signal that targets proteins for degradation.",
                    "offsetInBeginSection": 276,
                    "offsetInEndSection": 418,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798",
                    "text": "The crystal structure of MINDY-1 (also known as FAM63A) in complex with propargylated Ub reveals conformational changes that realign the active site for catalysis.",
                    "offsetInBeginSection": 614,
                    "offsetInEndSection": 777,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798",
                    "text": "Deubiquitinating enzymes (DUBs) remove ubiquitin (Ub) from Ub-conjugated substrates to regulate the\u00a0functional outcome of ubiquitylation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798",
                    "text": "MINDY-1 prefers cleaving long polyUb chains and\u00a0works by trimming chains from the distal end.",
                    "offsetInBeginSection": 778,
                    "offsetInEndSection": 872,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798",
                    "text": "Collectively, our results reveal a new family of DUBs that may have specialized roles in regulating proteostasis.",
                    "offsetInBeginSection": 873,
                    "offsetInEndSection": 986,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798",
                    "text": "We identify the catalytic activity to be encoded within a previously unannotated domain, the crystal structure of which reveals a distinct protein fold with no homology to any of the known DUBs.",
                    "offsetInBeginSection": 419,
                    "offsetInEndSection": 613,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a735c143b9d13c708000003",
            "body": "Is patisiran currently (November 2017) in clinical phase II trials?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26338094",
                "http://www.ncbi.nlm.nih.gov/pubmed/28893208"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094",
                    "text": "Patisiran 0.3\u00a0mg/kg Q3W is currently in phase III development.",
                    "offsetInBeginSection": 1672,
                    "offsetInEndSection": 1735,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094",
                    "text": "This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of patisiran (ALN-TTR02), a small interfering RNA encapsulated within lipid nanoparticles, in patients with transthyretin-mediated familial amyloid polyneuropathy (FAP).",
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 418,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208",
                    "text": "METHODS Here we describe the rationale and design of the Phase 3 APOLLO study, a randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy.",
                    "offsetInBeginSection": 242,
                    "offsetInEndSection": 486,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208",
                    "text": "BACKGROUND Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208",
                    "text": "TRIAL REGISTRATION This trial is registered at clinicaltrials.gov ( NCT01960348 ); October 9, 2013.",
                    "offsetInBeginSection": 1823,
                    "offsetInEndSection": 1922,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094",
                    "text": "TRIAL REGISTRATION NUMBER NCT01617967 .",
                    "offsetInBeginSection": 1738,
                    "offsetInEndSection": 1777,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094",
                    "text": "METHODS In this phase II study, patients with FAP were administered 2 intravenous infusions of patisiran at one of the following doses: 0.01 (n\u2009=\u20094), 0.05 (n\u2009=\u20093), 0.15 (n\u2009=\u20093), or 0.3 (n\u2009=\u20097) mg/kg every 4\u00a0weeks (Q4W), or 0.3\u00a0mg/kg (n\u2009=\u200912) every 3\u00a0weeks (Q3W).",
                    "offsetInBeginSection": 421,
                    "offsetInEndSection": 706,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094",
                    "text": "BACKGROUND Transthyretin-mediated amyloidosis is an inherited, progressively debilitating disease caused by mutations in the transthyretin gene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208",
                    "text": "DISCUSSION APOLLO represents the largest randomized, Phase 3 study to date in patients with hATTR amyloidosis, with endpoints that capture the multisystemic nature of this disease.",
                    "offsetInBeginSection": 1640,
                    "offsetInEndSection": 1820,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208",
                    "text": "Secondary objectives are to evaluate the effect of patisiran on Norfolk-Diabetic Neuropathy quality of life questionnaire score, nutritional status (as evaluated by modified body mass index), motor function (as measured by NIS-weakness and timed 10-m walk test), and autonomic symptoms (as measured by the Composite Autonomic Symptom Score-31 questionnaire).",
                    "offsetInBeginSection": 1078,
                    "offsetInEndSection": 1436,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a787544faa1ab7d2e00000b",
            "body": "Is Kummell\u2019s disease an avascular necrosis of the vertebral body?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9280031",
                "http://www.ncbi.nlm.nih.gov/pubmed/27446290",
                "http://www.ncbi.nlm.nih.gov/pubmed/19321060",
                "http://www.ncbi.nlm.nih.gov/pubmed/12865850",
                "http://www.ncbi.nlm.nih.gov/pubmed/19214087",
                "http://www.ncbi.nlm.nih.gov/pubmed/19124637",
                "http://www.ncbi.nlm.nih.gov/pubmed/22220246",
                "http://www.ncbi.nlm.nih.gov/pubmed/23814399"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23814399",
                    "text": "Kummell disease, or avascular necrosis of a vertebral body, presents as vertebral osteonecrosis typically affecting a thoracic vertebra with compression deformity, intravertebral vacuum cleft, and exaggerated kyphosis weeks to months after a minor traumatic injury.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 265,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19124637",
                    "text": "Kummel disease is the eponym for avascular necrosis of the vertebral body after a vertebral compression fracture.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22220246",
                    "text": "Kummell's disease is a spinal disorder characterized by delayed post-traumatic collapse of a vertebral body with avascular necrosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19321060",
                    "text": "Avascular necrosis of a vertebral body, a relatively uncommon entity, is caused by malignancy, infection, radiation, systemic steroid treatment, trauma, and the like.1 Vertebral osteonecrosis induced by trauma is called Kvmell's disease, because it was initially described by Hermann Kvmell of Germany in 1891.2 This paper reported a young female with posttraumatic vertebral osteonecrosis and analyzed the causes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 414,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031",
                    "text": "SUMMARY OF BACKGROUND DATA Avascular necrosis of a vertebral body is an uncommon entity.",
                    "offsetInBeginSection": 276,
                    "offsetInEndSection": 364,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19214087",
                    "text": "Surgical treatment is required in avascular necrosis of a vertebral body with progressive collapse and neurologic compromise secondary to osteoporotic fracture adjacent to a wedge-shaped vertebra at the thoracolumbar junction.",
                    "offsetInBeginSection": 1027,
                    "offsetInEndSection": 1253,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031",
                    "text": "The intravertebral vacuum cleft phenomenon seen on plain films has been strongly associated with vertebral body avascular necrosis.",
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 665,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12865850",
                    "text": "The indicators of the condition included spinal instability associated with avascular necrosis, which was diagnosed by a vacuum phenomenon or by fluid collection in the vertebral body as found from imaging studies.",
                    "offsetInBeginSection": 810,
                    "offsetInEndSection": 1024,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19214087",
                    "text": "CONCLUSION Despite solid posterior fusion segments, avascular necrosis of a vertebral body developed without trauma.",
                    "offsetInBeginSection": 774,
                    "offsetInEndSection": 890,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12865850",
                    "text": "STUDY DESIGN A retrospective clinical study on the effect of percutaneous vertebroplasty (PVP) in the treatment of intravertebral pseudarthrosis caused by avascular necrosis of a vertebral body.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 194,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a895a96fcd1d6a10c000003",
            "body": "Can a circRNA be translated into protein?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28344080",
                "http://www.ncbi.nlm.nih.gov/pubmed/28344082",
                "http://www.ncbi.nlm.nih.gov/pubmed/25449546",
                "http://www.ncbi.nlm.nih.gov/pubmed/28634583",
                "http://www.ncbi.nlm.nih.gov/pubmed/28223408",
                "http://www.ncbi.nlm.nih.gov/pubmed/29116363",
                "http://www.ncbi.nlm.nih.gov/pubmed/28705773",
                "http://www.ncbi.nlm.nih.gov/pubmed/29028266",
                "http://www.ncbi.nlm.nih.gov/pubmed/27612318",
                "http://www.ncbi.nlm.nih.gov/pubmed/29036403"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28344082",
                    "text": "Circ-ZNF609 is associated with heavy polysomes, and it is translated into a protein in a splicing-dependent and cap-independent manner, providing an example of a protein-coding circRNA in eukaryotes.",
                    "offsetInBeginSection": 910,
                    "offsetInEndSection": 1109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25449546",
                    "text": "The resulting circRNA can be translated to generate functional proteins.",
                    "offsetInBeginSection": 792,
                    "offsetInEndSection": 864,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28223408",
                    "text": "This subsequently results in back-splicing of the 5' cleavage product into a circRNA that can translate a reporter protein from an internal ribosomal entry site (IRES).",
                    "offsetInBeginSection": 698,
                    "offsetInEndSection": 866,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28223408",
                    "text": "Here we describe a switch for inducing back-splicing of an engineered circRNA that relies on the CRISPR endoribonuclease, Csy4, as an activator of circularization.",
                    "offsetInBeginSection": 271,
                    "offsetInEndSection": 434,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29028266",
                    "text": "To gain insights into the new area of circRNA translation, we introduce an integrated tool capable of detecting circRNAs with protein-coding potential from high-throughput sequencing data.",
                    "offsetInBeginSection": 645,
                    "offsetInEndSection": 833,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28705773",
                    "text": "Third, they can be translated into protein driven by N6-methyladenosine modification.",
                    "offsetInBeginSection": 446,
                    "offsetInEndSection": 531,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28344080",
                    "text": "In addition, we found that a circRNA generated from the muscleblind locus encodes a protein, which we detected in fly head extracts by mass spectrometry.",
                    "offsetInBeginSection": 466,
                    "offsetInEndSection": 619,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036403",
                    "text": "We constructed a cancer-specific circRNA database (CSCD, http://gb.whu.edu.cn/CSCD).",
                    "offsetInBeginSection": 643,
                    "offsetInEndSection": 727,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29036403",
                    "text": "Circular RNA (circRNA) is a large group of RNA family extensively existed in cells and tissues.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25449546",
                    "text": "Here we constructed a single exon minigene containing split GFP, and found that the pre-mRNA indeed produces circRNA through efficient backsplicing in human and Drosophila cells.",
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 483,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a67afb7b750ff445500000d",
            "body": "List main clinical features of the POEMS syndrome.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2227242",
                "http://www.ncbi.nlm.nih.gov/pubmed/10378364",
                "http://www.ncbi.nlm.nih.gov/pubmed/27208909",
                "http://www.ncbi.nlm.nih.gov/pubmed/25984208",
                "http://www.ncbi.nlm.nih.gov/pubmed/8699962",
                "http://www.ncbi.nlm.nih.gov/pubmed/22453306"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27208909",
                    "text": "POEMS is an acronym for the main clinical features of the syndrome, namely, Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin abnormalities.",
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 293,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27208909",
                    "text": "POEMS syndrome is a paraneoplastic manifestation associated with hematopoietic disorders such as multiple myeloma and Castleman disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27208909",
                    "text": "Glomeruloid hemangiomas are considered to be a specific clinical marker of POEMS syndrome.",
                    "offsetInBeginSection": 294,
                    "offsetInEndSection": 384,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25984208",
                    "text": "The acronym POEMS is derived from main features of the syndrome namely 'polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin lesions'.",
                    "offsetInBeginSection": 92,
                    "offsetInEndSection": 250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25984208",
                    "text": "POEMS syndrome is a rare conglomeration of disorders associated with plasma cell dyscrasia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 91,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364",
                    "text": "The patient had many clinical features of the described POEMS syndrome including sclerotic bone lesions, a persistent lambda-paraprotein and refractory ascites.",
                    "offsetInBeginSection": 541,
                    "offsetInEndSection": 701,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25984208",
                    "text": "Myeloma is the most common plasma cell dyscrasia associated with POEMS syndrome.",
                    "offsetInBeginSection": 422,
                    "offsetInEndSection": 502,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8699962",
                    "text": "The POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammapathy, and skin changes) syndrome is a rare variant of plasma cell dyscrasia with multisystemic manifestations.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364",
                    "text": "The POEMS syndrome is a rare multisystemic disorder with polyneuropathy, organomegaly, endocrinopathy of various forms, production of monoclonal (M) component, and skin changes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2227242",
                    "text": "A 39-year-old woman presented with polyneuropathy, hepatomegaly, splenomegaly, endocrinopathy, monoclonal protein and skin changes, several of the many clinical features of the recently described POEMS syndrome.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a89528dfcd1d6a10c000001",
            "body": "Where do centromeres locate according to the Rabl orientation of eukaryotic nuclei?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/9886774",
                "http://www.ncbi.nlm.nih.gov/pubmed/21674259",
                "http://www.ncbi.nlm.nih.gov/pubmed/11559751",
                "http://www.ncbi.nlm.nih.gov/pubmed/20501974",
                "http://www.ncbi.nlm.nih.gov/pubmed/26208647",
                "http://www.ncbi.nlm.nih.gov/pubmed/15102067"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11559751",
                    "text": "The Rabl orientation is an example of the non-random arrangement of chromosomes, centromeres are grouped in a limited area near the nuclear periphery and telomeres are located apart from centromeres.",
                    "offsetInBeginSection": 52,
                    "offsetInEndSection": 251,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20501974",
                    "text": "Small genome species have chromosomes in their interphase nuclei disposed in diffuse chromosome territories, without any Rabl arrangement, while in large genomes the chromosomes run string-like through the nucleus with a Rabl orientation following through the cell cycle.",
                    "offsetInBeginSection": 211,
                    "offsetInEndSection": 482,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774",
                    "text": "Both Rabl and non-Rabl distribution patterns of centromeres and telomeres were consistent in interphase nuclei derived from meristematic root tip cells, microspore mother cells and differentiated leaf cells.",
                    "offsetInBeginSection": 659,
                    "offsetInEndSection": 866,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15102067",
                    "text": "In wheat and its close relatives, the interphase chromosomes adopt a highly regular Rabl configuration, with the two chromosome arms lying next to each other and the centromeres and telomeres located at opposite poles of the nuclei.",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 575,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21674259",
                    "text": "Applying fluorescence in situ hybridization, we found that both rye A and B chromosomes added to hexaploid wheat showed in meristematic nuclei a string-like shape and a clear Rabl orientation.",
                    "offsetInBeginSection": 259,
                    "offsetInEndSection": 451,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11559751",
                    "text": "The existence of the triplex structure (centromere-microtubule-Sad1 body) suggests that the clustering of centromeres is controlled by a cytoplasmic microtubular system.",
                    "offsetInBeginSection": 944,
                    "offsetInEndSection": 1113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15102067",
                    "text": "By contrast, the chromosomes in most rice nuclei clearly do not show a Rabl configuration.",
                    "offsetInBeginSection": 576,
                    "offsetInEndSection": 666,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21674259",
                    "text": "Whereas in differentiated 4C nuclei A sister centromeres are separated, B sister centromeres align in nearly all nuclei.",
                    "offsetInBeginSection": 748,
                    "offsetInEndSection": 868,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774",
                    "text": "Such a polarized orientation of centromeres and telomeres is believed to be preserved in the interphase and is known as Rabl model.",
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 267,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21674259",
                    "text": "But the deletion of a B chromosome segment responsible for non-disjunction during gametogenesis induces released sister centromeres also in some interphase nuclei of somatic tissue.",
                    "offsetInBeginSection": 1059,
                    "offsetInEndSection": 1240,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e18d8b750ff4455000038",
            "body": "Are Conserved Nonexonic Elements (CNEEs) important in phylogenomics research?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28637293"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293",
                    "text": "Here we analyze and study the evolutionary properties of a new type of noncoding marker, conserved nonexonic elements (CNEEs), which consists of noncoding elements that are estimated to evolve slower than the neutral rate across a set of species.",
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 536,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293",
                    "text": "Thus far, ultraconserved elements (UCEs) and introns have been the most widely used noncoding markers.",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 289,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293",
                    "text": "Comparison of phylogenetic results across the three marker types indicated that one branch, the sister group to the passerine + falcon clade, was resolved differently and with moderate (>70%) bootstrap support between CNEEs and UCEs or introns.",
                    "offsetInBeginSection": 1314,
                    "offsetInEndSection": 1558,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293",
                    "text": "Overall, CNEEs appear to be promising as phylogenomic markers, yielding phylogenetic resolution as high as for UCEs and introns but with fewer gaps, less ambiguity in alignments and with patterns of nucleotide substitution more consistent with the assumptions of commonly used methods of phylogenetic analysis.",
                    "offsetInBeginSection": 1559,
                    "offsetInEndSection": 1869,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293",
                    "text": "Using a data set of 16 birds plus an alligator outgroup, and \u223c3600-\u223c3800 loci per marker type, we found that although CNEEs were less variable than bioinformatically derived UCEs or introns and in some cases exhibited a slower approach to branch resolution as determined by phylogenomic subsampling, the quality of CNEE alignments was superior to those of the other markers, with fewer gaps and missing species.",
                    "offsetInBeginSection": 747,
                    "offsetInEndSection": 1162,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293",
                    "text": "Although they often include UCEs, CNEEs are distinct from UCEs because they are not ultraconserved, and, most importantly, the core region alone is analyzed, rather than both the core and its flanking regions.",
                    "offsetInBeginSection": 537,
                    "offsetInEndSection": 746,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293",
                    "text": "Noncoding markers have a particular appeal as tools for phylogenomic analysis because, at least in vertebrates, they appear less subject to strong variation in GC content among lineages.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 186,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293",
                    "text": "Phylogenetic resolution using coalescent approaches was comparable among the three marker types, with most nodes being fully and congruently resolved.",
                    "offsetInBeginSection": 1163,
                    "offsetInEndSection": 1313,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7361d83b9d13c708000005",
            "body": "What is miravirsen?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25385103",
                "http://www.ncbi.nlm.nih.gov/pubmed/24068553",
                "http://www.ncbi.nlm.nih.gov/pubmed/24354366",
                "http://www.ncbi.nlm.nih.gov/pubmed/27805315",
                "http://www.ncbi.nlm.nih.gov/pubmed/23534542",
                "http://www.ncbi.nlm.nih.gov/pubmed/26503793",
                "http://www.ncbi.nlm.nih.gov/pubmed/25218783",
                "http://www.ncbi.nlm.nih.gov/pubmed/23109665",
                "http://www.ncbi.nlm.nih.gov/pubmed/22545703",
                "http://www.ncbi.nlm.nih.gov/pubmed/24385319"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385103",
                    "text": "Combination studies of miravirsen with interferon \u03b12b, ribavirin, and nonnucleoside (VX-222) and nucleoside (2'-methylcytidine) inhibitors of NS5B, NS5A (BMS-790052), or NS3 (telaprevir) indicated additive interactions.",
                    "offsetInBeginSection": 461,
                    "offsetInEndSection": 681,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385103",
                    "text": "Miravirsen is a \u03b2-D-oxy-locked nucleic acid-modified phosphorothioate antisense oligonucleotide targeting the liver-specific microRNA-122 (miR-122).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24385319",
                    "text": "Currently, the most advanced miR-122 targeting therapy is SPC3649 (miravirsen), a locked nucleic acid-modified oligonucleotide antagonizing miR-122.",
                    "offsetInBeginSection": 388,
                    "offsetInEndSection": 536,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27805315",
                    "text": "Miravirsen, a locked-nucleic acid oligonucleotide, sequesters miR-122 and inhibits HCV replication.",
                    "offsetInBeginSection": 207,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068553",
                    "text": "Miravirsen is composed of locked nucleic acid (LNAs) ribonucleotides interspaced throughout a DNA phosphorothioate sequence complementary to mature miR-122.",
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 678,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23534542",
                    "text": "Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting its function.",
                    "offsetInBeginSection": 176,
                    "offsetInEndSection": 364,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22545703",
                    "text": "Miravirsen, an oligonucleotide with locked nucleic acid, binds to miR-122, potently inhibiting its activity.",
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 234,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23109665",
                    "text": "The most advanced of these programs targets the liver-expressed miRNA-122 using the locked nucleic acid (LNA)-modified antisense oligonucleotide miravirsen.",
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 428,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068553",
                    "text": "It is the target of miravirsen (SPC3649), an antimiR drug candidate currently in clinical testing for treatment of HCV infections.",
                    "offsetInBeginSection": 391,
                    "offsetInEndSection": 521,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27805315",
                    "text": "In conclusion, miravirsen delivery during NEVLP is a potential strategy to prevent HCV reinfection after LT.",
                    "offsetInBeginSection": 1095,
                    "offsetInEndSection": 1203,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7a44b4faa1ab7d2e000010",
            "body": "Is Loss of function one of the cardinal signs of inflammation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29135930",
                "http://www.ncbi.nlm.nih.gov/pubmed/28282278",
                "http://www.ncbi.nlm.nih.gov/pubmed/23583354"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354",
                    "text": "The cardinal signs of inflammation dolor, calor, tumor and rubor are intrinsically associated with events including vasodilatation, edema and leukocyte trafficking into the site of inflammation.",
                    "offsetInBeginSection": 246,
                    "offsetInEndSection": 440,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29135930",
                    "text": "As early as 2000 years ago, the Roman encyclopaedist Aulus Cornelius Celsus recognised four cardinal signs of this response-redness, heat, swelling and pain; a fifth sign is loss of function.[...",
                    "offsetInBeginSection": 60,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354",
                    "text": "If uncontrolled or unresolved, inflammation itself can lead to further tissue damage and give rise to chronic inflammatory diseases and autoimmunity with eventual loss of organ function.",
                    "offsetInBeginSection": 441,
                    "offsetInEndSection": 627,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282278",
                    "text": "Tumor, calor, rubor, and dolor describe four cardinal signs of inflammation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282278",
                    "text": "The fifth-functio laesa, or loss of function-was promulgated by Rudolf Virchow, who, in the 19th century, also noted an intricate link between inflammation and cancer.",
                    "offsetInBeginSection": 77,
                    "offsetInEndSection": 244,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354",
                    "text": "It is now evident that the resolution of inflammation is an active continuous process that occurs during an acute inflammatory episode.",
                    "offsetInBeginSection": 628,
                    "offsetInEndSection": 763,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282278",
                    "text": "However, the role of cancer inflammation in driving loss of therapeutic efficacy has only recently been fully appreciated, as a result of molecular and immunohistochemical approaches applied in clinical medicine and the availability of novel agents for modulating inflammation.",
                    "offsetInBeginSection": 245,
                    "offsetInEndSection": 522,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354",
                    "text": "Successful resolution requires activation of endogenous programs with switch from production of pro-inflammatory towards pro-resolving molecules, such as specific lipid mediators and annexin A1, and the non-phlogistic elimination of granulocytes by apoptosis with subsequent removal by surrounding macrophages.",
                    "offsetInBeginSection": 764,
                    "offsetInEndSection": 1074,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354",
                    "text": "Such strategies have proved beneficial in several pre-clinical models of inflammatory diseases, suggesting that pharmacological modulation of the resolution process may be useful for the treatment of chronic inflammatory diseases in humans.",
                    "offsetInBeginSection": 1362,
                    "offsetInEndSection": 1602,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29135930",
                    "text": "Inflammation is the body's response to injury or infection.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 59,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a89a20ffcd1d6a10c00000e",
            "body": "List factors that promote lymphangiogenesis.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16557570",
                "http://www.ncbi.nlm.nih.gov/pubmed/28804221",
                "http://www.ncbi.nlm.nih.gov/pubmed/25142796",
                "http://www.ncbi.nlm.nih.gov/pubmed/26968383",
                "http://www.ncbi.nlm.nih.gov/pubmed/22967508",
                "http://www.ncbi.nlm.nih.gov/pubmed/18519975",
                "http://www.ncbi.nlm.nih.gov/pubmed/19958632",
                "http://www.ncbi.nlm.nih.gov/pubmed/16611067",
                "http://www.ncbi.nlm.nih.gov/pubmed/26706909",
                "http://www.ncbi.nlm.nih.gov/pubmed/16793912"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25142796",
                    "text": "Here, we report that sine oculis homeobox homolog 1 (SIX1), expressed in tumor cells, can promote tumor lymphangiogenesis and lymph node metastasis by coordinating with TGF\u03b2 to increase the expression of VEGF-C. Lymphangiogenesis and lymph node metastasis in cervical cancer were closely correlated with higher expression of SIX1 in tumor cells.",
                    "offsetInBeginSection": 210,
                    "offsetInEndSection": 556,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22967508",
                    "text": "Here we show that FGF-2 and VEGF-C, two lymphangiogenic factors, collaboratively promote angiogenesis and lymphangiogenesis in the tumor microenvironment, leading to widespread pulmonary and lymph-node metastases.",
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 346,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18519975",
                    "text": "Other signaling molecules that have been reported to promote lymphangiogenesis and/or lymphatic metastasis in cancer include VEGF-A, platelet-derived growth factor-BB, and hepatocyte growth factor.",
                    "offsetInBeginSection": 809,
                    "offsetInEndSection": 1006,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19958632",
                    "text": "Several members of vascular endothelial growth factor (VEGF) family, such as VEGF-C, VEGF-D, and VEGF receptor-3 (VEGFR-3), have been found to promote lymphangiogenesis in breast cancer.",
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 439,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26968383",
                    "text": "CONCLUSIONS This study suggested that HCM from MSCs contain high levels of secreted lymphangiogenic factors and promote lymphangiogenesis by regulating mitochondrial-related factors.",
                    "offsetInBeginSection": 1112,
                    "offsetInEndSection": 1294,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25142796",
                    "text": "Malignant tumors release growth factors such as VEGF-C to induce lymphangiogenesis, thereby promoting lymph node metastasis.",
                    "offsetInBeginSection": 85,
                    "offsetInEndSection": 209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16557570",
                    "text": "More recent studies have identified other signaling molecules that can also promote lymphangiogenesis in vivo, including hepatocyte growth factor and members of the fibroblast growth factor, angiopoietin, platelet-derived growth factor and insulin-like growth factor families of secreted proteins.",
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 1103,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16793912",
                    "text": "Our recent findings indicate that VEGF-A also acts as a potent tumor lymphangiogenesis factor that promotes lymphatic tumor spread.",
                    "offsetInBeginSection": 698,
                    "offsetInEndSection": 829,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26706909",
                    "text": "The most extensively accepted signaling pathways promoting lymphangiogenesis in tumors include the secreted lymphangiogenic proteins: vascular endothelial growth factor-C (VEGF-C) and VEGF-D, and their cognate receptor on lymphatic endothelium VEGF receptor-3 (VEGFR-3).",
                    "offsetInBeginSection": 555,
                    "offsetInEndSection": 825,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16557570",
                    "text": "The most extensively studied signaling system that promotes lymphangiogenesis in tumors involves the secreted lymphangiogenic proteins vascular endothelial growth factor-C (VEGF-C) and VEGF-D, and their cognate receptor on lymphatic endothelium VEGF receptor-3 (VEGFR-3).",
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a68f448b750ff4455000018",
            "body": "Which bacteria causes erythrasma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21393451",
                "http://www.ncbi.nlm.nih.gov/pubmed/7969634",
                "http://www.ncbi.nlm.nih.gov/pubmed/25477907",
                "http://www.ncbi.nlm.nih.gov/pubmed/6859802",
                "http://www.ncbi.nlm.nih.gov/pubmed/12010076",
                "http://www.ncbi.nlm.nih.gov/pubmed/27294050",
                "http://www.ncbi.nlm.nih.gov/pubmed/3965026",
                "http://www.ncbi.nlm.nih.gov/pubmed/9614412",
                "http://www.ncbi.nlm.nih.gov/pubmed/8469500",
                "http://www.ncbi.nlm.nih.gov/pubmed/15189194"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6859802",
                    "text": "Corynebacteria causes erythrasma, trichomycosis or pitted keratolysis.",
                    "offsetInBeginSection": 403,
                    "offsetInEndSection": 473,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12010076",
                    "text": "Corynebacterium minutissimum is the bacteria that leads to cutaneous eruptions of erythrasma and is the most common cause of interdigital foot infections.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9614412",
                    "text": "Bacterial skin infections caused by corynebacteria include erythrasma, trichomycosis axillaris and pitted keratolysis.",
                    "offsetInBeginSection": 215,
                    "offsetInEndSection": 333,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3965026",
                    "text": "It is a common mucocutaneous inhabitant which causes erythrasma.",
                    "offsetInBeginSection": 258,
                    "offsetInEndSection": 322,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21393451",
                    "text": "Erythrasma is a superficial skin disease caused by Gram-positive Corynebacterium species.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9614412",
                    "text": "The many dermatomycoses (skin infections caused by fungi or yeasts) include tinea capitis, tinea barbae, tinea cruris, tinea manus, tinea pedis and tinea unguium (onychomycosis).",
                    "offsetInBeginSection": 630,
                    "offsetInEndSection": 808,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25477907",
                    "text": "Erythrasma caused by Corynebacterium minutissimum can be confused with superficial mycoses.",
                    "offsetInBeginSection": 115,
                    "offsetInEndSection": 206,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15189194",
                    "text": "Pityriasis versicolor (PV) is a widespread dermatomycosis caused by yeasts.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 75,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9614412",
                    "text": "Skin infections are common and may be caused by bacteria, fungi or viruses.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 75,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25477907",
                    "text": "Interdigital foot infections are mostly caused initially by dermatophytes, yeasts and less frequently by bacteria.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a89537cfcd1d6a10c000002",
            "body": "Are mouse chromosomes acrocentric?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/6538846",
                "http://www.ncbi.nlm.nih.gov/pubmed/7606923",
                "http://www.ncbi.nlm.nih.gov/pubmed/8528584",
                "http://www.ncbi.nlm.nih.gov/pubmed/23030344",
                "http://www.ncbi.nlm.nih.gov/pubmed/2767161",
                "http://www.ncbi.nlm.nih.gov/pubmed/11387219",
                "http://www.ncbi.nlm.nih.gov/pubmed/6177004",
                "http://www.ncbi.nlm.nih.gov/pubmed/2832136",
                "http://www.ncbi.nlm.nih.gov/pubmed/100785",
                "http://www.ncbi.nlm.nih.gov/pubmed/1733676"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2832136",
                    "text": "Among centromeric C-bands, the heterochromatin in Robertsonian fusion biarmed chromosomes was more resistant to DNase I action than was the centromeric heterochromatin of the acrocentric chromosomes.",
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 717,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11387219",
                    "text": "Human ribosomal gene repeats are distributed among five nucleolar organizer regions (NORs) on the p arms of acrocentric chromosomes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7606923",
                    "text": "Chromosome 19 and the sex chromosomes are the only acrocentric chromosomes.",
                    "offsetInBeginSection": 574,
                    "offsetInEndSection": 649,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846",
                    "text": "The resulting metacentric chromosomes are very different in size and in morphology from normal mouse acrocentric chromosomes.",
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 452,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/100785",
                    "text": "The two mouse stocks exhibit karyotypes consisting of nine pairs of metacentric chromosomes as a result of centric fusions of acrocentric chromosomes in different combinations.",
                    "offsetInBeginSection": 240,
                    "offsetInEndSection": 416,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/100785",
                    "text": "In the hybrid cells these metacentric chromosomes can be distinguished from the acrocentric chromosomes of myeloma origin, permitting correlation of Ig chain expression with mitotic loss of individual metacentric chromosomes.",
                    "offsetInBeginSection": 417,
                    "offsetInEndSection": 642,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23030344",
                    "text": "In an Rb heterozygote, DNA probes from laboratory mouse chromosomes (MMUs) 1 and 10 were simultaneously hybridized to the long arm of a metacentric and a medium-sized acrocentric chromosome and to the short arm of the metacentric and a small acrocentric chromosome, respectively.",
                    "offsetInBeginSection": 388,
                    "offsetInEndSection": 667,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1733676",
                    "text": "As in V. faba, all acrocentric mouse chromosomes were labeled by in situ hybridization with a vertebrate telomeric probe at both ends of each chromatid exclusively.",
                    "offsetInBeginSection": 393,
                    "offsetInEndSection": 557,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2832136",
                    "text": "These were the centromeric heterochromatin of acro- and metacentric chromosomes and an interstitial C-band on chromosome 1 of wild mice, IS(HSR;1C5D)1Lub.",
                    "offsetInBeginSection": 227,
                    "offsetInEndSection": 381,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8528584",
                    "text": "It seems likely that the breakpoints required for a Robertsonian process do not include telomeric sites exclusively but extend to the adjacent pericentromeric regions of the original acrocentric chromosomes.",
                    "offsetInBeginSection": 597,
                    "offsetInEndSection": 804,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e1db0b750ff4455000039",
            "body": "What is Q-nexus?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27814676"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676",
                    "text": "An implementation of Q-nexus is available at http://charite.github.io/Q/ .",
                    "offsetInBeginSection": 1550,
                    "offsetInEndSection": 1624,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676",
                    "text": "CONCLUSIONS The Q-nexus software is efficient and easy to use.",
                    "offsetInBeginSection": 1046,
                    "offsetInEndSection": 1108,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676",
                    "text": "BACKGROUND ChIP-nexus, an extension of the ChIP-exo protocol, can be used to map the borders of protein-bound DNA sequences at nucleotide resolution, requires less input DNA and enables selective PCR duplicate removal using random barcodes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 240,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676",
                    "text": "RESULTS Here, we present a comprehensive software package for ChIP-nexus data that exploits the random barcodes for selective removal of PCR duplicates and for quality control.",
                    "offsetInBeginSection": 565,
                    "offsetInEndSection": 741,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676",
                    "text": "To date, only a very limited number of software packages are available for the analysis of ChIP-exo data, which have not yet been systematically tested and compared on ChIP-nexus data.",
                    "offsetInBeginSection": 378,
                    "offsetInEndSection": 562,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676",
                    "text": "Furthermore, we developed bespoke methods to estimate the width of the protected region resulting from protein-DNA binding and to infer binding positions from ChIP-nexus data.",
                    "offsetInBeginSection": 742,
                    "offsetInEndSection": 917,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676",
                    "text": "Finally, we applied our peak calling method as well as the two other methods MACE and MACS2 to the available ChIP-nexus data.",
                    "offsetInBeginSection": 918,
                    "offsetInEndSection": 1043,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676",
                    "text": "As judged by the irreproducible discovery rate (IDR), our peak calling algorithm shows a substantially better reproducibility.",
                    "offsetInBeginSection": 1423,
                    "offsetInEndSection": 1549,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676",
                    "text": "Our method for the estimation of the width of the protected region yields unbiased signatures that are highly reproducible for biological replicates and at the same time very specific for the respective factors analyzed.",
                    "offsetInBeginSection": 1202,
                    "offsetInEndSection": 1422,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676",
                    "text": "However, the use of random barcodes requires additional preprocessing of the mapping data, which complicates the computational analysis.",
                    "offsetInBeginSection": 241,
                    "offsetInEndSection": 377,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a74a8a70384be9551000005",
            "body": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27147553",
                "http://www.ncbi.nlm.nih.gov/pubmed/24432033",
                "http://www.ncbi.nlm.nih.gov/pubmed/19853645",
                "http://www.ncbi.nlm.nih.gov/pubmed/26930249",
                "http://www.ncbi.nlm.nih.gov/pubmed/26000366",
                "http://www.ncbi.nlm.nih.gov/pubmed/27316377",
                "http://www.ncbi.nlm.nih.gov/pubmed/28423924",
                "http://www.ncbi.nlm.nih.gov/pubmed/21744502",
                "http://www.ncbi.nlm.nih.gov/pubmed/28085753",
                "http://www.ncbi.nlm.nih.gov/pubmed/21330062"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27316377",
                    "text": "We hope that Nek2 siRNA will be a novel therapeutic strategy for pancreatic cancer with liver metastasis and peritoneal dissemination.",
                    "offsetInBeginSection": 1304,
                    "offsetInEndSection": 1438,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27147553",
                    "text": "LOcal Drug EluteR (LODER(TM)) is a novel biodegradable polymeric matrix that shields drugs against enzymatic degradation and releases small interfering RNA (siRNA) against G12D-mutated KRAS (siG12D).",
                    "offsetInBeginSection": 170,
                    "offsetInEndSection": 369,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26000366",
                    "text": "Additionally, potential of target based therapeutic agents and nanomedicines in clinical trials for the pancreatic cancer therapy are highlighted.",
                    "offsetInBeginSection": 1075,
                    "offsetInEndSection": 1221,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21330062",
                    "text": "Although gemcitabine has been established as the standard first-line treatment for advanced pancreatic cancer, gemcitabine-based combination chemotherapy showed either marginal or no improvement in survival.",
                    "offsetInBeginSection": 197,
                    "offsetInEndSection": 404,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19853645",
                    "text": "Using liposomes, nanoparticles, and carbon nanotubes to deliver cancer drugs and other therapeutic agents such as siRNA, suicide gene, oncolytic virus, small molecule inhibitor, and antibody has been a success in recent preclinical trials.",
                    "offsetInBeginSection": 301,
                    "offsetInEndSection": 540,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27316377",
                    "text": "Taken together, Nek2 is an effective therapeutic target in pancreatic cancer.",
                    "offsetInBeginSection": 969,
                    "offsetInEndSection": 1046,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27316377",
                    "text": "Nek2 siRNA inhibited tumor growth in a subcutaneous xenograft mouse model of pancreatic cancer, prolonged the survival time in an intraperitoneal xenograft mouse model and efficiently prevented the progression of liver metastasis using a portal venous port-catheter system.",
                    "offsetInBeginSection": 695,
                    "offsetInEndSection": 968,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27316377",
                    "text": "We reported the efficiency of Nek2 siRNA in several cancer xenograft models using cholangiocarcinoma, breast cancer and colorectal cancer.",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 268,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28423924",
                    "text": "Herein, we review the barriers, potential siRNA drug delivery systems, and application of siRNA in clinical trials for cancer therapy.",
                    "offsetInBeginSection": 528,
                    "offsetInEndSection": 662,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24432033",
                    "text": "Despite significant preclinical data, there are currently very few clinical trials involving pancreatic cancer targeted drug delivery.",
                    "offsetInBeginSection": 1019,
                    "offsetInEndSection": 1153,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a678d63b750ff4455000003",
            "body": "What are the 4 cardinal signs of inflammation according to Celsus?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12799851",
                "http://www.ncbi.nlm.nih.gov/pubmed/29135930",
                "http://www.ncbi.nlm.nih.gov/pubmed/15041917",
                "http://www.ncbi.nlm.nih.gov/pubmed/7734328"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12799851",
                    "text": "It was Galen who added the disturbance of function (functio laesa) as the fifth cardinal sign of inflammation to the four well-known cardinal signs of Celsus (rubor, calor, tumor, dolor).",
                    "offsetInBeginSection": 1008,
                    "offsetInEndSection": 1195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15041917",
                    "text": "In fact it has been understood that behind the typical signs of inflammation (the famous four cardinal signs of Celsus: pain, redness, swelling, heat) no abstract entities or strange alchemies are concealed, but a series of well-known, classified substance, the so-called \"inflammation mediators\", namely a variety of substances of cellular or plasmatic origin united by the fact that exist, in stationary state conditions, in the form of inactive precursors, or sequestered in intracellular sites where they are unable to carry out their action.",
                    "offsetInBeginSection": 936,
                    "offsetInEndSection": 1482,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29135930",
                    "text": "As early as 2000 years ago, the Roman encyclopaedist Aulus Cornelius Celsus recognised four cardinal signs of this response-redness, heat, swelling and pain; a fifth sign is loss of function.[...",
                    "offsetInBeginSection": 60,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7734328",
                    "text": "He bases his observations on the four cardinal signs of Celsus (redness, heat, swelling and pain).",
                    "offsetInBeginSection": 575,
                    "offsetInEndSection": 673,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12799851",
                    "text": "According to semiotics, which may be defined as the doctrine of the essential nature and fundamental varieties of signs, objects, and interpretants, pain is considered to be a sign (significant) with very different meanings (significance) either as a naturalistic symptom (of disease) or as a symbol used in a metaphorical context.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 331,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7734328",
                    "text": "Although unaware of the role of infecting organisms as a cause of inflammation, he makes observations on inflammation in smallpox, venereal infections and tuberculosis.",
                    "offsetInBeginSection": 1057,
                    "offsetInEndSection": 1225,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12799851",
                    "text": "Aristotle (4th century B. C.), Celsus (1st century A. D.), and the famous experimental physiologist Galen (2nd century A. D.) agreed that pain was a sign of evil which should be fought without exception.",
                    "offsetInBeginSection": 804,
                    "offsetInEndSection": 1007,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15041917",
                    "text": "Following an inflammatory stimulus, they are activated, or their synthesis can be induced, or their release from intracellular sequestration sites in favoured; in any case they are stored in the disturbance district in concentrations that are such as to act on their respective targets, triggering event s that characterise the various stages of the inflammatory process.",
                    "offsetInBeginSection": 1483,
                    "offsetInEndSection": 1854,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29135930",
                    "text": "Inflammation is the body's response to injury or infection.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 59,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15041917",
                    "text": "Vatous observations carried out in the course of the years have shown that certain neuropeptides have a possible role to play as inflammation mediators.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8a9abdfcd1d6a10c000019",
            "body": "List polyubiquitin binding proteins involved in NF-kappaB signaling.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19285159"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159",
                    "text": "Protein array screening using polyubiquitin enabled rapid identification of many known and novel polyubiquitin binding proteins and the identification of novel NF-kappaB regulators.",
                    "offsetInBeginSection": 1136,
                    "offsetInEndSection": 1317,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159",
                    "text": "We have used protein arrays to identify polyubiquitin binding proteins that regulate NF-kappaB activity.",
                    "offsetInBeginSection": 358,
                    "offsetInEndSection": 462,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159",
                    "text": "Novel polyubiquitin binders AWP1, CALCOCO2, N4BP1, RIO3, TEX27, TTC3, UBFD1 and ZNF313 were identified using this approach, while known NF-kappaB regulators including NEMO, A20, ABIN-1, ABIN-2, optineurin and p62 were also identified.",
                    "offsetInBeginSection": 559,
                    "offsetInEndSection": 793,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159",
                    "text": "Other polyubiquitin binding proteins can antagonize this pathway by competing with NEMO for polyubiquitin.",
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 357,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159",
                    "text": "In the NF-kappaB pathway, binding of NEMO to polyubiquitinated substrates initiates the pathway in response to cellular stimuli.",
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159",
                    "text": "Overexpressed AWP1 and RIO3 repressed NF-kappaB activity in a manner similar to optineurin, while siRNAs directed against AWP1 and RIO3 also reduced NF-kappaB activity.",
                    "offsetInBeginSection": 794,
                    "offsetInEndSection": 962,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159",
                    "text": "Using polyubiquitin as bait, protein arrays were screened and polyubiquitin binders identified.",
                    "offsetInBeginSection": 463,
                    "offsetInEndSection": 558,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159",
                    "text": "TNFalpha-dependent degradation of IkappaBalpha was also suppressed by overexpression of AWP1 and RIO3, possibly due to the polyubiquitin binding activity of these proteins.",
                    "offsetInBeginSection": 963,
                    "offsetInEndSection": 1135,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159",
                    "text": "Attachment of ubiquitin to proteins represents a central mechanism for the regulation of protein metabolism and function.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a690487b750ff445500001f",
            "body": "Which virus can be diagnosed with the monospot test?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26275628",
                "http://www.ncbi.nlm.nih.gov/pubmed/28130396",
                "http://www.ncbi.nlm.nih.gov/pubmed/20086647",
                "http://www.ncbi.nlm.nih.gov/pubmed/24650116",
                "http://www.ncbi.nlm.nih.gov/pubmed/19772007",
                "http://www.ncbi.nlm.nih.gov/pubmed/23918629",
                "http://www.ncbi.nlm.nih.gov/pubmed/17217023",
                "http://www.ncbi.nlm.nih.gov/pubmed/11369969",
                "http://www.ncbi.nlm.nih.gov/pubmed/21108750",
                "http://www.ncbi.nlm.nih.gov/pubmed/11298158"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20086647",
                    "text": "Subsequent clinical, laboratory, and serologic evaluation revealed that he, in fact, had a latent infection with Epstein-Barr virus (EBV), a current viral syndrome, and a false-positive Monospot test.",
                    "offsetInBeginSection": 143,
                    "offsetInEndSection": 343,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17217023",
                    "text": "Infectious mononucleosis cases were diagnosed by clinical triad of fever, pharyngitis and cervical lymphadenopathy, relative lymphocytosis, monocytosis and positive monospot test.",
                    "offsetInBeginSection": 784,
                    "offsetInEndSection": 963,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17217023",
                    "text": "Patients were subjected to careful history, thorough clinical examination, complete blood picture, tuberculin test, chest x-ray, Monospot test, indirect fluorescent antibody test for toxoplasmosis, detection of cytomegalovirus antibodies and lymph node biopsy with histopathological examination.",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 448,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17217023",
                    "text": "Cytomegalovirus case was diagnosed by lymphocytosis, monocytosis and negative monospot test.",
                    "offsetInBeginSection": 964,
                    "offsetInEndSection": 1056,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11369969",
                    "text": "His septic screen was negative, but he had a positive Monospot test and immunoglobulin G for Epstein-Barr virus.",
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 355,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396",
                    "text": "Heterophile antibody tests, including the Monospot test, are red cell or latex agglutination assays, which detect antired cell antibodies produced as part of a polyclonal antibody response occurring during EBV infection.",
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 419,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628",
                    "text": "Initial investigations revealed atypical lymphocytosis, thrombocytopenia, elevated liver enzymes, and a positive monospot test result.",
                    "offsetInBeginSection": 103,
                    "offsetInEndSection": 237,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396",
                    "text": "Epstein-Barr virus (EBV) is a highly prevalent virus, transmitted via saliva, which often causes asymptomatic infection in children but frequently results in infectious mononucleosis in adolescents.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628",
                    "text": "This case conveys that monospot test can yield false-positive result in the setting of acute CMV infection.",
                    "offsetInBeginSection": 697,
                    "offsetInEndSection": 804,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628",
                    "text": "Further investigation showed the Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV infection.",
                    "offsetInBeginSection": 238,
                    "offsetInEndSection": 547,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a896a06fcd1d6a10c000006",
            "body": "What is the phenomenon of gene kissing?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23099887",
                "http://www.ncbi.nlm.nih.gov/pubmed/17933509",
                "http://www.ncbi.nlm.nih.gov/pubmed/27785578",
                "http://www.ncbi.nlm.nih.gov/pubmed/26063576",
                "http://www.ncbi.nlm.nih.gov/pubmed/21059491",
                "http://www.ncbi.nlm.nih.gov/pubmed/25918627",
                "http://www.ncbi.nlm.nih.gov/pubmed/27403349",
                "http://www.ncbi.nlm.nih.gov/pubmed/26370077",
                "http://www.ncbi.nlm.nih.gov/pubmed/27721082",
                "http://www.ncbi.nlm.nih.gov/pubmed/9534425"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26063576",
                    "text": "Here, we show that the replication terminator protein Fob1 of Saccharomyces cerevisiae promoted chromosome kissing that initiated rDNA recombination and controlled the replicative life span (RLS).",
                    "offsetInBeginSection": 252,
                    "offsetInEndSection": 448,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27785578",
                    "text": "Ictal kissing is a rare semiological manifestation in patients with epilepsy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23099887",
                    "text": "This positioning can also result in the clustering of genes with similar expression patterns, a phenomenon sometimes called \"gene kissing.\"",
                    "offsetInBeginSection": 135,
                    "offsetInEndSection": 274,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25918627",
                    "text": "But, phenomenon of kissing molars is an extremely rare phenomenon.",
                    "offsetInBeginSection": 66,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26063576",
                    "text": "Oligomerization of Fob1 caused synaptic (kissing) interactions between pairs of terminator (Ter) sites that initiated recombination in rDNA.",
                    "offsetInBeginSection": 449,
                    "offsetInEndSection": 589,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26063576",
                    "text": "Protein-mediated \"chromosome kissing\" between two DNA sites in trans (or in cis) is known to facilitate three-dimensional control of gene expression and DNA replication.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27721082",
                    "text": "Kissing occurred at a median time of 71s (1-95s) after the onset of seizure, and ictal epileptiform discharges usually involved TL during kissing episode.",
                    "offsetInBeginSection": 920,
                    "offsetInEndSection": 1074,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27785578",
                    "text": "The most common underlying etiology for ictal kissing is hippocampal sclerosis.",
                    "offsetInBeginSection": 1116,
                    "offsetInEndSection": 1195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27403349",
                    "text": "In some cases kissing molars can be seen but occurrence of bilateral kissing molars is extremely rare phenomenon in the dental literature and the aetiology of this phenomenon is still unknown.",
                    "offsetInBeginSection": 198,
                    "offsetInEndSection": 390,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17933509",
                    "text": "Nevertheless, several contacts between different chromosomal loci have been documented, a phenomenon called chromosome kissing.",
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 260,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e24a5b750ff445500003c",
            "body": "Which workflow in Bioconductor has been developed for accessing human RNA-seq samples?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29043067"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29043067",
                    "text": "The recount2 resource is composed of over 70,000 uniformly processed human RNA-seq samples spanning TCGA and SRA, including GTEx.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29043067",
                    "text": "This workflow explains in detail how to use the  package and how to integrate it with other Bioconductor packages for several analyses that can be carried out with the recount2 resource.",
                    "offsetInBeginSection": 221,
                    "offsetInEndSection": 407,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29043067",
                    "text": "The processed data can be accessed via the recount2 website and the  Bioconductor package.",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 220,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29043067",
                    "text": "This workflow thus provides further information to understand the data in recount2 and a compendium of R code to use the data.",
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 898,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29043067",
                    "text": "In particular, we describe how the coverage count matrices were computed in recount2 as well as different ways of obtaining public metadata, which can facilitate downstream analyses.",
                    "offsetInBeginSection": 408,
                    "offsetInEndSection": 590,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29043067",
                    "text": "Step-by-step directions show how to do a gene-level differential expression analysis, visualize base-level genome coverage data, and perform an analyses at multiple feature levels.",
                    "offsetInBeginSection": 591,
                    "offsetInEndSection": 771,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a74b1730384be9551000007",
            "body": "Which retinal dystrophy related gene is targeted by the AAV2-hRPE65v2 drug?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27375040",
                "http://www.ncbi.nlm.nih.gov/pubmed/29097191",
                "http://www.ncbi.nlm.nih.gov/pubmed/22323828"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097191",
                    "text": "Among many clinical trials of gene therapy for hereditary retinal diseases, a phase 3 clinical trial of voretigene neparvovec (AAV2-hRPE65v2, Luxturna) recently showed significant efficacy for RPE65-mediated inherited retinal dystrophy including Leber congenital amaurosis and RP.",
                    "offsetInBeginSection": 1047,
                    "offsetInEndSection": 1327,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375040",
                    "text": "BACKGROUND Safety and efficacy have been shown in a phase 1 dose-escalation study involving a unilateral subretinal injection of a recombinant adeno-associated virus (AAV) vector containing the RPE65 gene (AAV2-hRPE65v2) in individuals with inherited retinal dystrophy caused by RPE65 mutations.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 295,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375040",
                    "text": "INTERPRETATION To our knowledge, AAV2-hRPE65v2 is the first successful gene therapy administered to the contralateral eye.",
                    "offsetInBeginSection": 2135,
                    "offsetInEndSection": 2257,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22323828",
                    "text": "Demonstration of safe and stable reversal of blindness after a single unilateral subretinal injection of a recombinant adeno-associated virus (AAV) carrying the RPE65 gene (AAV2-hRPE65v2) prompted us to determine whether it was possible to obtain additional benefit through a second administration of the AAV vector to the contralateral eye.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 341,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097191",
                    "text": "Despite current limitations such as limited target genes and indicated patients, modest efficacy, and the invasive administration method, development in gene editing technology and novel gene delivery carriers make gene therapy a promising therapeutic modality for RP and other hereditary retinal dystrophies in the future.",
                    "offsetInBeginSection": 1406,
                    "offsetInEndSection": 1729,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097191",
                    "text": "Current therapies for RP in ongoing or completed clinical trials include gene therapy, cell therapy, and retinal prostheses.",
                    "offsetInBeginSection": 738,
                    "offsetInEndSection": 862,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097191",
                    "text": "Gene therapy, a strategy to correct the genetic defects using viral or non-viral vectors, has the potential to achieve definitive treatment by replacing or silencing a causative gene.",
                    "offsetInBeginSection": 863,
                    "offsetInEndSection": 1046,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22323828",
                    "text": "Results (through 6 months) including evaluations of immune response, retinal and visual function testing, and functional magnetic resonance imaging indicate that readministration is both safe and efficacious after previous exposure to AAV2-hRPE65v2.",
                    "offsetInBeginSection": 580,
                    "offsetInEndSection": 829,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097191",
                    "text": "It is about to be approved as the first ocular gene therapy biologic product.",
                    "offsetInBeginSection": 1328,
                    "offsetInEndSection": 1405,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097191",
                    "text": "Retinitis Pigmentosa (RP) is a hereditary retinopathy that affects about 2.5 million people worldwide.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a679875b750ff4455000004",
            "body": "Do bacteria from the genus Morexella cause respiratory infections?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
                "http://www.ncbi.nlm.nih.gov/pubmed/28063019",
                "http://www.ncbi.nlm.nih.gov/pubmed/28369241",
                "http://www.ncbi.nlm.nih.gov/pubmed/24786571",
                "http://www.ncbi.nlm.nih.gov/pubmed/25362808",
                "http://www.ncbi.nlm.nih.gov/pubmed/18619696",
                "http://www.ncbi.nlm.nih.gov/pubmed/28059171"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28059171",
                    "text": "Bacteria of the genus Legionella cause water-based infections resulting in severe pneumonia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24786571",
                    "text": "RESULTS Some plant species, such as Alchornea floribunda, Musanga cecropioides (both leaves and stem bark), Tetracera potatoria and Xylopia aethiopica (stem bark), were effective in inhibiting Morexella cattarhalis, having MIC values between 65 and 250 \u03bcg/mL.",
                    "offsetInBeginSection": 1221,
                    "offsetInEndSection": 1481,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369241",
                    "text": "The Gram-negative bacteria genus Neisseria includes both pathogenic and commensal species that are found primarily in the upper respiratory tract of humans and animals.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629",
                    "text": "The most common species recovered from the sputum specimens of these patients were Haemophilus influenzae, followed by Streptococcus pneumoniae (S. pneumoniae), Staphylococcus aureus (S. aureus), Gram positive cocci unidentified, Pseudomonas aeruginosa (P. aeruginosa), Morexella catarrhalis, Streptococcus epidermidis, and another Haemophilus species in this order.",
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 512,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28063019",
                    "text": "are opportunistic bacteria, which usually cause infections of the biliary tract, pneumonia and bacteraemia in oncologic and with lower immunity patients.",
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 675,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25362808",
                    "text": "At the concentration recommended by the producer, the preparation showed biocidal activity (MBC, MFC) against the strains of the pathogenic microorganisms, which cause respiratory infections most frequently, including, among others, Peptostreptococcus anaerobius, Parvimonas micra, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus anginosus, Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa and Candida albicans, already after 15 min.",
                    "offsetInBeginSection": 631,
                    "offsetInEndSection": 1124,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24786571",
                    "text": "CONCLUSION While moderate activity was shown for pathogens causing respiratory tract infections, these plant species seems to be selectively targeting Mycobacteria spp.",
                    "offsetInBeginSection": 1616,
                    "offsetInEndSection": 1784,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18619696",
                    "text": "Infections caused by species of the genus Mannheimia cause diverse disease complexes in many wild and domestic animals worldwide.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28369241",
                    "text": "These include Neisseria meningitidis, an obligate commensal that can cause invasive disease, and N. gonorrhoeae, the causative agent of gonorrhea.",
                    "offsetInBeginSection": 311,
                    "offsetInEndSection": 457,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28059171",
                    "text": "Illumina MiSeq 16S rRNA gene sequencing analyses of Legionella-positive and Legionella-negative sputum samples, confirmed that indeed, Legionella was present in the PCR-positive sputum samples.",
                    "offsetInBeginSection": 506,
                    "offsetInEndSection": 699,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8aa253fcd1d6a10c00001b",
            "body": "Which is the specificity of deubiquitinase USP25?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28327663",
                "http://www.ncbi.nlm.nih.gov/pubmed/23754700",
                "http://www.ncbi.nlm.nih.gov/pubmed/28538147",
                "http://www.ncbi.nlm.nih.gov/pubmed/26305951"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754700",
                    "text": "Ubiquitin Specific Protease 25 (USP25), a member of the deubiquitinase family, is involved in several disease-related signal pathways including myogenesis, immunity and protein degradation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28538147",
                    "text": "Ubiquitin-specific protease 25 (Usp25) is a deubiquitinase that is involved in multiple biological processes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26305951",
                    "text": "Here, we found that a viral infection-induced deubiquitinase (DUB), ubiquitin-specific protease 25 (USP25) was required for host defense against RNA and DNA viruses.",
                    "offsetInBeginSection": 210,
                    "offsetInEndSection": 375,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754700",
                    "text": "USP25 contains one ubiquitin-associated domain and two ubiquitin-interacting motifs (UIMs) in its N-terminal region, which interact with ubiquitin and play a role in substrate recognition.",
                    "offsetInBeginSection": 283,
                    "offsetInEndSection": 471,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28538147",
                    "text": "The N-terminal ubiquitin-binding region (UBR) of Usp25 contains one ubiquitin-associated domain, one small ubiquitin-like modifier (SUMO)-interacting motif and two ubiquitin-interacting motifs.",
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26305951",
                    "text": "Host pathogen-recognition receptors detect nucleic acid from invading viruses and initiate a series of signaling pathways that lead to the production of type I interferons (IFNs) and proinflammatory cytokines.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28327663",
                    "text": "Mutations that disrupted the ubiquitin-binding ability of the tandem UIMs resulted in a reduced ubiquitin isopeptidase activity of USP25, suggesting a role for the UIMs in exerting the full catalytic activity of USP25.",
                    "offsetInBeginSection": 532,
                    "offsetInEndSection": 750,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28327663",
                    "text": "Ubiquitin-specific protease (USP) 25, belonging to the USP family of deubiquitinases, harbors two tandem ubiquitin-interacting motifs (UIMs), a ~20-amino-acid \u03b1-helical stretch that binds to ubiquitin.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754700",
                    "text": "Besides, it has been shown that the catalysis activity of USP25 is either impaired by sumoylation or enhanced by ubiquitination within its UIM.",
                    "offsetInBeginSection": 472,
                    "offsetInEndSection": 615,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26305951",
                    "text": "USP25 was associated with TRAF3 and TRAF6 after infection by RNA or DNA viruses and protected virus-induced proteasome-dependent or independent degradation of TRAF3 and TRAF6, respectively.",
                    "offsetInBeginSection": 736,
                    "offsetInEndSection": 925,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70dbe599e2c3af26000004",
            "body": "Which two genes are implicated in Juvenile polyposis syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16152648",
                "http://www.ncbi.nlm.nih.gov/pubmed/9491322",
                "http://www.ncbi.nlm.nih.gov/pubmed/27326320",
                "http://www.ncbi.nlm.nih.gov/pubmed/21834858",
                "http://www.ncbi.nlm.nih.gov/pubmed/21465659",
                "http://www.ncbi.nlm.nih.gov/pubmed/25841492",
                "http://www.ncbi.nlm.nih.gov/pubmed/22171123",
                "http://www.ncbi.nlm.nih.gov/pubmed/17573831",
                "http://www.ncbi.nlm.nih.gov/pubmed/26837502",
                "http://www.ncbi.nlm.nih.gov/pubmed/26159157"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27326320",
                    "text": "These include familial adenomatous polyposis (FAP), Lynch syndromes (LS), Juvenile polyposis syndrome, Peutz-Jeghers syndrome, Crohn's disease (CD) and celiac disease.",
                    "offsetInBeginSection": 359,
                    "offsetInEndSection": 526,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21465659",
                    "text": "Juvenile polyposis syndrome (JPS) is caused by heterozygous mutations in either SMAD4 or BMPR1A.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25841492",
                    "text": "Other polyposis syndromes include the hamartomatous polyp syndromes, including juvenile polyposis syndrome, Peutz-Jeghers syndrome, Cowden syndrome, and Bannayan-Ruvalcaba-Riley syndrome.",
                    "offsetInBeginSection": 1975,
                    "offsetInEndSection": 2162,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22171123",
                    "text": "Juvenile polyposis syndrome is a rare autosomal dominant syndrome characterized by multiple distinct juvenile polyps in the gastrointestinal tract and an increased risk of colorectal cancer.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 190,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21834858",
                    "text": "Juvenile polyposis (JP) is an autosomal dominant hamartomatous polyposis syndrome that carries a significant risk for the development of colorectal cancer.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16152648",
                    "text": "SMAD4 germline mutations are responsible for a more aggressive digestive phenotype in patients with juvenile polyposis.",
                    "offsetInBeginSection": 1007,
                    "offsetInEndSection": 1126,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21834858",
                    "text": "Microdeletions of one of the two predisposing genes to JP, BMPR1A, have been associated with a severe form of JP called juvenile polyposis of infancy.",
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9491322",
                    "text": "The findings in this patient with a constitutional 10q23 deletion raise the issue of whether there are separate genes in this region that are involved in Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, juvenile polyposis, and tumor progression, or whether all of these entities could be due to a single gene.",
                    "offsetInBeginSection": 758,
                    "offsetInEndSection": 1070,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26159157",
                    "text": "Juvenile polyposis syndrome (JPS) is a rare autosomal dominant disorder characterized by the development of multiple hamartomatous polyps in the gastrointestinal tract.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22171123",
                    "text": "In about 50%-60% of patients diagnosed with juvenile polyposis syndrome a germline mutation in the SMAD4 or BMPR1A gene is found.",
                    "offsetInBeginSection": 754,
                    "offsetInEndSection": 883,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a86bf2efaa1ab7d2e000033",
            "body": "What is the mechanism of the auxin-inducible degron system?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23836714",
                "http://www.ncbi.nlm.nih.gov/pubmed/19915560",
                "http://www.ncbi.nlm.nih.gov/pubmed/24236031",
                "http://www.ncbi.nlm.nih.gov/pubmed/28680098",
                "http://www.ncbi.nlm.nih.gov/pubmed/26519318",
                "http://www.ncbi.nlm.nih.gov/pubmed/26081484",
                "http://www.ncbi.nlm.nih.gov/pubmed/27010248",
                "http://www.ncbi.nlm.nih.gov/pubmed/25181302"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27010248",
                    "text": "To this end, a degradation system was developed in yeast exploiting TIR1, a plant F box protein, which can recruit proteins with an auxin-inducible degron to an E3 ubiquitin ligase complex, but only in the presence of the phytohormone auxin.",
                    "offsetInBeginSection": 837,
                    "offsetInEndSection": 1078,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28680098",
                    "text": "The auxin-inducible degron harbors great potential for dynamic protein depletion in yeast.",
                    "offsetInBeginSection": 73,
                    "offsetInEndSection": 163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26081484",
                    "text": "Strategies that use ubiquitin-mediated protein degradation to eliminate the product of a gene of interest, such as heat-inducible degron (td) and auxin-inducible degron (AID), are powerful methods for constructing conditional mutants.",
                    "offsetInBeginSection": 130,
                    "offsetInEndSection": 364,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714",
                    "text": "We now report the construction of a series of vectors that significantly enhance the versatility of this auxin-inducible degron (AID) system in Saccharomyces cerevisiae.",
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 429,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19915560",
                    "text": "Other eukaryotes lack the auxin response but share the SCF degradation pathway, allowing us to transplant the auxin-inducible degron (AID) system into nonplant cells and use a small molecule to conditionally control protein stability.",
                    "offsetInBeginSection": 205,
                    "offsetInEndSection": 439,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27010248",
                    "text": "Neither auxin nor TIR1 expression have obvious toxic effects in this organism, and in combination they result in rapid degradation of a target protein fused to the auxin-inducible degron.",
                    "offsetInBeginSection": 1198,
                    "offsetInEndSection": 1385,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19915560",
                    "text": "Plants have evolved a unique system in which the plant hormone auxin directly induces rapid degradation of the AUX/IAA family of transcription repressors by a specific form of the SCF E3 ubiquitin ligase.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25181302",
                    "text": "The auxin-inducible degron (AID) system allows the rapid and reversible proteolysis of proteins of interest, and enables the generation of conditional mutants of budding yeast.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714",
                    "text": "Recently, a degron system relying on the plant hormone auxin has been described for use in yeast and vertebrate cells.",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 259,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26519318",
                    "text": "We describe a protocol for the generation of temperature-sensitive and auxin-inducible degron mutants.",
                    "offsetInBeginSection": 361,
                    "offsetInEndSection": 463,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e3155b750ff445500003f",
            "body": "Which R/Bioconductor package has been developed for cancer subtype identification?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28605519",
                "http://www.ncbi.nlm.nih.gov/pubmed/26607490"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490",
                    "text": "Here, we present the genefu R/Bioconductor package, a multi-tiered compendium of bioinformatics algorithms and gene signatures for molecular subtyping and prognostication in breast cancer.",
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 664,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519",
                    "text": "We introduce CancerSubtypes, an R package for identifying cancer subtypes using multi-omics data, including gene expression, miRNA expression and DNA methylation data.",
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 286,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519",
                    "text": "The package is useful for inferring cancer subtypes from an input genomic dataset, comparing the predictions from different well-known methods and testing new subtype discovery methods, as shown with different application scenarios in the Supplementary Material.",
                    "offsetInBeginSection": 723,
                    "offsetInEndSection": 985,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490",
                    "text": "Extensive studies into the molecular heterogeneity of breast cancer have produced a plethora of molecular subtype classification and prognosis prediction algorithms, as well as numerous gene expression signatures.",
                    "offsetInBeginSection": 74,
                    "offsetInEndSection": 287,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519",
                    "text": "CancerSubtypes integrates four main computational methods which are highly cited for cancer subtype identification and provides a standardized framework for data pre-processing, feature selection, and result follow-up analyses, including results computing, biology validation and visualization.",
                    "offsetInBeginSection": 287,
                    "offsetInEndSection": 581,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519",
                    "text": "Availability and implementation The package is implemented in R and available under GPL-2 license from the Bioconductor website (http://bioconductor.org/packages/CancerSubtypes/).",
                    "offsetInBeginSection": 988,
                    "offsetInEndSection": 1167,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490",
                    "text": "AVAILABILITY AND IMPLEMENTATION The genefu package is available from Bioconductor.",
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 749,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519",
                    "text": "Summary Identifying molecular cancer subtypes from multi-omics data is an important step in the personalized medicine.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490",
                    "text": "http://www.bioconductor.org/packages/devel/bioc/html/genefu.html Source code is also available on Github https://github.com/bhklab/genefu   CONTACT bhaibeka@uhnresearch.ca   SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.",
                    "offsetInBeginSection": 750,
                    "offsetInEndSection": 1008,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490",
                    "text": "UNLABELLED Breast cancer is one of the most frequent cancers among women.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 73,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75fbf383b0d9ea6600000a",
            "body": "Name the phase 3 clinical trials for tofacitinib in colitis.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                "http://www.ncbi.nlm.nih.gov/pubmed/26376350",
                "http://www.ncbi.nlm.nih.gov/pubmed/27177233",
                "http://www.ncbi.nlm.nih.gov/pubmed/22894574",
                "http://www.ncbi.nlm.nih.gov/pubmed/25651782",
                "http://www.ncbi.nlm.nih.gov/pubmed/29051788",
                "http://www.ncbi.nlm.nih.gov/pubmed/26669566",
                "http://www.ncbi.nlm.nih.gov/pubmed/28829236",
                "http://www.ncbi.nlm.nih.gov/pubmed/25110261",
                "http://www.ncbi.nlm.nih.gov/pubmed/25047498"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25651782",
                    "text": "BACKGROUND Tofacitinib, a novel, oral Janus kinase inhibitor, demonstrated a dose-dependent efficacy for induction of clinical response and remission in patients with active ulcerative colitis (UC).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26669566",
                    "text": "BACKGROUND Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "text": "BACKGROUND Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26669566",
                    "text": "Serious infections have been reported in tofacitinib RA trials.",
                    "offsetInBeginSection": 324,
                    "offsetInEndSection": 387,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869",
                    "text": "METHODS We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis.",
                    "offsetInBeginSection": 262,
                    "offsetInEndSection": 407,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29051788",
                    "text": "For example, the JAK1 blocker filgotinib was tested in Crohn's disease, whereas the JAK1/3 inhibitor tofacitinib was tested in clinical trials for both Crohn's disease and ulcerative colitis.",
                    "offsetInBeginSection": 1695,
                    "offsetInEndSection": 1886,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236",
                    "text": "Expert opinion: Although tofacitinib plus MTX is statistically more clinically effective, tofacitinib monotherapy is effective in many patients with RA.",
                    "offsetInBeginSection": 1043,
                    "offsetInEndSection": 1195,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25110261",
                    "text": "Based on data from clinical trials in rheumatoid arthritis and phase 2 studies in inflammatory bowel disease, tofacitinib and other JAK inhibitors are likely to become a new form of medical therapy for the treatment of inflammatory bowel disease.",
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 568,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25047498",
                    "text": "Tofacitinib must have been used as monotherapy or in combination therapy with disease-modifying antirheumatic drugs (DMARDs) in the treatment of RA.",
                    "offsetInBeginSection": 407,
                    "offsetInEndSection": 555,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25047498",
                    "text": "The results of the Phase II trials show that tofacitinib at doses \u22653 mg BID was efficacious among the nonresponders.",
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1156,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a679be1b750ff4455000005",
            "body": "Are organisms in the genus Morexella associated with sepsis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24669633",
                "http://www.ncbi.nlm.nih.gov/pubmed/9587088",
                "http://www.ncbi.nlm.nih.gov/pubmed/24786571",
                "http://www.ncbi.nlm.nih.gov/pubmed/6954635",
                "http://www.ncbi.nlm.nih.gov/pubmed/3071072",
                "http://www.ncbi.nlm.nih.gov/pubmed/10403734",
                "http://www.ncbi.nlm.nih.gov/pubmed/18696148",
                "http://www.ncbi.nlm.nih.gov/pubmed/8909835"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24786571",
                    "text": "RESULTS Some plant species, such as Alchornea floribunda, Musanga cecropioides (both leaves and stem bark), Tetracera potatoria and Xylopia aethiopica (stem bark), were effective in inhibiting Morexella cattarhalis, having MIC values between 65 and 250 \u03bcg/mL.",
                    "offsetInBeginSection": 1221,
                    "offsetInEndSection": 1481,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633",
                    "text": "Acinetobacter species, Staphylococcus epidermidis, Klebseila, Streptococci, Enterobacter cloacae and Morexella species were found in 17 (13.1%), 17 (13.1%), 13 (10%), 7 (5.4%), 6 (4.6%), and 5 (3.8%) cases respectively.",
                    "offsetInBeginSection": 1173,
                    "offsetInEndSection": 1392,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9587088",
                    "text": "The genus Citrobacter includes three species of organisms that are uncommonly associated with human infection.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18696148",
                    "text": "Species of Aeromonas (A. hydrophila, A. caviae, A. veronii) have been shown to be associated with food borne gastroenteritis, with wound infections acquired via water or with sepsis, peritonitis or meningitis.",
                    "offsetInBeginSection": 923,
                    "offsetInEndSection": 1132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9587088",
                    "text": "The authors report a case of Citrobacter freundii empyema in a patient with occult pulmonary histoplasmosis.",
                    "offsetInBeginSection": 440,
                    "offsetInEndSection": 548,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6954635",
                    "text": "Organisms of the genus Bacterioides represent the major group of obligate anaerobes involved in human infections.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18696148",
                    "text": "Members of the mesophilic genus Aeromonas spp.",
                    "offsetInBeginSection": 233,
                    "offsetInEndSection": 279,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633",
                    "text": "CONCLUSION Staphylococcus aureus are the most common gram positive bacteria and Escherichia coli are the most common gram negative bacteria causing neonatal sepsis.",
                    "offsetInBeginSection": 1934,
                    "offsetInEndSection": 2098,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6954635",
                    "text": "B. fragilis and Bacteroides melaninogenicus have chemically incomplete lipopolysaccharides as compared with the lipopolysaccharides (endotoxins) of aerobic bacteria, and the lipopolysaccharides of Bacteroides lack of biologic potency characteristic of endotoxin.",
                    "offsetInBeginSection": 289,
                    "offsetInEndSection": 551,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3071072",
                    "text": "Fusobacteria-like organisms in placentae have previously been associated with prematurity.",
                    "offsetInBeginSection": 228,
                    "offsetInEndSection": 318,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70e1d999e2c3af26000007",
            "body": "Is Solanezumab effective for Alzheimer's Disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22288451",
                "http://www.ncbi.nlm.nih.gov/pubmed/25459121",
                "http://www.ncbi.nlm.nih.gov/pubmed/21504387",
                "http://www.ncbi.nlm.nih.gov/pubmed/27239538",
                "http://www.ncbi.nlm.nih.gov/pubmed/26238576",
                "http://www.ncbi.nlm.nih.gov/pubmed/27025080",
                "http://www.ncbi.nlm.nih.gov/pubmed/26271177",
                "http://www.ncbi.nlm.nih.gov/pubmed/23574434",
                "http://www.ncbi.nlm.nih.gov/pubmed/24450890",
                "http://www.ncbi.nlm.nih.gov/pubmed/22339463"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27239538",
                    "text": "INTRODUCTION Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459121",
                    "text": "Results from amyloid-based immunotherapy studies in clinical trials indicate that intervention appears to be more effective in early stages of amyloid accumulation in particular solanezumab with a potential impact at mild Alzheimer's disease, highlighting the importance of diagnosing Alzheimer's disease as early as possible and undertaking clinical trials at this stage.",
                    "offsetInBeginSection": 883,
                    "offsetInEndSection": 1255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451",
                    "text": "Solanezumab (LY2062430) is a humanized monoclonal antibody that binds to the central region of \u03b2-amyloid, a peptide believed to play a key role in the pathogenesis of Alzheimer's disease (AD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459121",
                    "text": "So a new third phase 3 clinical trial for solanezumab, called Expedition 3, in patients with mild Alzheimer's disease and evidence of amyloid burden has been started.",
                    "offsetInBeginSection": 1487,
                    "offsetInEndSection": 1653,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504387",
                    "text": "Solanezumab is a monoclonal antibody that binds to \u03b2-amyloid (A\u03b2), a protein that plays a key role in the pathogenesis of AD.",
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 253,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451",
                    "text": "While there is a strong hope that solanezumab may represent the first effective passive vaccine for AD treatment, skepticism still exists on the ability of the drug to slow the rate of deterioration in patients with fully established disease.",
                    "offsetInBeginSection": 790,
                    "offsetInEndSection": 1032,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22339463",
                    "text": "The results of the large, ongoing Phase III trials with bapineuzumab and solanezumab will tell us if monoclonal anti-A\u03b2 antibodies may slow down the rate of deterioration of AD.",
                    "offsetInBeginSection": 1956,
                    "offsetInEndSection": 2134,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451",
                    "text": "Eli Lilly & Co is developing an intravenous formulation of solanezumab for the treatment of mild-to-moderate AD.",
                    "offsetInBeginSection": 194,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27025080",
                    "text": "Solanezumab is now on a large scale phase III trial in mild AD cases in the world.",
                    "offsetInBeginSection": 604,
                    "offsetInEndSection": 686,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22339463",
                    "text": "Anti-A\u03b2 monoclonal antibodies (bapineuzumab and solanezumab) are now being developed.",
                    "offsetInBeginSection": 1005,
                    "offsetInEndSection": 1091,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a86ecc7faa1ab7d2e000039",
            "body": "What is the function of the H19 (ICR) locus in the human genome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24023912",
                "http://www.ncbi.nlm.nih.gov/pubmed/19546235",
                "http://www.ncbi.nlm.nih.gov/pubmed/16006531",
                "http://www.ncbi.nlm.nih.gov/pubmed/20427289",
                "http://www.ncbi.nlm.nih.gov/pubmed/21991322",
                "http://www.ncbi.nlm.nih.gov/pubmed/20047949",
                "http://www.ncbi.nlm.nih.gov/pubmed/26328763",
                "http://www.ncbi.nlm.nih.gov/pubmed/17948025",
                "http://www.ncbi.nlm.nih.gov/pubmed/21600199",
                "http://www.ncbi.nlm.nih.gov/pubmed/16815976"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16006531",
                    "text": "A maternally inherited H19 ICR inhibits Igf2 gene activation by the downstream enhancer due to its insulator function while it suppresses H19 gene transcription by promoter DNA methylation when paternally inherited.",
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 520,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912",
                    "text": "Mono-allelic expression at the mouse IGF2/H19 locus is controlled by differential allelic DNA methylation of the imprinting control region (ICR).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20047949",
                    "text": "Imprinted expression of the mouse Igf2/H19 locus is controlled by parent-of-origin-specific methylation of the imprinting control region (ICR).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16006531",
                    "text": "Thus, the ICR autonomously recapitulated imprinting within the normally nonimprinted transgenic beta-globin gene locus, but the temporal establishment of imprinting methylation differs from that at the endogenous Igf2/H19 locus.",
                    "offsetInBeginSection": 1560,
                    "offsetInEndSection": 1788,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21600199",
                    "text": "Individually, both mutant alleles (H19(ICR\u2206IVS) and H19(ICR-8nrCG)) show loss of imprinted repression of paternal H19.",
                    "offsetInBeginSection": 891,
                    "offsetInEndSection": 1011,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19546235",
                    "text": "By grafting a 2.9-kbp H19 ICR fragment into a human beta-globin yeast artificial chromosome in transgenic mice, we previously showed that the ICR could recapitulate imprinted methylation and expression at a heterologous locus, suggesting that the H19 ICR in the beta-globin locus contained sufficient information to maintain the methylation mark (K. Tanimoto, M. Shimotsuma, H. Matsuzaki, A. Omori, J. Bungert, J. D. Engel, and A. Fukamizu, Proc.",
                    "offsetInBeginSection": 262,
                    "offsetInEndSection": 708,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16815976",
                    "text": "It is thought that the H19 imprinting control region (ICR) directs the silencing of the maternally inherited Igf2 allele through a CTCF-dependent chromatin insulator.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16815976",
                    "text": "Mutation of CTCF binding sites in the H19 ICR leads to loss of CTCF binding and de novo methylation of a CTCF target site within Igf2 DMR1, showing that CTCF can coordinate regional epigenetic marks.",
                    "offsetInBeginSection": 990,
                    "offsetInEndSection": 1189,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17948025",
                    "text": "The imprinting control region (ICR) upstream of H19 is the key regulatory element conferring monoallelic expression on H19 and Igf2 (insulin-like growth factor 2).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21600199",
                    "text": "Like most imprinted genes, H19 and Igf2 are regulated by a differentially methylated imprinting control region (ICR).",
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 221,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e354fb750ff4455000042",
            "body": "Which R/bioconductor package has been developed to aid in epigenomic analysis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28334349",
                "http://www.ncbi.nlm.nih.gov/pubmed/26704973",
                "http://www.ncbi.nlm.nih.gov/pubmed/26415965",
                "http://www.ncbi.nlm.nih.gov/pubmed/26424858"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334349",
                    "text": "Results To make public epigenomic data conveniently available for analysis in R, we developed an R/Bioconductor package that connects to the DeepBlue Epigenomic Data Server, enabling users to quickly gather and transform epigenomic data from selected experiments for analysis in the Bioconductor ecosystem.",
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 649,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704973",
                    "text": "We developed an R/Bioconductor package called TCGAbiolinks to address these challenges and offer bioinformatics solutions by using a guided workflow to allow users to query, download and perform integrative analyses of TCGA data.",
                    "offsetInBeginSection": 728,
                    "offsetInEndSection": 957,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704973",
                    "text": "Using four different TCGA tumor types (Kidney, Brain, Breast and Colon) as examples, we provide case studies to illustrate examples of reproducibility, integrative analysis and utilization of different Bioconductor packages to advance and accelerate novel discoveries.",
                    "offsetInBeginSection": 1128,
                    "offsetInEndSection": 1396,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26415965",
                    "text": "RESULTS To overcome the burden of integrating various data types with multiple tools, we developed two companion R/Bioconductor packages.",
                    "offsetInBeginSection": 780,
                    "offsetInEndSection": 917,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334349",
                    "text": "The DeepBlue Epigenomic Data Server provides a powerful interface and API for filtering, transforming, aggregating and downloading data from several epigenomic consortia.",
                    "offsetInBeginSection": 170,
                    "offsetInEndSection": 340,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26415965",
                    "text": "CONCLUSIONS methylPipe and compEpiTools provide a comprehensive Bioconductor-compliant solution for the integrative analysis of heterogeneous epigenomics data.",
                    "offsetInBeginSection": 1944,
                    "offsetInEndSection": 2103,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26415965",
                    "text": "Large epigenomic datasets are then generated, and often combined with other high-throughput data, including RNA-seq, ChIP-seq for transcription factors (TFs) binding and DNase-seq experiments.",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 333,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334349",
                    "text": "Motivation While large amounts of epigenomic data are publicly available, their retrieval in a form suitable for downstream analysis is a bottleneck in current research.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26415965",
                    "text": "Multiple tools must be identified and combined to jointly analyze histone marks, TFs binding and other -omics data together with DNA methylation data, complicating the analysis of these data and their integration with publicly available datasets.",
                    "offsetInBeginSection": 531,
                    "offsetInEndSection": 777,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26415965",
                    "text": "Finally, the package includes a flexible method based on heatmaps for the integration of various data types, combining annotation tracks with continuous or categorical data tracks.",
                    "offsetInBeginSection": 1761,
                    "offsetInEndSection": 1941,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a76dd749e632bc066000008",
            "body": "What does VBP15 do to skeletal muscle?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24014378"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378",
                    "text": "We find VBP15 protects and promotes efficient repair of skeletal muscle cells upon laser injury, in opposition to prednisolone.",
                    "offsetInBeginSection": 617,
                    "offsetInEndSection": 744,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378",
                    "text": "Absence of dystrophin makes skeletal muscle more susceptible to injury, resulting in breaches of the plasma membrane and chronic inflammation in Duchenne muscular dystrophy (DMD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378",
                    "text": "These data demonstrate successful improvement of dystrophy independent of hormonal, growth, or immunosuppressive effects, indicating VBP15 merits clinical investigation for DMD and would benefit other chronic inflammatory diseases.",
                    "offsetInBeginSection": 1108,
                    "offsetInEndSection": 1339,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378",
                    "text": "The translation of these drug mechanisms into DMD model mice improves muscle strength, live-imaging and pathology through both preventive and post-onset intervention regimens.",
                    "offsetInBeginSection": 932,
                    "offsetInEndSection": 1107,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378",
                    "text": "Potent inhibition of NF-\u03baB is mediated through protein interactions of the glucocorticoid receptor, however VBP15 shows significantly reduced hormonal receptor transcriptional activity.",
                    "offsetInBeginSection": 745,
                    "offsetInEndSection": 931,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378",
                    "text": "It is uncertain whether therapies that avoid hormonal stunting of growth and development, and/or immunosuppression, would be more or less beneficial.",
                    "offsetInBeginSection": 273,
                    "offsetInEndSection": 422,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378",
                    "text": "Here, we discover an oral drug with mechanisms that provide efficacy through anti-inflammatory signaling and membrane-stabilizing pathways, independent of hormonal or immunosuppressive effects.",
                    "offsetInBeginSection": 423,
                    "offsetInEndSection": 616,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378",
                    "text": "Current management by glucocorticoids has unclear molecular benefits and harsh side effects.",
                    "offsetInBeginSection": 180,
                    "offsetInEndSection": 272,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6a02a3b750ff4455000021",
            "body": "What protein is the most common cause of hereditary  renal amyloidosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29142973",
                "http://www.ncbi.nlm.nih.gov/pubmed/25331409",
                "http://www.ncbi.nlm.nih.gov/pubmed/26299174",
                "http://www.ncbi.nlm.nih.gov/pubmed/22540225",
                "http://www.ncbi.nlm.nih.gov/pubmed/22967253",
                "http://www.ncbi.nlm.nih.gov/pubmed/19073821",
                "http://www.ncbi.nlm.nih.gov/pubmed/28153807",
                "http://www.ncbi.nlm.nih.gov/pubmed/16468976",
                "http://www.ncbi.nlm.nih.gov/pubmed/8560604",
                "http://www.ncbi.nlm.nih.gov/pubmed/19013120"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29142973",
                    "text": "Introduction Fibrinogen A alpha chain amyloidosis is an autosomal dominant disease associated with mutations in the fibrinogen A alpha chain (FGA) gene, and it is the most common cause of hereditary renal amyloidosis in the UK.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19013120",
                    "text": "The predominant cause of hereditary renal amyloidosis is a mutation of the fibrinogen Aalpha chain (AFib), the most common being the E526V mutation.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25331409",
                    "text": "Mutations in the fibrinogen A\u03b1-chain genes are the most common cause of hereditary renal amyloidosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22967253",
                    "text": "Amyloid-A (AA) amyloidosis is the most common form of systemic amyloidosis worldwide, AA amyloidosis occurs in the course of chronic inflammatory diseases, hereditary periodic fevers, and with certain neoplasms such as Hodgkin disease and renal cell carcinoma.",
                    "offsetInBeginSection": 459,
                    "offsetInEndSection": 719,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19073821",
                    "text": "Mutations in the fibrinogen A alpha-chain gene are the most common cause of hereditary renal amyloidosis in the United Kingdom.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22540225",
                    "text": "Fibrinogen A \u03b1-chain (AFib) and apolipoprotein AI (AApoAI) amyloidosis due to variants in the AFib and ApoAI genes are the most common types of hereditary amyloidosis in Europe and the United States.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8560604",
                    "text": "In developed countries, rheumatoid arthritis is the most common cause of renal amyloidosis, while in developing countries patients with familial Mediterranean fever (FMF) (untreated) and chronic suppurative infections constitute a large proportion of renal amyloidosis cases.",
                    "offsetInBeginSection": 1088,
                    "offsetInEndSection": 1363,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174",
                    "text": "Hereditary renal amyloidosis is an autosomal dominant condition with considerable overlap with other amyloidosis types.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174",
                    "text": "We suspected amyloidosis with fibrinogen A alpha chain deposits, which is the most frequent cause of hereditary amyloidosis in Europe, with a glomerular preferential affectation.",
                    "offsetInBeginSection": 427,
                    "offsetInEndSection": 605,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22967253",
                    "text": "Kidney biopsy revealed AA renal amyloidosis.",
                    "offsetInBeginSection": 1191,
                    "offsetInEndSection": 1235,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7234352dc08e987e000007",
            "body": "What is the most common histological diagnosis of \"butterfly glioma\"?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/1656290",
                "http://www.ncbi.nlm.nih.gov/pubmed/28361164"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361164",
                    "text": "Other neoplastic and non-neoplastic conditions that may involve the corpus callosum and mimic a butterfly glioma, as well as associated imaging features, are discussed.",
                    "offsetInBeginSection": 448,
                    "offsetInEndSection": 616,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290",
                    "text": "A previous steroid medication over several weeks for treatment of increased intracranial pressure may be considered as an important factor in the origin of the pulmonary aspergillosis complicating the butterfly glioma.",
                    "offsetInBeginSection": 779,
                    "offsetInEndSection": 997,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290",
                    "text": "In addition to a large butterfly glioblastoma originating from the frontal part of the corpus callosum, neuropathologic examination revealed a mycotic encephalitis with formation of numerous fungi-containing inflammatory foci in all parts of the brain and in the glioma.",
                    "offsetInBeginSection": 416,
                    "offsetInEndSection": 686,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361164",
                    "text": "The diagnosis of butterfly glioma (glioblastoma multiforme) was made based on imaging characteristics and was further confirmed by biopsy findings.",
                    "offsetInBeginSection": 134,
                    "offsetInEndSection": 281,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290",
                    "text": "A 45 year-old male with a butterfly glioma received stereotactic biopsy for histologic confirmation of the clinical diagnosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290",
                    "text": "Microscopically, the results were controversial since some biopsy specimens showed distinct inflammatory changes, while others displayed typical features of a malignant glioma.",
                    "offsetInBeginSection": 127,
                    "offsetInEndSection": 303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361164",
                    "text": "As the corpus callosum is usually resistant to infiltration by tumours, a mass that involves and crosses the corpus callosum is suggestive of an aggressive neoplasm.",
                    "offsetInBeginSection": 282,
                    "offsetInEndSection": 447,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290",
                    "text": "General autopsy disclosed pulmonary aspergillosis as the source of the inflammatory spread.",
                    "offsetInBeginSection": 687,
                    "offsetInEndSection": 778,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361164",
                    "text": "A 54-year-old man presented with change in behaviour, nocturnal enuresis, abnormal limb movement and headache of one week's duration.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290",
                    "text": "The patient died four days after the stereotactic approach due to therapy-resistant intracranial pressure rise.",
                    "offsetInBeginSection": 304,
                    "offsetInEndSection": 415,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a86fd5bfaa1ab7d2e00003b",
            "body": "Is a CpG island methylator phenotype involved in ependymomas?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24553142",
                "http://www.ncbi.nlm.nih.gov/pubmed/22109108",
                "http://www.ncbi.nlm.nih.gov/pubmed/28548123",
                "http://www.ncbi.nlm.nih.gov/pubmed/25182241",
                "http://www.ncbi.nlm.nih.gov/pubmed/23619990",
                "http://www.ncbi.nlm.nih.gov/pubmed/24674026",
                "http://www.ncbi.nlm.nih.gov/pubmed/17096326",
                "http://www.ncbi.nlm.nih.gov/pubmed/19136926",
                "http://www.ncbi.nlm.nih.gov/pubmed/10411935",
                "http://www.ncbi.nlm.nih.gov/pubmed/19571709"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553142",
                    "text": "CpG island methylator phenotype-positive hindbrain ependymomas are responsive to clinical drugs that target either DNA or H3K27 methylation both in vitro and in vivo.",
                    "offsetInBeginSection": 822,
                    "offsetInEndSection": 988,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10411935",
                    "text": "In contrast, methylation of the cancer-specific clones was found exclusively in a subset of colorectal cancers, which appear to display a CpG island methylator phenotype (CIMP).",
                    "offsetInBeginSection": 721,
                    "offsetInEndSection": 898,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19136926",
                    "text": "In hepatocellular carcinomas, hypermethylation of CpG islands, and CpG island methylator phenotype status seems to correlate with levels of long interspersed nuclear element-1 hypomethylation.",
                    "offsetInBeginSection": 1541,
                    "offsetInEndSection": 1733,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25182241",
                    "text": "Although no recurrently mutated genes were found throughout these groups of ependymomas, PFA exhibited a CpG island methylator phenotype, PFB was associated with extensive chromosomal aberrations, and the C11orf95-RELA fusion gene was frequently observed in supratentorial ependymomas.",
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 594,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23619990",
                    "text": "Neuroblastomas with the CpG island methylator phenotype include almost all neuroblastomas with MYCN amplification, and, even among neuroblastomas without MYCN amplification, have worse prognosis.",
                    "offsetInBeginSection": 107,
                    "offsetInEndSection": 302,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553142",
                    "text": "Although devoid of recurrent single nucleotide variants and focal copy number aberrations, poor-prognosis hindbrain ependymomas exhibit a CpG island methylator phenotype.",
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 614,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23619990",
                    "text": "OBJECTIVE The CpG island methylator phenotype is strongly associated with poor survival in neuroblastomas.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24674026",
                    "text": "In colorectal cancer, the CpG island methylator phenotype (CIMP) is defined as widespread and elevated levels of DNA methylation and CIMP+ tumors have distinctive clinicopathological and molecular features.",
                    "offsetInBeginSection": 140,
                    "offsetInEndSection": 346,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28548123",
                    "text": "Of the 34 miRNAs associated with CpG island methylator phenotype-high tumors, 16 were more likely to have a CpG island methylator phenotype-high tumor and 19 were less likely to be CpG island methylator phenotype-high.",
                    "offsetInBeginSection": 1130,
                    "offsetInEndSection": 1348,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23619990",
                    "text": "CONCLUSION The CpG island methylator phenotype is likely to have stronger prognostic power than methylation of individual genes in neuroblastomas.",
                    "offsetInBeginSection": 1556,
                    "offsetInEndSection": 1702,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e4814b750ff445500004a",
            "body": "Are loop domains preserved upon cohesin loss?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28985562"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562",
                    "text": "\"Loop domains\" form because of tethering between two loci-almost always bound by CTCF and cohesin-lying on the same chromosome.",
                    "offsetInBeginSection": 142,
                    "offsetInEndSection": 269,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562",
                    "text": "All loop domains are eliminated, but neither compartment domains nor histone marks are affected.",
                    "offsetInBeginSection": 412,
                    "offsetInEndSection": 508,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562",
                    "text": "In particular, cohesin loss causes superenhancers to co-localize, forming hundreds of links within and across chromosomes and affecting the regulation of nearby genes.",
                    "offsetInBeginSection": 638,
                    "offsetInEndSection": 805,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562",
                    "text": "Loss of loop domains does not lead to widespread ectopic gene activation but does affect a significant minority of active genes.",
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 637,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562",
                    "text": "\"Compartment domains\" form when genomic intervals with similar histone marks co-segregate.",
                    "offsetInBeginSection": 270,
                    "offsetInEndSection": 360,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562",
                    "text": "The human genome folds to create thousands of intervals, called \"contact domains,\" that exhibit enhanced contact frequency within themselves.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562",
                    "text": "We then restore cohesin and monitor the re-formation of each loop.",
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 872,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562",
                    "text": "Although re-formation rates vary greatly, many megabase-sized loops recovered in under an hour, consistent with a model where loop extrusion is rapid.",
                    "offsetInBeginSection": 873,
                    "offsetInEndSection": 1023,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562",
                    "text": "Here, we explore the effects of degrading cohesin.",
                    "offsetInBeginSection": 361,
                    "offsetInEndSection": 411,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7723b79e632bc06600000b",
            "body": "What are the prednisone side effects in DMD patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19488064",
                "http://www.ncbi.nlm.nih.gov/pubmed/12548530",
                "http://www.ncbi.nlm.nih.gov/pubmed/10951436",
                "http://www.ncbi.nlm.nih.gov/pubmed/8882570",
                "http://www.ncbi.nlm.nih.gov/pubmed/25809413",
                "http://www.ncbi.nlm.nih.gov/pubmed/22655511",
                "http://www.ncbi.nlm.nih.gov/pubmed/19306039",
                "http://www.ncbi.nlm.nih.gov/pubmed/16980656",
                "http://www.ncbi.nlm.nih.gov/pubmed/28450193",
                "http://www.ncbi.nlm.nih.gov/pubmed/9128400"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064",
                    "text": "Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570",
                    "text": "The results suggest that (i) DFC and PRED in equal anti-inflammatory dosage are similarly or equally efficient in slowing down the decline of muscle strength in DMD; (ii) benefits outweigh the side effects.",
                    "offsetInBeginSection": 1274,
                    "offsetInEndSection": 1480,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9128400",
                    "text": "In 1974 Drachman and his colleagues first raised the possibility of beneficial effect of glucocorticoid in an uncontrolled trial of Duchenne muscular dystrophy (DMD) patients.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064",
                    "text": "Whole blood was obtained from 14 children and adolescents with DMD treated with corticosteroids (DMD-STEROID) and 20 DMD children and adolescents na\u00efve to corticosteroids (DMD).",
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 499,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16980656",
                    "text": "BACKGROUND Steroid administration is beneficial in Duchenne muscular dystrophy (DMD), but the response, incidence, and the severity of side effects are variable.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12548530",
                    "text": "Because steroids are effective in prolonging function, but not in recovering lost function, we propose that treatment be started with low-dose prednisone in DMD patients as soon as the diagnosis is definite.",
                    "offsetInBeginSection": 719,
                    "offsetInEndSection": 926,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570",
                    "text": "Deflazacort (DFC) is supposed to have fewer side effects than prednisone (PRED).",
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 224,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10951436",
                    "text": "Steroid treatment with deflazacort appears to cause fewer side effects than with prednisone, particularly weight gain, which could be important to maximize motor performances.",
                    "offsetInBeginSection": 1190,
                    "offsetInEndSection": 1365,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064",
                    "text": "The DMD-STEROID group was further subdivided into Deflazacort and prednisone groups.",
                    "offsetInBeginSection": 500,
                    "offsetInEndSection": 584,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16980656",
                    "text": "RESULTS Mutation studies revealed an heterozygous A to G mutation at GRL cDNA position 1220 in three DMD patients resulting in an asparagine to serine amino acid change at amino acid position 363 (N363S).",
                    "offsetInBeginSection": 434,
                    "offsetInEndSection": 638,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e42f1b750ff4455000046",
            "body": "What gene is mutated in Familial Mediterranean Fever?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12387810",
                "http://www.ncbi.nlm.nih.gov/pubmed/20437121",
                "http://www.ncbi.nlm.nih.gov/pubmed/24980720",
                "http://www.ncbi.nlm.nih.gov/pubmed/12615073",
                "http://www.ncbi.nlm.nih.gov/pubmed/18347298",
                "http://www.ncbi.nlm.nih.gov/pubmed/10666224",
                "http://www.ncbi.nlm.nih.gov/pubmed/18219832",
                "http://www.ncbi.nlm.nih.gov/pubmed/28690860",
                "http://www.ncbi.nlm.nih.gov/pubmed/17431422",
                "http://www.ncbi.nlm.nih.gov/pubmed/20645115"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28690860",
                    "text": "Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease that is inherited in an autosomal recessive manner and is caused by mutations in the MEFV gene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 171,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18347298",
                    "text": "Cryopyrin and pyrin (protein mutated in familial Mediterranean fever) belong to the family of PYRIN domain-containing proteins.",
                    "offsetInBeginSection": 1013,
                    "offsetInEndSection": 1140,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24980720",
                    "text": "BACKGROUND Familial Mediterranean Fever (FMF), characterized by recurrent fever and inflammation of serous membranes, is an autosomal recessive disease caused by mutations in the Mediterranean fever (MEFV) gene.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12387810",
                    "text": "Familial Mediterranean fever (FMF) has been traced to mutations in the MEFV gene.",
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 543,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20437121",
                    "text": "We identified 1 homozygous (E148Q/E148Q), 1 compound heterozygous (M694V/E148Q) and 5 heterozygous MEFV gene mutations; none had their own and/or family history compatible with familial Mediterranean fever.",
                    "offsetInBeginSection": 370,
                    "offsetInEndSection": 576,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17431422",
                    "text": "In patients with another autoinflammatory disorder, familial Mediterranean fever (FMF), mutations in the SPRY domain of the Pyrin protein are frequently found.",
                    "offsetInBeginSection": 314,
                    "offsetInEndSection": 473,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20645115",
                    "text": "Mediterranean fever (MEFV) gene mutations might be one of the genetic predisposition factors in the development of ARF/RHD since defect in familial Mediterranean fever (FMF) patients is proposed to be heightened inflammatory response to certain stimuli.",
                    "offsetInBeginSection": 139,
                    "offsetInEndSection": 392,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18219832",
                    "text": "On the other hand, asthma is less frequent in individuals with familial Mediterranean fever, an autoinflammatory disease prevalent in the Iraqi Jewish community and linked to mutations in the familial Mediterranean fever gene, designated MEFV.",
                    "offsetInBeginSection": 230,
                    "offsetInEndSection": 473,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20437121",
                    "text": "We aimed to investigate the rate of MEFV, the gene mutated in familial Mediterranean fever, mutations in patients with myeloid neoplasm and to determine if known mutations of MEFV cause a tendency for myeloid neoplasms.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 219,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12387810",
                    "text": "The tumour necrosis factor(TNF)-receptor-associated periodic syndromes (TRAPS) have been linked to mutations in theTNFRSF1A gene, encoding a TNF-alpha receptor, and the CIAS1 gene is mutated in familial cold autoinflammatory syndrome.",
                    "offsetInBeginSection": 662,
                    "offsetInEndSection": 896,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7242a22dc08e987e00000e",
            "body": "Describe swirl sign in intracerebral hemorrhage.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23013418",
                "http://www.ncbi.nlm.nih.gov/pubmed/23517301"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418",
                    "text": "Swirl sign was found in 30% of the study population.",
                    "offsetInBeginSection": 691,
                    "offsetInEndSection": 743,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418",
                    "text": "CONCLUSIONS As swirl sign showed to be an ominous sign, we recommend identification of this sign in cases of ICHs.",
                    "offsetInBeginSection": 1401,
                    "offsetInEndSection": 1515,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418",
                    "text": "Only 19% of patients with swirl sign exhibited favorable outcome at three months compared with 53% of those with no swirl sign (p < 0.001).",
                    "offsetInBeginSection": 858,
                    "offsetInEndSection": 997,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418",
                    "text": "61% of patients with swirl sign were dead at one month compared with 21% of those with no swirl sign (p < 0.001).",
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 857,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418",
                    "text": "Patients with swirl sign exhibited larger ICHs with average ICH-volume 52 \u00b1 50 ml (median 42 ml) compared with 15 \u00b1 25 ml (median 6) in patients whose CT did not show swirl sign (p < 0.001).",
                    "offsetInBeginSection": 998,
                    "offsetInEndSection": 1190,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418",
                    "text": "The aims of this study were to describe swirl sign in ICH, study its prevalence, study the reliability of the subjective evaluation on computed tomography (CT), and to explore its prognostic value.",
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 335,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418",
                    "text": "Association between swirl sign and different clinical and radiological variables was studied.",
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 531,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418",
                    "text": "RESULTS Inter- and intraobserver agreement with regard to the occurrence of swirl sign was substantial (\u041a 0.80) and almost perfect (\u041a 0.87), respectively.",
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 690,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517301",
                    "text": "The most discriminating characteristics to predict BD were included in two models; Model 1 contained \u22653 abolished brainstem responses [adjusted odds ratios (OR)\u00a0=\u00a08.4 (2.4, 29.1)] and the swirl sign on the baseline CT-scan [adjusted OR\u00a0=\u00a05.0 (1.6, 15.9)] and Model 2 addressed the abolition of corneal reflexes [unilateral/bilateral: adjusted OR\u00a0=\u00a04.2 (0.9, 20.1)/8.8 (2.4, 32.3)] and the swirl sign on the baseline CT-scan [adjusted OR\u00a0=\u00a06.2 (1.9, 20.0)].",
                    "offsetInBeginSection": 441,
                    "offsetInEndSection": 907,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418",
                    "text": "METHODS CTs of 203 patients with ICH were retrospectively evaluated for the presence of swirl sign.",
                    "offsetInBeginSection": 338,
                    "offsetInEndSection": 437,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8718a261bb38fb24000007",
            "body": "What is the function of yeast TERRA RNAs?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19026778",
                "http://www.ncbi.nlm.nih.gov/pubmed/24698720",
                "http://www.ncbi.nlm.nih.gov/pubmed/29145644",
                "http://www.ncbi.nlm.nih.gov/pubmed/20376293",
                "http://www.ncbi.nlm.nih.gov/pubmed/21525956",
                "http://www.ncbi.nlm.nih.gov/pubmed/22139922",
                "http://www.ncbi.nlm.nih.gov/pubmed/28666128",
                "http://www.ncbi.nlm.nih.gov/pubmed/24550456",
                "http://www.ncbi.nlm.nih.gov/pubmed/24074956",
                "http://www.ncbi.nlm.nih.gov/pubmed/20679250"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778",
                    "text": "Thus, telomeric transcription combined with Rat1p-dependent TERRA degradation is important for regulating telomerase in yeast.",
                    "offsetInBeginSection": 681,
                    "offsetInEndSection": 807,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145644",
                    "text": "The conserved PAF1 complex (Cdc73, Paf1, Ctr9, Leo1 and Rtf1, in yeast), binds RNA pol II, and affects levels of many RNAs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24074956",
                    "text": "Simultaneous time-lapse imaging of telomerase RNA and TERRA reveals spontaneous events of telomerase nucleation on TERRA foci in early S phase, generating TERRA-telomerase clusters.",
                    "offsetInBeginSection": 573,
                    "offsetInEndSection": 754,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24550456",
                    "text": "Moreover, because TERRA is a long noncoding RNA, these results reveal a function for long noncoding RNA in regulating recombination.",
                    "offsetInBeginSection": 1207,
                    "offsetInEndSection": 1339,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778",
                    "text": "Yeast TERRA is polyadenylated and stabilized by Pap1p and regulated by the 5' to 3' exonuclease, Rat1p.",
                    "offsetInBeginSection": 273,
                    "offsetInEndSection": 376,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28666128",
                    "text": "At telomeres, TERRA competes with telomeric DNA for ATRX binding, suppresses ATRX localization, and ensures telomeric stability.",
                    "offsetInBeginSection": 618,
                    "offsetInEndSection": 746,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28666128",
                    "text": "TERRA and ATRX share hundreds of target genes and are functionally antagonistic at these loci: whereas TERRA activates, ATRX represses gene expression.",
                    "offsetInBeginSection": 466,
                    "offsetInEndSection": 617,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29145644",
                    "text": "Analysis of double mutants shows that Paf1 and Ctr9 can affect TERRA independently of Sir4, Rat1, and Trf4, previously identified regulators of TERRA.",
                    "offsetInBeginSection": 542,
                    "offsetInEndSection": 692,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21525956",
                    "text": "We demonstrate that yeast TERRA is regulated by telomere-binding proteins in a chromosome-end-specific manner that is dependent on subtelomeric repetitive DNA elements.",
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 278,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21525956",
                    "text": "Telomeric repeat-containing RNA (TERRA) has been implicated in the control of heterochromatin and telomerase.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e4d22b750ff445500004d",
            "body": "Mutations in which gene cause Schimke immune-osseous dysplasia?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28623093",
                "http://www.ncbi.nlm.nih.gov/pubmed/26354575",
                "http://www.ncbi.nlm.nih.gov/pubmed/27813696",
                "http://www.ncbi.nlm.nih.gov/pubmed/15523612",
                "http://www.ncbi.nlm.nih.gov/pubmed/24589093",
                "http://www.ncbi.nlm.nih.gov/pubmed/23359635",
                "http://www.ncbi.nlm.nih.gov/pubmed/16648978",
                "http://www.ncbi.nlm.nih.gov/pubmed/18520775"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28623093",
                    "text": "Mutations in this gene are the cause of Schimke immune-osseous dysplasia (SIOD), an autosomal recessive disorder characterized by T-cell immunodeficiency and growth dysfunctions.",
                    "offsetInBeginSection": 219,
                    "offsetInEndSection": 397,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27813696",
                    "text": "Mutations in SMARCAL1, which encodes a DNA annealing helicase with roles in DNA replication fork restart, DNA repair, and gene expression modulation, cause Schimke immuno-osseous dysplasia (SIOD), an autosomal recessive disease characterized by skeletal dysplasia, renal disease, T-cell immunodeficiency, and arteriosclerosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 326,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18520775",
                    "text": "Schimke immuno-osseous dysplasia (OMIM 242900) is an uncommon autosomal-recessive multisystem disease caused by mutations in SMARCAL1 (swi/snf-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1), a gene encoding a putative chromatin remodeling protein.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 288,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16648978",
                    "text": "BACKGROUND Schimke immuno-osseous dysplasia (SIOD) is a rare autosomal recessive multisystemic disorder caused by mutations of the SMARCAL 1 gene (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 243,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26354575",
                    "text": "Schimke immune-osseous dysplasia (SIOD) is a rare autosomal recessive disorder characterized by spondylo-epiphyseal dysplasia (SED), progressive renal insufficiency beginning as steroid-resistant nephrotic syndrome (SRNS) and defective cellular immunity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 254,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23359635",
                    "text": "Schimke immuno-osseous dysplasia is a rare autosomal recessive multisystem disorder characterized by steroid-resistant nephrotic syndrome, immunodeficiency, and spondyloepiphyseal dysplasia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 190,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24589093",
                    "text": "BACKGROUND Schimke immuno-osseous dysplasia (SIOD, OMIM #242900) is an autosomal-recessive pleiotropic disorder characterized by spondyloepiphyseal dysplasia, renal dysfunction and T-cell immunodeficiency.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 205,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15523612",
                    "text": "Schimke immuno-osseous dysplasia (SIOD) is a rare autosomal recessive disorder characterized by spondyloepiphyseal dysplasia, nephrotic syndrome, and cell-mediated immunodeficiency.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24589093",
                    "text": "SIOD is caused by mutations in the gene SMARCAL1.",
                    "offsetInBeginSection": 206,
                    "offsetInEndSection": 255,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24589093",
                    "text": "CONCLUSION This report provided the clinical and genetic description of a mild phenotype of Schimke immuno-osseous dysplasia associated with nephrotic proteinuria, decreasing after combined therapy with ACE inhibitors and sartans.",
                    "offsetInBeginSection": 788,
                    "offsetInEndSection": 1018,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7727f39e632bc06600000d",
            "body": "What are the side effects of deflazacort in DMD patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11148511",
                "http://www.ncbi.nlm.nih.gov/pubmed/19488064",
                "http://www.ncbi.nlm.nih.gov/pubmed/8882570",
                "http://www.ncbi.nlm.nih.gov/pubmed/10951436",
                "http://www.ncbi.nlm.nih.gov/pubmed/22655511"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064",
                    "text": "Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511",
                    "text": "OBJECTIVE We report the long-term effects on muscle strength and side effects with deflazacort in Duchenne muscular dystrophy (DMD).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511",
                    "text": "CONCLUSIONS We conclude that deflazacort can preserve gross motor and pulmonary function in boys with DMD with limited side effects.",
                    "offsetInBeginSection": 1166,
                    "offsetInEndSection": 1298,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570",
                    "text": "Deflazacort (DFC) is supposed to have fewer side effects than prednisone (PRED).",
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 224,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064",
                    "text": "The DMD-STEROID group was further subdivided into Deflazacort and prednisone groups.",
                    "offsetInBeginSection": 500,
                    "offsetInEndSection": 584,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22655511",
                    "text": "The clinical outcomes showed increased function in the treated boys, and in a single trial with deflazacort, prolongation of ambulation but with different side effects.",
                    "offsetInBeginSection": 143,
                    "offsetInEndSection": 311,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511",
                    "text": "Asymptomatic cataracts developed in 10 of 30 boys who received deflazacort.",
                    "offsetInBeginSection": 959,
                    "offsetInEndSection": 1034,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10951436",
                    "text": "Steroid treatment with deflazacort appears to cause fewer side effects than with prednisone, particularly weight gain, which could be important to maximize motor performances.",
                    "offsetInBeginSection": 1190,
                    "offsetInEndSection": 1365,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064",
                    "text": "Whole blood was obtained from 14 children and adolescents with DMD treated with corticosteroids (DMD-STEROID) and 20 DMD children and adolescents na\u00efve to corticosteroids (DMD).",
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 499,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8882570",
                    "text": "The results suggest that (i) DFC and PRED in equal anti-inflammatory dosage are similarly or equally efficient in slowing down the decline of muscle strength in DMD; (ii) benefits outweigh the side effects.",
                    "offsetInBeginSection": 1274,
                    "offsetInEndSection": 1480,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6e47b1b750ff4455000049",
            "body": "Is overproduction of transthyretin is associated with amyloidosis associated neuropathy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12762139",
                "http://www.ncbi.nlm.nih.gov/pubmed/28802308",
                "http://www.ncbi.nlm.nih.gov/pubmed/28217248",
                "http://www.ncbi.nlm.nih.gov/pubmed/25819286",
                "http://www.ncbi.nlm.nih.gov/pubmed/8579098",
                "http://www.ncbi.nlm.nih.gov/pubmed/24082415",
                "http://www.ncbi.nlm.nih.gov/pubmed/17554795",
                "http://www.ncbi.nlm.nih.gov/pubmed/14987380",
                "http://www.ncbi.nlm.nih.gov/pubmed/10694917",
                "http://www.ncbi.nlm.nih.gov/pubmed/2847318"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28217248",
                    "text": "DLT for transthyretin amyloidosis is associated with the risk of developing de novo systemic amyloidosis and amyloid neuropathy, and the risk may be greater with some non-Val30Met mutations.",
                    "offsetInBeginSection": 333,
                    "offsetInEndSection": 523,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25819286",
                    "text": "Hereditary transthyretin amyloidosis (ATTR) is a genetically and clinically heterogeneous disease manifesting with predominant peripheral and autonomic neuropathy; cardiomyopathy, or both.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24082415",
                    "text": "The senile types of cardiac amyloidosis can result from overproduction of atrial natriuretic factor or from accumulation of otherwise normal or wild-type transthyretin.",
                    "offsetInBeginSection": 703,
                    "offsetInEndSection": 871,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139",
                    "text": "Peripheral neuropathy is the most common clinical presentation in TTR amyloidosis although the carpal tunnel syndrome (CTS) may be the first symptom and skin can be involved, as transthyretin amyloidosis is a systemic disease.",
                    "offsetInBeginSection": 109,
                    "offsetInEndSection": 335,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24082415",
                    "text": "Some of the more common diseases associated with amyloidosis include plasma cell dyscrasias, chronic inflammatory disorders, hereditary-familial mutations involving transthyretin, Alzheimer's disease, and so-called \"senile\" or age-related amyloidosis.",
                    "offsetInBeginSection": 306,
                    "offsetInEndSection": 557,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802308",
                    "text": "BACKGROUND Hereditary transthyretin amyloidosis is an autosomal dominant inherited disorder, first described in families with sensorimotor and autonomic neuropathy.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139",
                    "text": "CONCLUSION This TTR mutation (Tyr78Phe) is associated with peripheral neuropathy, carpal tunnel syndrome and skin amyloidosis.",
                    "offsetInBeginSection": 1235,
                    "offsetInEndSection": 1361,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17554795",
                    "text": "It is most frequently seen in patients with hereditary transthyretin (TTR) amyloidosis, but is also present in 20% of patients with systemic immunoglobulin light chain (primary) amyloidosis.",
                    "offsetInBeginSection": 67,
                    "offsetInEndSection": 257,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139",
                    "text": "BACKGROUND More than 80 transthyretin (TTR) mutations have been described, most associated with amyloidosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17554795",
                    "text": "Neuropathy is often a major manifestation of systemic amyloidosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7244aa2dc08e987e00000f",
            "body": "Which two interleukins are inhibited by Ustekinumab?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22123062",
                "http://www.ncbi.nlm.nih.gov/pubmed/19882785",
                "http://www.ncbi.nlm.nih.gov/pubmed/18486739",
                "http://www.ncbi.nlm.nih.gov/pubmed/19217154",
                "http://www.ncbi.nlm.nih.gov/pubmed/19886505",
                "http://www.ncbi.nlm.nih.gov/pubmed/18703004",
                "http://www.ncbi.nlm.nih.gov/pubmed/29042094",
                "http://www.ncbi.nlm.nih.gov/pubmed/21436972",
                "http://www.ncbi.nlm.nih.gov/pubmed/20421912",
                "http://www.ncbi.nlm.nih.gov/pubmed/22758911"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062",
                    "text": "A recent example is ustekinumab, a first-in-class therapeutic human immunoglobulin G1 kappa mAb that binds to the interleukins (IL)-12 and IL-23, cytokines that modulate lymphocyte function, including T-helper (Th) 1 and Th17 cell subsets.",
                    "offsetInBeginSection": 499,
                    "offsetInEndSection": 738,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29042094",
                    "text": "Ustekinumab is a monoclonal antibody directed against the p40 subunit, which is part of interleukins IL-12 and IL-23.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882785",
                    "text": "); (2) Ustekinumab is an inhibitor of interleukins 12 and 23, which are believed to be implicated in the onset of psoriasis.",
                    "offsetInBeginSection": 266,
                    "offsetInEndSection": 390,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21436972",
                    "text": "At present an anti-CD11a antibody (efalizumab), an anti-LFA3/CD2 receptor (alefacept) and 3 antitumor necrosis factor alpha agents (adalimumab, etanercept, infliximab) are now commercially available for the treatment of both psoriasis and psoriatic arthritis.",
                    "offsetInBeginSection": 488,
                    "offsetInEndSection": 747,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21436972",
                    "text": "Ustekinumab (CNTO 1275, Centocor Inc, Malvern, PA, USA) is a human monoclonal antibody that binds to the shared p40 protein subunit of human interleukins 12 and 23 with high affinity and specificity, thereby preventing interaction with their surface IL-12R\u03b21 receptor.",
                    "offsetInBeginSection": 1027,
                    "offsetInEndSection": 1296,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22758911",
                    "text": "Recent Phase 2 and Phase 3 trials have illustrated the benefits of briakinumab (in Phase 3 clinical development) and ustekinumab (approved in the EU, and also in other territories worldwide) in the treatment of moderate to severe plaque psoriasis.",
                    "offsetInBeginSection": 361,
                    "offsetInEndSection": 608,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19217154",
                    "text": "Ustekinumab is a human monoclonal antibody that inhibits receptor-binding of these cytokines.",
                    "offsetInBeginSection": 255,
                    "offsetInEndSection": 348,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20421912",
                    "text": "Ustekinumab is a monoclonal antibody belonging to a newly developed class of biological, anti-cytokine medications that notably targets the p40 subunit of both IL-12 and -23, both naturally occurring proteins that are important in regulating the immune system and are understood to play a role in immune-mediated inflammatory disorders.",
                    "offsetInBeginSection": 757,
                    "offsetInEndSection": 1093,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062",
                    "text": "Ustekinumab binds to the p40 subunit common to IL-12 and IL-23 and prevents their interaction with the IL-12 receptor \u03b21 subunit of the IL-12 and IL-23 receptor complexes.",
                    "offsetInBeginSection": 855,
                    "offsetInEndSection": 1027,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19886505",
                    "text": "ABT-874 (Abbott Laboratories, Saint-Laurent, QC,) and ustekinumab (CNTO 1275, Ortho Biotech, Toronto, ON) are two monoclonal antibodies against interleukins 12 and 23 (IL-12/23), key mediators of T-cell differentiation in the pathogenesis of psoriasis.",
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 513,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8863948cb19eca6b000002",
            "body": "How can network assortativity be applied in the three-dimensional analysis of the genome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27391817",
                "http://www.ncbi.nlm.nih.gov/pubmed/23536826",
                "http://www.ncbi.nlm.nih.gov/pubmed/25121490",
                "http://www.ncbi.nlm.nih.gov/pubmed/26816262",
                "http://www.ncbi.nlm.nih.gov/pubmed/26172652",
                "http://www.ncbi.nlm.nih.gov/pubmed/25981854",
                "http://www.ncbi.nlm.nih.gov/pubmed/27967190",
                "http://www.ncbi.nlm.nih.gov/pubmed/25894574",
                "http://www.ncbi.nlm.nih.gov/pubmed/24505274",
                "http://www.ncbi.nlm.nih.gov/pubmed/15697429"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826",
                    "text": "Our analysis demonstrates that Hi-C data can be effectively applied to study tissue-specific genome conformation, chromosome-chromosome interaction, chromosomal translocations, and spatial gene-gene interaction and regulation in a three-dimensional genome of primary tumor cells.",
                    "offsetInBeginSection": 1091,
                    "offsetInEndSection": 1370,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27391817",
                    "text": "We propose a new approach, using chromatin assortativity, to integrate the epigenomic landscape of a specific cell type with its chromatin interaction network and thus investigate which proteins or chromatin marks mediate genomic contacts.",
                    "offsetInBeginSection": 206,
                    "offsetInEndSection": 445,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25121490",
                    "text": "Here, we use publicly available DNaseI-seq data to measure the assortativity signatures of genome-wide TFNs in 41 distinct human cell and tissue types.",
                    "offsetInBeginSection": 1641,
                    "offsetInEndSection": 1792,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26816262",
                    "text": "In this study we develop a metric, the vector assortativity index (VA-index for short), based on network randomization and (empirical) statistical hypothesis testing that is able to quantify the assortativity patterns of a network with respect to a vector attribute.",
                    "offsetInBeginSection": 793,
                    "offsetInEndSection": 1059,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826",
                    "text": "Particularly, for the first time, we constructed genome-scale spatial gene-gene interaction network, transcription factor binding site (TFBS) - TFBS interaction network, and TFBS-gene interaction network from chromosomal contact information.",
                    "offsetInBeginSection": 1371,
                    "offsetInEndSection": 1612,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826",
                    "text": "We developed and applied a set of bioinformatics methods to reliably generate spatial chromosomal contacts from high-throughput sequencing data and to effectively use them to study the properties of the genome structures in one-dimension (1D) and two-dimension (2D).",
                    "offsetInBeginSection": 824,
                    "offsetInEndSection": 1090,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826",
                    "text": "In this work, we conducted a comprehensive, large-scale computational analysis of this new stream of genome conformation data generated for three different human leukemia cells or cell lines by the Hi-C technique.",
                    "offsetInBeginSection": 610,
                    "offsetInEndSection": 823,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26816262",
                    "text": "In particular, the assortativity coefficient is used to capture the level of correlation between a single-dimensional attribute (categorical or scalar) of the network nodes and the observed connections, i.e., the edges.",
                    "offsetInBeginSection": 245,
                    "offsetInEndSection": 464,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27391817",
                    "text": "Our approach facilitates the study of multiple genome-wide epigenomic profiles, considering network topology and allowing the comparison of chromatin interaction networks.",
                    "offsetInBeginSection": 1668,
                    "offsetInEndSection": 1839,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26172652",
                    "text": "Using the network Kuramoto model as an example, we find that frequency assortativity can induce chaos in the macroscopic dynamics.",
                    "offsetInBeginSection": 178,
                    "offsetInEndSection": 308,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6fabfeb750ff4455000062",
            "body": "Are there mammalian promoters with distal enhancer functions?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28581502"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502",
                    "text": "Several studies have suggested that some promoters might have enhancer functions.",
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 219,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502",
                    "text": "Gene expression in mammals is precisely regulated by the combination of promoters and gene-distal regulatory regions, known as enhancers.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502",
                    "text": "Extensive CRISPR-Cas9 genomic manipulation demonstrated the involvement of these promoters in the cis regulation of expression of distal genes in their natural loci.",
                    "offsetInBeginSection": 613,
                    "offsetInEndSection": 778,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502",
                    "text": "Here, by exploiting a high-throughput enhancer reporter assay, we unravel a set of mammalian promoters displaying enhancer activity.",
                    "offsetInBeginSection": 367,
                    "offsetInEndSection": 499,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502",
                    "text": "These promoters have distinct genomic and epigenomic features and frequently interact with other gene promoters.",
                    "offsetInBeginSection": 500,
                    "offsetInEndSection": 612,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502",
                    "text": "However, the extent of this type of promoters and whether they actually function to regulate the expression of distal genes have remained elusive.",
                    "offsetInBeginSection": 220,
                    "offsetInEndSection": 366,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502",
                    "text": "Our results have important implications for the understanding of complex gene regulation in normal development and disease.",
                    "offsetInBeginSection": 779,
                    "offsetInEndSection": 902,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a774431faa1ab7d2e000004",
            "body": "Why is the Fyn kinase considered a promising therapeutic target for Alzheimer's Disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                "http://www.ncbi.nlm.nih.gov/pubmed/28709498",
                "http://www.ncbi.nlm.nih.gov/pubmed/24495408"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28709498",
                    "text": "I discuss preclinical studies targeting Fyn as a therapeutic intervention in AD and our recent experience with the safety, tolerability, and cerebrospinal fluid penetration of the Src family kinase inhibitor saracatinib in patients with AD.",
                    "offsetInBeginSection": 884,
                    "offsetInEndSection": 1124,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                    "text": "Targeting Fyn kinase may be a promising therapeutic approach in AD, and a larger Phase IIa clinical trial of AZD0530 for the treatment of patients with AD has recently launched.",
                    "offsetInBeginSection": 2493,
                    "offsetInEndSection": 2670,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                    "text": "Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.",
                    "offsetInBeginSection": 598,
                    "offsetInEndSection": 800,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                    "text": "Fyn kinase has been implicated in AD pathophysiology both in in vitro models and in human subjects, and is a promising new therapeutic target for AD.",
                    "offsetInBeginSection": 448,
                    "offsetInEndSection": 597,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24495408",
                    "text": "We are currently enrolling patients in a phase Ib study of saracatinib (AZD0530), a small molecule inhibitor with high potency for Src and Fyn, for the treatment of AD.",
                    "offsetInBeginSection": 686,
                    "offsetInEndSection": 854,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28709498",
                    "text": "A phase 2a proof-of-concept clinical trial in patients with AD is currently under way, providing critical first data on the potential effectiveness of targeting Fyn in AD.",
                    "offsetInBeginSection": 1533,
                    "offsetInEndSection": 1704,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24495408",
                    "text": "Several lines of evidence implicate Fyn in the pathogenesis of AD, and its interaction with both A\u03b2 and Tau renders Fyn a unique therapeutic target that addresses both of the major pathologic hallmarks of AD.",
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 685,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28709498",
                    "text": "Fyn is an attractive target for AD therapeutics, not only based on its activation by A\u03b2 via cellular prion protein but also due to its known interaction with tau, uniquely linking the two key pathologies in AD.",
                    "offsetInBeginSection": 1125,
                    "offsetInEndSection": 1336,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28709498",
                    "text": "Fyn is also a challenging target, with broad expression throughout the body and significant homology with other members of the Src family kinases, which may lead to unintended off-target effects.",
                    "offsetInBeginSection": 1337,
                    "offsetInEndSection": 1532,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001",
                    "text": "We recently described a signaling cascade whereby oligomeric amyloid beta binds to cellular prion protein on the neuronal cell surface, activating intracellular Fyn kinase to mediate synaptotoxicity.",
                    "offsetInBeginSection": 248,
                    "offsetInEndSection": 447,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f7138b750ff445500004f",
            "body": "How does parathyroid hormone affect circulating levels of periostin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23918682",
                "http://www.ncbi.nlm.nih.gov/pubmed/26721738",
                "http://www.ncbi.nlm.nih.gov/pubmed/22927401",
                "http://www.ncbi.nlm.nih.gov/pubmed/20654714"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682",
                    "text": "Serum samples for periostin, 25-hydroxyvitamin D, parathyroid hormone (PTH), C-terminal telopeptide of type I collagen (CTx), and total alkaline phosphatase (tALP) were obtained from 46 postmenopausal women with low bone mass at baseline and 3 months after zoledronic acid infusion and from 30 age-matched, postmenopausal controls with normal bone mass at baseline.",
                    "offsetInBeginSection": 498,
                    "offsetInEndSection": 863,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22927401",
                    "text": "Periostin (Postn) is a matricellular protein preferentially expressed by osteocytes and periosteal osteoblasts in response to mechanical stimulation and parathyroid hormone (PTH).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26721738",
                    "text": "The development of periostin null mice has allowed to elucidate the crucial role of periostin on dentinogenesis and osteogenesis, as well as on the skeletal response to mechanical loading and parathyroid hormone.",
                    "offsetInBeginSection": 418,
                    "offsetInEndSection": 630,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22927401",
                    "text": "Osteoblastic gene expression levels confirmed a defect of Postn(-/-) osteoblast differentiation with and without PTH, as well as an increased osteoblast apoptosis in the absence of periostin.",
                    "offsetInBeginSection": 1373,
                    "offsetInEndSection": 1564,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22927401",
                    "text": "Recombinant periostin also suppressed Sost expression, which was mediated through the integrin \u03b1V\u03b23 receptor, whereas periostin-blocking antibody prevented inhibition of MEF2C and Sost by PTH.",
                    "offsetInBeginSection": 890,
                    "offsetInEndSection": 1084,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682",
                    "text": "Women with higher tALP have independently higher periostin levels.",
                    "offsetInBeginSection": 1654,
                    "offsetInEndSection": 1720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20654714",
                    "text": "Knock-down of periostin mRNA, down-regulated PTHrP, but did not affect the expression of other important markers of differentiation such as RUNX2.",
                    "offsetInBeginSection": 761,
                    "offsetInEndSection": 907,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22927401",
                    "text": "PTH stimulated periostin and inhibited MEF2C and sclerostin (Sost) expression in bone and osteoblasts in vitro.",
                    "offsetInBeginSection": 778,
                    "offsetInEndSection": 889,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20654714",
                    "text": "The hFOB 1.19 and three hOS (MHM, KPDXM and Eggen) showed highly variable periostin mRNA levels and protein.",
                    "offsetInBeginSection": 375,
                    "offsetInEndSection": 483,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682",
                    "text": "Reduced periostin expression may affect osteoblast differentiation and collagen type I synthesis and predispose to osteoporosis and increased fracture risk.",
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 284,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7247182dc08e987e000010",
            "body": "Describe mechanism of action of Ozanimod.",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28783871",
                "http://www.ncbi.nlm.nih.gov/pubmed/29125718",
                "http://www.ncbi.nlm.nih.gov/pubmed/27144850",
                "http://www.ncbi.nlm.nih.gov/pubmed/28398597",
                "http://www.ncbi.nlm.nih.gov/pubmed/26239599",
                "http://www.ncbi.nlm.nih.gov/pubmed/26879276",
                "http://www.ncbi.nlm.nih.gov/pubmed/26702336",
                "http://www.ncbi.nlm.nih.gov/pubmed/28812220"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26702336",
                    "text": "Ocrelizumab is a CD20-positive B-cell-targeting monoclonal antibody with a promising new mechanism of action.",
                    "offsetInBeginSection": 508,
                    "offsetInEndSection": 617,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26239599",
                    "text": "Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple sclerosis (MS).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28812220",
                    "text": "Sphingosine 1-phosphate receptor (S1PR) modulators possess a unique mechanism of action in the treatment of multiple sclerosis (MS).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28398597",
                    "text": "Ozanimod safety, PK, and PD properties support the once-daily regimens under clinical investigation.",
                    "offsetInBeginSection": 1601,
                    "offsetInEndSection": 1701,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28398597",
                    "text": "This first-in-human study characterized the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ozanimod in 88 healthy volunteers using a range of single and multiple doses (7 and 28 days) and a dose-escalation regimen.",
                    "offsetInBeginSection": 401,
                    "offsetInEndSection": 628,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26879276",
                    "text": "We assessed the safety and efficacy of the oral selective S1P receptor modulator ozanimod in patients with relapsing multiple sclerosis.",
                    "offsetInBeginSection": 189,
                    "offsetInEndSection": 325,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718",
                    "text": "The effects of high-fat and low-fat meals on the pharmacokinetics (PK) of a single oral dose of ozanimod were evaluated in 24 healthy volunteers in a randomized, open-label crossover trial.",
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 388,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718",
                    "text": "Given this lack of a food effect on the exposure of ozanimod and its active metabolites, ozanimod can be taken without regard to meals.",
                    "offsetInBeginSection": 1166,
                    "offsetInEndSection": 1301,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27144850",
                    "text": "METHODS We conducted a double-blind, placebo-controlled phase 2 trial of ozanimod in 197 adults with moderate-to-severe ulcerative colitis.",
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 399,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26702336",
                    "text": "The majority of investigational trials involve selective sphingosine-1-phosphate receptor 1 immunomodulators, such as laquinimod, ozanimod, ponesimod, and siponimod, in an effort to build on the success of fingolimod.",
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 507,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a895f51fcd1d6a10c000004",
            "body": "What is the preferred orientation of CTCF binding sites for chromatin looping?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26527277",
                "http://www.ncbi.nlm.nih.gov/pubmed/28536180",
                "http://www.ncbi.nlm.nih.gov/pubmed/25135475",
                "http://www.ncbi.nlm.nih.gov/pubmed/26276636",
                "http://www.ncbi.nlm.nih.gov/pubmed/27569350",
                "http://www.ncbi.nlm.nih.gov/pubmed/28137913",
                "http://www.ncbi.nlm.nih.gov/pubmed/24990380",
                "http://www.ncbi.nlm.nih.gov/pubmed/29076501",
                "http://www.ncbi.nlm.nih.gov/pubmed/21282187",
                "http://www.ncbi.nlm.nih.gov/pubmed/23650640"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29076501",
                    "text": "CTCF, a conserved 3D genome architecture protein, determines proper genome-wide chromatin looping interactions through directional binding to specific sequence elements of four modules within numerous CTCF-binding sites (CBSs) by its 11 zinc fingers (ZFs).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282187",
                    "text": "We further show that in BWS and SRS cells, there is opposing chromatin looping conformation mediated by CTCF--cohesin binding sites surrounding the locus.",
                    "offsetInBeginSection": 1118,
                    "offsetInEndSection": 1272,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25135475",
                    "text": "Chromatin looping was recently identified as a conserved feature of silent HOX clusters, with CCCTC-binding factor (CTCF) binding sites located at the loop bases.",
                    "offsetInBeginSection": 225,
                    "offsetInEndSection": 387,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990380",
                    "text": "We demonstrate that MeCP2 is required for ATRX recruitment and that deficiency of either ATRX or MeCP2 causes decreased frequency of long-range chromatin interactions associated with altered nucleosome density at CTCF-binding sites and reduced CTCF occupancy.",
                    "offsetInBeginSection": 525,
                    "offsetInEndSection": 784,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26276636",
                    "text": "Recent studies identified a correlation between the orientation of CTCF-binding sites (CBSs) and chromatin loops.",
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 257,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569350",
                    "text": "A self-organizing map approach subdivided the vitamin D-sensitive CTCF sites into seven classes that can be distinguished by participation in DNA loop formation, binding to open chromatin, carrying binding motifs for CTCF or its relative BORIS, overlap with transcription start site (TSS) regions and binding of VDR.",
                    "offsetInBeginSection": 934,
                    "offsetInEndSection": 1250,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27569350",
                    "text": "Some 55% of these CTCF sites contribute to DNA looping and mark the anchors of 587 putative topologically associating domains (TADs) containing at least one VDR binding site and one 1,25(OH)2D3 target gene.",
                    "offsetInBeginSection": 633,
                    "offsetInEndSection": 839,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990380",
                    "text": "These findings indicate that MeCP2 and ATRX regulate gene expression at a subset of imprinted domains by maintaining a nucleosome configuration conducive to CTCF binding and to the maintenance of higher order chromatin structure.",
                    "offsetInBeginSection": 785,
                    "offsetInEndSection": 1014,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282187",
                    "text": "DNA methylation of the ICR controls the reciprocal imprinting of IGF2 and H19 by preventing the binding of the insulator protein, CTCF.",
                    "offsetInBeginSection": 238,
                    "offsetInEndSection": 373,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277",
                    "text": "As recently reported, our data also suggest that chromatin loops preferentially form between CTCF binding sites oriented in a convergent manner.",
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 393,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a761ac7aacfb9cd4c000003",
            "body": "What is the ReliableGenome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27605105"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105",
                    "text": "By applying RG to 219 deep human WGS datasets, we demonstrate that VC concordance depends predominantly on genomic context rather than the actual sequencing data which manifests in high recurrence of regions that can/cannot be reliably genotyped by a single method.",
                    "offsetInBeginSection": 805,
                    "offsetInEndSection": 1070,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105",
                    "text": "MOTIVATION The increasing adoption of clinical whole-genome resequencing (WGS) demands for highly accurate and reproducible variant calling (VC) methods.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105",
                    "text": "RESULTS Here, we describe our method ReliableGenome (RG) for partitioning genomes into high and low concordance regions with respect to a set of surveyed VC pipelines.",
                    "offsetInBeginSection": 470,
                    "offsetInEndSection": 637,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105",
                    "text": "RG allows focusing resource-intensive algorithms (e.g.",
                    "offsetInBeginSection": 1399,
                    "offsetInEndSection": 1453,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105",
                    "text": "RG outperforms comparable efforts in predicting VC concordance and false positive calls in low-concordance regions which underlines its usefulness for variant filtering, annotation and prioritization.",
                    "offsetInBeginSection": 1198,
                    "offsetInEndSection": 1398,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105",
                    "text": "The observed discordance between state-of-the-art VC pipelines, however, indicates that the current practice still suffers from non-negligible numbers of false positive and negative SNV and INDEL calls that were shown to be enriched among discordant calls but also in genomic regions with low sequence complexity.",
                    "offsetInBeginSection": 154,
                    "offsetInEndSection": 467,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105",
                    "text": "AVAILABILITY AND IMPLEMENTATION RG was implemented in Java, source code and binaries are freely available for non-commercial use at https://github.com/popitsch/wtchg-rg/ CONTACT: niko@wtchg.ox.ac.ukSupplementary information: Supplementary data are available at Bioinformatics online.",
                    "offsetInBeginSection": 1821,
                    "offsetInEndSection": 2104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105",
                    "text": "This enables the application of pre-computed regions to other data created with comparable sequencing technology and software.",
                    "offsetInBeginSection": 1071,
                    "offsetInEndSection": 1197,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105",
                    "text": "Our method combines call sets derived by multiple pipelines from arbitrary numbers of datasets and interpolates expected concordance for genomic regions without data.",
                    "offsetInBeginSection": 638,
                    "offsetInEndSection": 804,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27605105",
                    "text": "Our method and analysis of discordant calls may further be useful for development, benchmarking and optimization of VC algorithms and for the relative comparison of call sets between different studies/pipelines.",
                    "offsetInBeginSection": 1607,
                    "offsetInEndSection": 1818,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a774585faa1ab7d2e000005",
            "body": "What is masitinib an inhibitor of?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25961655",
                "http://www.ncbi.nlm.nih.gov/pubmed/19789626",
                "http://www.ncbi.nlm.nih.gov/pubmed/18823406",
                "http://www.ncbi.nlm.nih.gov/pubmed/25122671",
                "http://www.ncbi.nlm.nih.gov/pubmed/19614621",
                "http://www.ncbi.nlm.nih.gov/pubmed/19541476",
                "http://www.ncbi.nlm.nih.gov/pubmed/26978025",
                "http://www.ncbi.nlm.nih.gov/pubmed/20033487",
                "http://www.ncbi.nlm.nih.gov/pubmed/27400786",
                "http://www.ncbi.nlm.nih.gov/pubmed/21504563"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20033487",
                    "text": "Masitinib mesilate is a potent and selective tyrosine kinase inhibitor of the c-KIT receptor.",
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25122671",
                    "text": "BACKGROUND Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19614621",
                    "text": "CONCLUSIONS Masitinib, a c-kit and PDGF-receptor tyrosine kinase inhibitor, may represent an innovative avenue of treatment in corticosteroid-dependent asthma.",
                    "offsetInBeginSection": 1472,
                    "offsetInEndSection": 1631,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789626",
                    "text": "CONCLUSIONS Masitinib is a potent and selective tyrosine kinase inhibitor targeting KIT that is active, orally bioavailable in vivo, and has low toxicity.",
                    "offsetInBeginSection": 1675,
                    "offsetInEndSection": 1829,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504563",
                    "text": "Masitinib, a selective oral tyrosine kinase inhibitor, effectively inhibits the survival, migration and activity of mast cells.",
                    "offsetInBeginSection": 231,
                    "offsetInEndSection": 358,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961655",
                    "text": "Masitinib is in Phase III clinical trials for the treatment of malignant melanoma, mastocytosis, multiple myeloma, gastrointestinal cancer and pancreatic cancer.",
                    "offsetInBeginSection": 853,
                    "offsetInEndSection": 1014,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26978025",
                    "text": "This study investigated the therapeutic potential of masitinib, a pharmacologic inhibitor of the SCF receptor cKit, for prevention of diabetes-induced breakdown of blood retinal barrier (BRB).",
                    "offsetInBeginSection": 201,
                    "offsetInEndSection": 393,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823406",
                    "text": "HYPOTHESIS/OBJECTIVE To evaluate the efficacy of masitinib, a potent and selective inhibitor of KIT, in the treatment of canine MCT.",
                    "offsetInBeginSection": 129,
                    "offsetInEndSection": 261,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21504563",
                    "text": "METHODS A randomised, placebo-controlled, phase 2 study was performed in patients with mild-to-moderate Alzheimer's disease, receiving masitinib as an adjunct to cholinesterase inhibitor and/or memantine.",
                    "offsetInBeginSection": 493,
                    "offsetInEndSection": 697,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25122671",
                    "text": "Further development of masitinib in imatinib-resistant/intolerant patients with advanced GIST is warranted.",
                    "offsetInBeginSection": 2437,
                    "offsetInEndSection": 2544,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f7245b750ff4455000050",
            "body": "What is the mode of action of teriparatide?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24870841",
                "http://www.ncbi.nlm.nih.gov/pubmed/20872215",
                "http://www.ncbi.nlm.nih.gov/pubmed/15262455",
                "http://www.ncbi.nlm.nih.gov/pubmed/16234962",
                "http://www.ncbi.nlm.nih.gov/pubmed/17538470",
                "http://www.ncbi.nlm.nih.gov/pubmed/15940379",
                "http://www.ncbi.nlm.nih.gov/pubmed/22451221",
                "http://www.ncbi.nlm.nih.gov/pubmed/19281056",
                "http://www.ncbi.nlm.nih.gov/pubmed/26104116",
                "http://www.ncbi.nlm.nih.gov/pubmed/24086927"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16234962",
                    "text": "INTRODUCTION The effects of combining two approved treatments for osteoporosis with different modes of action were examined by comparing teriparatide [rhPTH(1-34)] monotherapy with combination teriparatide and raloxifene therapy.",
                    "offsetInBeginSection": 542,
                    "offsetInEndSection": 771,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15940379",
                    "text": "CONCLUSIONS These results confirm the opposite mechanisms of action of teriparatide and alendronate on bone remodeling and confirm the bone formation effect of teriparatide.",
                    "offsetInBeginSection": 2373,
                    "offsetInEndSection": 2546,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26104116",
                    "text": "Teriparatide promotes bone formation, while bisphosphonates suppress bone resorption.",
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215",
                    "text": "Most bone-quality data for PTH is from teriparatide.",
                    "offsetInBeginSection": 250,
                    "offsetInEndSection": 302,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15262455",
                    "text": "RESULTS Teriparatide has been studied in postmenopausal women with osteoporosis, drug-induced osteoporosis (specifically, corticosteroid-induced osteoporosis), and men with osteoporosis.",
                    "offsetInBeginSection": 1274,
                    "offsetInEndSection": 1460,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16234962",
                    "text": "Combination treatment with raloxifene may thus enhance the bone forming effects of teriparatide.",
                    "offsetInBeginSection": 2490,
                    "offsetInEndSection": 2586,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215",
                    "text": "Strontium ranelate is thought to have a mixed mode of action, increasing bone formation and decreasing bone resorption.",
                    "offsetInBeginSection": 1075,
                    "offsetInEndSection": 1194,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19281056",
                    "text": "Teriparatide is the only anabolic agent currently approved for treatment of osteoporosis in men.",
                    "offsetInBeginSection": 536,
                    "offsetInEndSection": 632,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870841",
                    "text": "Teriparatide is an only available bone anabolic drug in practice.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 65,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215",
                    "text": "Teriparatide results in a rapid increase in bone-formation markers, followed by increases in bone-resorption markers, opening an \"anabolic window,\" a period of time when PTH is maximally anabolic.",
                    "offsetInBeginSection": 303,
                    "offsetInEndSection": 499,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7340962dc08e987e000017",
            "body": "Is Apremilast effective for Behcet\u2019s syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
                "http://www.ncbi.nlm.nih.gov/pubmed/26676621",
                "http://www.ncbi.nlm.nih.gov/pubmed/24882690",
                "http://www.ncbi.nlm.nih.gov/pubmed/24797159",
                "http://www.ncbi.nlm.nih.gov/pubmed/28823583",
                "http://www.ncbi.nlm.nih.gov/pubmed/27747762",
                "http://www.ncbi.nlm.nih.gov/pubmed/28213862",
                "http://www.ncbi.nlm.nih.gov/pubmed/26555450",
                "http://www.ncbi.nlm.nih.gov/pubmed/27486641",
                "http://www.ncbi.nlm.nih.gov/pubmed/26089047"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24797159",
                    "text": "Apremilast (Otezla(\u00ae)), an oral small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4), is under development with Celgene Corporation for the treatment of psoriatic arthritis, psoriasis, ankylosing spondylitis, Beh\u00e7et's syndrome, atopic dermatitis, and rheumatoid arthritis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 300,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24882690",
                    "text": "Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in psoriasis, psoriatic arthropathies, and Beh\u00e7et's syndrome.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 215,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27747762",
                    "text": "The most recently introduced treatment option is apremilast, an oral phosphodiesterase 4 inhibitor.",
                    "offsetInBeginSection": 477,
                    "offsetInEndSection": 576,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27747762",
                    "text": "RESULTS These trials demonstrate that apremilast is effective for the treatment of active PsA, despite prior conventional DMARDs or biologic treatment.",
                    "offsetInBeginSection": 855,
                    "offsetInEndSection": 1006,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28213862",
                    "text": "Apremilast (Otezla\u00ae) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
                    "text": "CONCLUSIONS Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.",
                    "offsetInBeginSection": 1732,
                    "offsetInEndSection": 1853,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24797159",
                    "text": "Apremilast is indicated for the treatment of active psoriatic arthritis in adults.",
                    "offsetInBeginSection": 301,
                    "offsetInEndSection": 383,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27486641",
                    "text": "Apremilast, an oral immunosuppressant that inhibits phosphodiesterase type 4, has been authorised in the European Union for use in these settings.",
                    "offsetInBeginSection": 317,
                    "offsetInEndSection": 463,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27486641",
                    "text": "This would suggest that apremilast is less effective than a TNF alpha antagonist.",
                    "offsetInBeginSection": 1333,
                    "offsetInEndSection": 1414,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256",
                    "text": "Apremilast is an oral phosphodiesterase-4 inhibitor that modulates several inflammatory pathways.",
                    "offsetInBeginSection": 146,
                    "offsetInEndSection": 243,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a857bfffaa1ab7d2e000030",
            "body": "Can the yeast protein Abf1 act as insulator?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7663308",
                "http://www.ncbi.nlm.nih.gov/pubmed/10601031",
                "http://www.ncbi.nlm.nih.gov/pubmed/7608180",
                "http://www.ncbi.nlm.nih.gov/pubmed/9430660",
                "http://www.ncbi.nlm.nih.gov/pubmed/18996839",
                "http://www.ncbi.nlm.nih.gov/pubmed/8536307",
                "http://www.ncbi.nlm.nih.gov/pubmed/1545789",
                "http://www.ncbi.nlm.nih.gov/pubmed/25748434",
                "http://www.ncbi.nlm.nih.gov/pubmed/15456886",
                "http://www.ncbi.nlm.nih.gov/pubmed/2511628"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15456886",
                    "text": "Autonomously replicating sequence binding factor 1 (ABF1) and repressor/activator protein 1 (RAP1) from budding yeast are multifunctional, site-specific DNA-binding proteins, with roles in gene activation and repression, replication, and telomere structure and function.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 270,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1545789",
                    "text": "Autonomously replicating sequence (ARS) binding factor 1 (ABF1) is an abundant DNA-binding protein that specifically recognizes the motif RTCRYN5ACG at many sites in the yeast genome, including promoter elements, mating-type silencers, and ARSs.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9430660",
                    "text": "In budding yeast Saccharomyces cerevisiae, an ARS binding factor 1 (Abf1) binds to the sequence-specific DNA element involved in DNA replication and transcription.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2511628",
                    "text": "The yeast ARS binding factor 1 (ABF1)--where ARS is an autonomously replicating sequence--and repressor/activator protein 1 (RAP1) have been implicated in DNA replication, transcriptional activation, and transcriptional silencing.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7663308",
                    "text": "Autonomously replicating sequence (ARS)-binding factor 1 (ABF1) is a multifunctional protein involved in transcriptional activation and repression, as well as DNA replication, in yeast.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18996839",
                    "text": "ABF1 functions in transcription, replication, gene silencing, and NER in yeast.",
                    "offsetInBeginSection": 328,
                    "offsetInEndSection": 407,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10601031",
                    "text": "Yeast ABF1 protein is encoded by an essential gene required for DNA replication, transcriptional regulation, and gene silencing.",
                    "offsetInBeginSection": 345,
                    "offsetInEndSection": 473,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7608180",
                    "text": "ABF1 is a multifunctional phosphoprotein that binds specifically to yeast origins of replication and to transcriptional regulatory sites of a variety of genes.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7608180",
                    "text": "Although three CKII enzymes, yeast, sea star, and recombinant human, utilize casein as a substrate with similar efficiencies, only the yeast enzyme efficiently phosphorylates the ABF1 protein.",
                    "offsetInBeginSection": 1051,
                    "offsetInEndSection": 1243,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9430660",
                    "text": "We describe in this study how yeast Cdc6 protein stimulates Abf1 protein DNA binding activities.",
                    "offsetInBeginSection": 164,
                    "offsetInEndSection": 260,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8053effaa1ab7d2e00001e",
            "body": "Describe the Manta algorithm for detection of structural variants",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26647377"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377",
                    "text": "UNLABELLED : We describe Manta, a method to discover structural variants and indels from next generation sequencing data.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377",
                    "text": "Manta is optimized for rapid germline and somatic analysis, calling structural variants, medium-sized indels and large insertions on standard compute hardware in less than a tenth of the time that comparable methods require to identify only subsets of these variant types: for example NA12878 at 50\u00d7 genomic coverage is analyzed in less than 20\u2009min.",
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 474,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377",
                    "text": "Manta can discover and score variants based on supporting paired and split-read evidence, with scoring models optimized for germline analysis of diploid individuals and somatic analysis of tumor-normal sample pairs.",
                    "offsetInBeginSection": 475,
                    "offsetInEndSection": 690,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377",
                    "text": "We provide Manta as a community resource to facilitate practical and routine structural variant analysis in clinical and research sequencing scenarios.",
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1189,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377",
                    "text": "Manta consistently assembles a higher fraction of its calls to base-pair resolution, allowing for improved downstream annotation and analysis of clinical significance.",
                    "offsetInBeginSection": 870,
                    "offsetInEndSection": 1037,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377",
                    "text": "Call quality is similar to or better than comparable methods, as determined by pedigree consistency of germline calls and comparison of somatic calls to COSMIC database variants.",
                    "offsetInBeginSection": 691,
                    "offsetInEndSection": 869,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377",
                    "text": "Source code, documentation and Linux binaries are available from https://github.com/Illumina/manta.",
                    "offsetInBeginSection": 1279,
                    "offsetInEndSection": 1378,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377",
                    "text": "AVAILABILITY AND IMPLEMENTATION Manta is released under the open-source GPLv3 license.",
                    "offsetInBeginSection": 1192,
                    "offsetInEndSection": 1278,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377",
                    "text": "CONTACT csaunders@illumina.com   SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.",
                    "offsetInBeginSection": 1381,
                    "offsetInEndSection": 1498,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7d4e9afaa1ab7d2e000013",
            "body": "How many amino acids does davunetide consist of?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21902667",
                "http://www.ncbi.nlm.nih.gov/pubmed/24210139",
                "http://www.ncbi.nlm.nih.gov/pubmed/24533805",
                "http://www.ncbi.nlm.nih.gov/pubmed/22956189"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667",
                    "text": "NAP (davunetide), an eight amino acid peptide derived from ADNP partly ameliorated deficits associated with ADNP deficiency.",
                    "offsetInBeginSection": 583,
                    "offsetInEndSection": 707,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22956189",
                    "text": "Davunetide is an eight-amino-acid peptide fragment derived by structure-activity studies from activity-dependent neuroprotective protein, activity-dependent neuroprotective protein (ADNP).",
                    "offsetInBeginSection": 77,
                    "offsetInEndSection": 265,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22956189",
                    "text": "ADNP haploinsufficiency in mice results in tauopathy and cognitive deficits ameliorated by davunetide treatment.",
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 417,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667",
                    "text": "Based on these extensive preclinical results, davunetide (NAP) is now being evaluated in a Phase II/III study of the tauopathy, progressive supranuclear palsy (PSP); (Allon Therapeutics Inc.).",
                    "offsetInBeginSection": 1515,
                    "offsetInEndSection": 1707,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667",
                    "text": "In conclusion, NAP (davunetide) provided potent neuroprotection in a broad range of neurodegenerative models, protecting the neuroglial cytoskeleton in vitro and inhibiting tau pathology (tauopathy) in vivo.",
                    "offsetInBeginSection": 1307,
                    "offsetInEndSection": 1514,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667",
                    "text": "NAP (davunetide) interacted with microtubules, protected against microtubule toxicity associated with zinc, nocodazole and oxidative stress in vitro and against tau pathology and MAP6 (stable tubuleonly polypeptide - STOP) pathology in vivo.",
                    "offsetInBeginSection": 708,
                    "offsetInEndSection": 949,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667",
                    "text": "This review focuses on the discovery of activity-dependent neuroprotective protein (ADNP) and the ensuing discovery of NAP (davunetide) toward clinical development with emphasis on microtubule protection.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667",
                    "text": "NAP (davunetide) protection against neurodegeneration has recently been shown to extend to katanin-related microtubule disruption under conditions of tau deficiencies.",
                    "offsetInBeginSection": 1139,
                    "offsetInEndSection": 1306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667",
                    "text": "NAP (davunetide) provided neurotrophic functions promoting neurite outgrowth as measured by increases in MAP2 immunoreactivity and synapse formation by increasing synaptophysin expression.",
                    "offsetInBeginSection": 950,
                    "offsetInEndSection": 1138,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24210139",
                    "text": "This review focuses on the therapeutic effects and mechanisms of action of NAP (davunetide), an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP) which was discovered in our laboratory.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 223,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a6f77d7b750ff4455000051",
            "body": "Is autosomal dominant inheritanced form of Osteogenesis imperfecta caused by mutations in the genes associated with collagen production?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/2886666",
                "http://www.ncbi.nlm.nih.gov/pubmed/17192541",
                "http://www.ncbi.nlm.nih.gov/pubmed/23771926",
                "http://www.ncbi.nlm.nih.gov/pubmed/18566967",
                "http://www.ncbi.nlm.nih.gov/pubmed/19533842",
                "http://www.ncbi.nlm.nih.gov/pubmed/20839288",
                "http://www.ncbi.nlm.nih.gov/pubmed/27312322",
                "http://www.ncbi.nlm.nih.gov/pubmed/25656619",
                "http://www.ncbi.nlm.nih.gov/pubmed/8100856",
                "http://www.ncbi.nlm.nih.gov/pubmed/25007323"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2886666",
                    "text": "Autosomal dominant osteogenesis imperfecta is caused by mutations in the COL1A2 and COL1A1 genes of type I collagen.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541",
                    "text": "Classic osteogenesis imperfecta, an autosomal dominant disorder associated with osteoporosis and bone fragility, is caused by mutations in the genes for type I collagen.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18566967",
                    "text": "Autosomal dominant osteogenesis imperfecta (OI) is caused by mutations in the genes (COL1A1 or COL1A2) encoding the chains of type I collagen.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25656619",
                    "text": "Whereas the vast majority of osteogenesis imperfecta (OI) is caused by autosomal dominant defects in the genes encoding type I procollagen, mutations in a myriad of genes affecting type I procollagen biosynthesis or bone formation and homeostasis have now been associated with rare autosomal recessive OI forms.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 311,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8100856",
                    "text": "Most forms of osteogenesis imperfecta are caused by dominant mutations in either of the two genes, COL1A1 and COL1A2, that encode the pro alpha 1(I) and pro alpha 2(I) chains of type I collagen, respectively.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 208,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20839288",
                    "text": "Autosomal dominant OI is caused by mutations in the genes (COL1A1 or COL1A2) encoding the chains of type I collagen.",
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 303,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771926",
                    "text": "Most cases of OI (classical types) have autosomal dominant inheritance and are caused by mutations in the type I collagen genes.",
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 256,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25007323",
                    "text": "PURPOSE OF REVIEW Osteogenesis imperfecta or 'brittle bone disease' has mainly been considered a bone disorder caused by collagen mutations.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25007323",
                    "text": "Within the last decade, however, a surge of genetic discoveries has created a new paradigm for osteogenesis imperfecta as a collagen-related disorder, where most cases are due to autosomal dominant type I collagen defects, while rare, mostly recessive, forms are due to defects in genes whose protein products interact with collagen protein.",
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 482,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19533842",
                    "text": "In approximately 90% of individuals with osteogenesis imperfecta, mutations in either of the genes encoding the pro-alpha1 or pro-alpha2 chains of type I collagen (COL1A1 or COL1A2) can be identified.",
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 326,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7346662dc08e987e00001a",
            "body": "What causes \"Puffy hand syndrome\"?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19216010",
                "http://www.ncbi.nlm.nih.gov/pubmed/16911735",
                "http://www.ncbi.nlm.nih.gov/pubmed/15529083",
                "http://www.ncbi.nlm.nih.gov/pubmed/17072191",
                "http://www.ncbi.nlm.nih.gov/pubmed/27269656",
                "http://www.ncbi.nlm.nih.gov/pubmed/24198977",
                "http://www.ncbi.nlm.nih.gov/pubmed/23856549"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27269656",
                    "text": "There is a syndrome, rarely observed in rheumatology, resulting in \"puffy hands\": the puffy hand syndrome.",
                    "offsetInBeginSection": 103,
                    "offsetInEndSection": 209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23856549",
                    "text": "Association of puffy hand syndrome with comorbid psychosis and major depression explained immediate recurrence of ulcerations despite fitted medication and long-term psychotherapy.",
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 528,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17072191",
                    "text": "Lymphedema treatment currently consists of low-stretch bandaging and wearing elastic garments, which is effective in decreasing the volume of puffy hand syndrome.",
                    "offsetInBeginSection": 1251,
                    "offsetInEndSection": 1413,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15529083",
                    "text": "Puffy hand syndrome appears to be the end result of lymphatic obstruction.",
                    "offsetInBeginSection": 1030,
                    "offsetInEndSection": 1104,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198977",
                    "text": "Puffy hand syndrome develops after long-term intravenous drug addiction.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19216010",
                    "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19216010",
                    "text": "Low-stretch bandage and elastic garment, usually used in lymphedema treatment, are proposed to treat the puffy hand syndrome.",
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 634,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15529083",
                    "text": "The puffy hand sign is a more uncommon complication of hard-core injection addicts.",
                    "offsetInBeginSection": 162,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198977",
                    "text": "We retained the diagnosis of puffy hand syndrome revealed by a severe staphylococcal infection with toxic involvement mimicking a four limbs cellulitis.",
                    "offsetInBeginSection": 849,
                    "offsetInEndSection": 1001,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23856549",
                    "text": "The authors report an original clinical presentation of factitious disorders of the upper extremity in an ex-drug-addict patient with puffy hand syndrome.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 154,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a86e66dfaa1ab7d2e000035",
            "body": "Does the association of PARP1 and CTCF follow a circadian rhythm?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26321255"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255",
                    "text": "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation.",
                    "offsetInBeginSection": 487,
                    "offsetInEndSection": 760,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255",
                    "text": "Furthermore, depletion of H3K9me2/3, inhibition of PARP activity by olaparib, or downregulation of PARP1 or CTCF expression counteracts both recruitment to the envelope and circadian transcription.",
                    "offsetInBeginSection": 761,
                    "offsetInEndSection": 958,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255",
                    "text": "PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity.",
                    "offsetInBeginSection": 959,
                    "offsetInEndSection": 1127,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255",
                    "text": "The interactome is regulated by PARP1 and its co-factor CTCF.",
                    "offsetInBeginSection": 307,
                    "offsetInEndSection": 368,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255",
                    "text": "They not only mediate chromatin fiber interactions but also promote the recruitment of circadian genes to the lamina.",
                    "offsetInBeginSection": 369,
                    "offsetInEndSection": 486,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255",
                    "text": "However, here we uncovered an inter-chromosomal network connecting active loci enriched in circadian genes to repressed lamina-associated domains (LADs).",
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255",
                    "text": "Transcriptionally active and inactive chromatin domains tend to segregate into separate sub-nuclear compartments to maintain stable expression patterns.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a805974faa1ab7d2e000020",
            "body": "What is the Strelka workflow?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22581179"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179",
                    "text": "AVAILABILITY The Strelka workflow source code is available at ftp://strelka@ftp.illumina.com/.",
                    "offsetInBeginSection": 1179,
                    "offsetInEndSection": 1273,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179",
                    "text": "RESULTS We describe Strelka, a method for somatic SNV and small indel detection from sequencing data of matched tumor-normal samples.",
                    "offsetInBeginSection": 331,
                    "offsetInEndSection": 464,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179",
                    "text": "The method uses a novel Bayesian approach which represents continuous allele frequencies for both tumor and normal samples, while leveraging the expected genotype structure of the normal.",
                    "offsetInBeginSection": 465,
                    "offsetInEndSection": 652,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179",
                    "text": "We demonstrate that the method has superior accuracy and sensitivity on impure samples compared with approaches based on either diploid genotype likelihoods or general allele-frequency tests.",
                    "offsetInBeginSection": 985,
                    "offsetInEndSection": 1176,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179",
                    "text": "MOTIVATION Whole genome and exome sequencing of matched tumor-normal sample pairs is becoming routine in cancer research.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179",
                    "text": "The consequent increased demand for somatic variant analysis of paired samples requires methods specialized to model this problem so as to sensitively call variants at any practical level of tumor impurity.",
                    "offsetInBeginSection": 122,
                    "offsetInEndSection": 328,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179",
                    "text": "CONTACT csaunders@illumina.com",
                    "offsetInBeginSection": 1276,
                    "offsetInEndSection": 1306,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179",
                    "text": "A natural consequence of the model structure is that sensitivity can be maintained at high tumor impurity without requiring purity estimates.",
                    "offsetInBeginSection": 843,
                    "offsetInEndSection": 984,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179",
                    "text": "This is achieved by representing the normal sample as a mixture of germline variation with noise, and representing the tumor sample as a mixture of the normal sample with somatic variation.",
                    "offsetInBeginSection": 653,
                    "offsetInEndSection": 842,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a7d535ffaa1ab7d2e000018",
            "body": "What does the human IVIG treatment for Alzheimer's disease contain?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24760109",
                "http://www.ncbi.nlm.nih.gov/pubmed/28381506",
                "http://www.ncbi.nlm.nih.gov/pubmed/24760112",
                "http://www.ncbi.nlm.nih.gov/pubmed/23861639",
                "http://www.ncbi.nlm.nih.gov/pubmed/18294736",
                "http://www.ncbi.nlm.nih.gov/pubmed/20329802",
                "http://www.ncbi.nlm.nih.gov/pubmed/25115546",
                "http://www.ncbi.nlm.nih.gov/pubmed/18956886",
                "http://www.ncbi.nlm.nih.gov/pubmed/21138577",
                "http://www.ncbi.nlm.nih.gov/pubmed/23735288"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506",
                    "text": "OBJECTIVE We tested biweekly infusions of IV immunoglobulin (IVIg) as a possible treatment for mild to moderate Alzheimer disease (AD) dementia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18294736",
                    "text": "Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer's disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Abeta).",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23735288",
                    "text": "Pilot studies with the IVIG preparations Octagam and Gammagard in individuals with mild-to-moderate Alzheimer's disease (AD) suggested stabilization of cognitive functioning in these patients, and a phase II trial with Gammagard reported similar findings.",
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 386,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21138577",
                    "text": "IVIG contains naturally occurring auto-antibodies, including antibodies (Abs) against \u03b2-amyloid (A\u03b2) peptides accumulating in the brains of Alzheimer's disease (AD) patients.",
                    "offsetInBeginSection": 211,
                    "offsetInEndSection": 387,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25115546",
                    "text": "Human intravenous immunoglobulin (IVIG) is a mixture of polyclonal IgG antibodies isolated and pooled from thousands of healthy human donors.",
                    "offsetInBeginSection": 188,
                    "offsetInEndSection": 329,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112",
                    "text": "The human polyclonal IgG antibody preparation known as Intravenous Immunoglobulin (IVIG) has been under study as a potential treatment for Alzheimer's disease (AD) since 2002.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760109",
                    "text": "Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 271,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18294736",
                    "text": "Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease.",
                    "offsetInBeginSection": 1260,
                    "offsetInEndSection": 1372,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20329802",
                    "text": "Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the hypothesis that IVIG contains naturally occurring autoantibodies (nAbs-Abeta) that specifically recognize and block the toxic effects of Abeta.",
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 760,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23861639",
                    "text": "A small pilot study of passive immunotherapy using IVIg has suggested cognitive improvement.",
                    "offsetInBeginSection": 577,
                    "offsetInEndSection": 669,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70ce4ab750ff4455000064",
            "body": "List the 6 genes associated with the autosomal recessive form of Osteogenesis imperfecta",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12110407",
                "http://www.ncbi.nlm.nih.gov/pubmed/17192541",
                "http://www.ncbi.nlm.nih.gov/pubmed/25565926",
                "http://www.ncbi.nlm.nih.gov/pubmed/25656619",
                "http://www.ncbi.nlm.nih.gov/pubmed/8100856",
                "http://www.ncbi.nlm.nih.gov/pubmed/23613367",
                "http://www.ncbi.nlm.nih.gov/pubmed/23054245",
                "http://www.ncbi.nlm.nih.gov/pubmed/12110406",
                "http://www.ncbi.nlm.nih.gov/pubmed/23301918",
                "http://www.ncbi.nlm.nih.gov/pubmed/21670757"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25565926",
                    "text": "Autosomal recessive osteogenesis imperfecta (OI) accounts for 10% of all OI cases, and, currently, mutations in 10 genes (CRTAP, LEPRE1, PPIB, SERPINH1, FKBP10, SERPINF1, SP7, BMP1, TMEM38B, and WNT1) are known to be responsible for this form of the disease.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 258,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23301918",
                    "text": "Cultured skin fibroblasts demonstrated compound heterozygosity for mutations in the LEPRE1 gene encoding prolyl 3-hydroxylase 1 confirming the diagnosis of autosomal recessive osteogenesis imperfecta type VIII, perinatal lethal type.",
                    "offsetInBeginSection": 487,
                    "offsetInEndSection": 720,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12110407",
                    "text": "By linkage analysis, we mapped this unique autosomal recessive variant of osteogenesis imperfecta to chromosome 3p22-24.1.",
                    "offsetInBeginSection": 276,
                    "offsetInEndSection": 398,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541",
                    "text": "Classic osteogenesis imperfecta, an autosomal dominant disorder associated with osteoporosis and bone fragility, is caused by mutations in the genes for type I collagen.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21670757",
                    "text": "Other causes of recessive osteogenesis imperfecta include deficiency of the collagen chaperones FKBP10 or Serpin H1.",
                    "offsetInBeginSection": 926,
                    "offsetInEndSection": 1042,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21670757",
                    "text": "Murine models are crucial to uncovering the common pathways in dominant and recessive osteogenesis imperfecta bone dysplasia.",
                    "offsetInBeginSection": 1043,
                    "offsetInEndSection": 1168,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12110407",
                    "text": "We have identified a novel form of autosomal recessive osteogenesis imperfecta (OI) in a small First Nations community from northern Quebec.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21670757",
                    "text": "The more prevalent autosomal dominant forms of osteogenesis imperfecta are caused by primary defects in type I collagen, whereas autosomal recessive forms are caused by deficiency of proteins which interact with type I procollagen for post-translational modification and/or folding.",
                    "offsetInBeginSection": 87,
                    "offsetInEndSection": 369,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25656619",
                    "text": "Whereas the vast majority of osteogenesis imperfecta (OI) is caused by autosomal dominant defects in the genes encoding type I procollagen, mutations in a myriad of genes affecting type I procollagen biosynthesis or bone formation and homeostasis have now been associated with rare autosomal recessive OI forms.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 311,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613367",
                    "text": "Autosomal recessive osteogenesis imperfecta (AR-OI) is an inherited condition which in recent years has been shown with increasing genetic and clinical heterogeneity.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a737e233b9d13c70800000d",
            "body": "Does Enzastaurin improve survival of glioblastoma patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20124186",
                "http://www.ncbi.nlm.nih.gov/pubmed/23911595",
                "http://www.ncbi.nlm.nih.gov/pubmed/28259301",
                "http://www.ncbi.nlm.nih.gov/pubmed/26643807",
                "http://www.ncbi.nlm.nih.gov/pubmed/20150385",
                "http://www.ncbi.nlm.nih.gov/pubmed/25398844",
                "http://www.ncbi.nlm.nih.gov/pubmed/19098118",
                "http://www.ncbi.nlm.nih.gov/pubmed/21896554",
                "http://www.ncbi.nlm.nih.gov/pubmed/22917813"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301",
                    "text": "CONCLUSIONS antiangiogenic drugs did not improve overall survival in glioblastoma patients, either as first or second-line treatment, and either as single agent or in combination with chemotherapy.",
                    "offsetInBeginSection": 1438,
                    "offsetInEndSection": 1635,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22917813",
                    "text": "CONCLUSIONS Enzastaurin was well tolerated but did not improve TTP of BMs, ORR, OS, PFS, or HRQoL after WBRT in LC patients with BMs.",
                    "offsetInBeginSection": 1499,
                    "offsetInEndSection": 1632,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20150385",
                    "text": "Enzastaurin has anti-glioma activity in patients with recurrent high-grade glioma, but does not appear to have enough single-agent activity to be useful as monotherapy.",
                    "offsetInBeginSection": 1516,
                    "offsetInEndSection": 1684,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25398844",
                    "text": "Despite promising phase II clinical trial results and patient benefit in terms of clinical improvement and longer progression-free survival, an overall survival benefit has not been demonstrated in four randomized phase III trials of bevacizumab or cilengitide in newly diagnosed glioblastoma or cediranib or enzastaurin in recurrent glioblastoma.",
                    "offsetInBeginSection": 580,
                    "offsetInEndSection": 927,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19098118",
                    "text": "Enzastaurin is currently in Phase III clinical trials.",
                    "offsetInBeginSection": 1527,
                    "offsetInEndSection": 1581,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21896554",
                    "text": "This open-label, single-arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT) to treat glioblastoma multiforme (GBM) and gliosarcoma.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22917813",
                    "text": "This study was designed to determine if maintenance enzastaurin improved the outcome of whole brain radiotherapy (WBRT) in lung cancer (LC) patients with brain metastases (BMs).",
                    "offsetInBeginSection": 83,
                    "offsetInEndSection": 260,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26643807",
                    "text": "Enzastaurin (LY317615) in combination with bevacizumab for recurrent malignant gliomas is well-tolerated, with response and progression-free survival similar to bevacizumab monotherapy.",
                    "offsetInBeginSection": 1766,
                    "offsetInEndSection": 1951,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301",
                    "text": "Bevacizumab did not improve overall survival.",
                    "offsetInBeginSection": 1017,
                    "offsetInEndSection": 1062,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186",
                    "text": "CONCLUSION Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine in patients with recurrent glioblastoma.",
                    "offsetInBeginSection": 1641,
                    "offsetInEndSection": 1828,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a8965f6fcd1d6a10c000005",
            "body": "Are splicing speckles associated with transcription?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16467386",
                "http://www.ncbi.nlm.nih.gov/pubmed/10444064",
                "http://www.ncbi.nlm.nih.gov/pubmed/26496460",
                "http://www.ncbi.nlm.nih.gov/pubmed/10366587",
                "http://www.ncbi.nlm.nih.gov/pubmed/21984414",
                "http://www.ncbi.nlm.nih.gov/pubmed/15093744",
                "http://www.ncbi.nlm.nih.gov/pubmed/26441864",
                "http://www.ncbi.nlm.nih.gov/pubmed/9135155",
                "http://www.ncbi.nlm.nih.gov/pubmed/22871813",
                "http://www.ncbi.nlm.nih.gov/pubmed/12473687"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12473687",
                    "text": "Removal of the reversible inhibitor DRB resulted in the reactivation of transcription and a rapid, synchronous redistribution of lamins and splicing factors to normal-sized speckles, indicating a close association between lamin speckles and SFCs.",
                    "offsetInBeginSection": 538,
                    "offsetInEndSection": 784,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26441864",
                    "text": "When the nuclear export signal of RSV Gag is mutated (Gag.L219A), the protein accumulates in discrete subnuclear foci reminiscent of nuclear bodies such as splicing speckles, paraspeckles, and PML bodies.",
                    "offsetInBeginSection": 793,
                    "offsetInEndSection": 997,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12473687",
                    "text": "Our results suggest a unique role for lamin speckles in the spatial organization of RNA splicing factors and pol II transcription in the nucleus.",
                    "offsetInBeginSection": 1010,
                    "offsetInEndSection": 1155,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386",
                    "text": "\"Splicing speckles\" are major nuclear domains rich in components of the splicing machinery and polyA(+) RNA.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12473687",
                    "text": "Treatment of HeLa cells with alpha-amanitin or 5,6-dichlorobenzimidazole riboside (DRB) inhibited RNA polymerase II (pol II) transcription and led to the enlargement of lamin speckles as well as SFCs.",
                    "offsetInBeginSection": 337,
                    "offsetInEndSection": 537,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22871813",
                    "text": "Immunofluorescence microscopy with anti-P-SF3b155 antibodies, coupled with transcription inhibition and a block in splicing after SF3b155 phosphorylation, indicates that post-transcriptional splicing occurs in nuclear speckles and that release of post-transcriptionally spliced mRNA from speckles is coupled to the nuclear mRNA export pathway.",
                    "offsetInBeginSection": 766,
                    "offsetInEndSection": 1109,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21984414",
                    "text": "RBM11 is localized in the nucleoplasm and enriched in SRSF2-containing splicing speckles.",
                    "offsetInBeginSection": 831,
                    "offsetInEndSection": 920,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9135155",
                    "text": "Staining of nuclear factors involved in pre-mRNA splicing or, more recently, transcription, reveals 20-40 speckles per nucleus, resulting in the intriguing suggestion that speckles are nuclear sites of transcription and processing.",
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 467,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15093744",
                    "text": "It has been found in different nuclear distributions: in discrete sites throughout the nucleoplasm, consistent with a role in transcription, and/or concentrated in \"splicing speckles\", a nuclear compartment mostly devoid of transcriptional activity.",
                    "offsetInBeginSection": 361,
                    "offsetInEndSection": 610,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386",
                    "text": "RNA polymerase II transcribes mRNAs and is required for splicing, with some reports suggesting that the inactive complexes are stored in splicing speckles.",
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 476,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a80a63ffaa1ab7d2e000023",
            "body": "What is the HPG pore?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26921234",
                "http://www.ncbi.nlm.nih.gov/pubmed/26148840"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234",
                    "text": "HPG Pore is available in GitHub at http://github.com/opencb/hpg-pore.",
                    "offsetInBeginSection": 1162,
                    "offsetInEndSection": 1231,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840",
                    "text": "Increasing the HPG content increased the pore size of the hydrogel scaffold, as well as the porosity, elongation at break, degree of degradation and swelling ratio.",
                    "offsetInBeginSection": 569,
                    "offsetInEndSection": 733,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234",
                    "text": "RESULTS Here we present HPG Pore, a toolkit for exploring and analysing nanopore sequencing data.",
                    "offsetInBeginSection": 674,
                    "offsetInEndSection": 771,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234",
                    "text": "HPG Pore can run on both individual computers and in the Hadoop distributed computing framework, which allows easy scale-up to manage the large amounts of data expected to result from extensive use of nanopore technologies in the future.",
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 1009,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840",
                    "text": "The pore size of hydrogel scaffolds could be easily tailored by controlling the content of HPG in the polymer blend.",
                    "offsetInBeginSection": 921,
                    "offsetInEndSection": 1037,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234",
                    "text": "CONCLUSIONS HPG Pore allows for virtually unlimited sequencing data scalability, thus guaranteeing its continued management in near future scenarios.",
                    "offsetInBeginSection": 1012,
                    "offsetInEndSection": 1161,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840",
                    "text": "These results indicate that cross-linked HPG/PEO hydrogel can function as a potential material for tissue engineering scaffolds.",
                    "offsetInBeginSection": 1190,
                    "offsetInEndSection": 1318,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840",
                    "text": "Evaluation of the cytotoxicity demonstrated that HPG/PEO hydrogel scaffold has potential for use as a matrix for cellular attachment and proliferation.",
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1189,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840",
                    "text": "A microporous hydrogel scaffold was developed from hyperbranched poly(glycidol) (HPG) and poly(ethylene oxide) (PEO) using electron beam (e-beam) induced cross-linking for tissue engineering applications.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 204,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840",
                    "text": "In this study, HPG was synthesized from glycidol using trimethylol propane as a core initiator and cross-linked hydrogels were made using 0, 10, 20, and 30% HPG with respect to PEO.",
                    "offsetInBeginSection": 205,
                    "offsetInEndSection": 386,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a70ce82b750ff4455000065",
            "body": "What is the mode of action of the drug Prolia?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25052047",
                "http://www.ncbi.nlm.nih.gov/pubmed/19836866",
                "http://www.ncbi.nlm.nih.gov/pubmed/25509894",
                "http://www.ncbi.nlm.nih.gov/pubmed/22023901"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25509894",
                    "text": "AIM To evaluate the efficacy and safety of Denosumab (Prolia), a first-line osteoporosis (OP) medication that is a fully human monoclonal antibody to the receptor activator of nuclear factor xB ligand (RANKL), within an open-label observational study.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 251,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19836866",
                    "text": "Recently anti-RANKL agents (receptor activator of nuclear factor-kappaB ligand) such as denosumab (Prolia, Amgen Inc., California, USA) that have a similar mode of action to bisphosphonates have been introduced to treat such diseases.",
                    "offsetInBeginSection": 231,
                    "offsetInEndSection": 465,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023901",
                    "text": "Denosumab (Prolia) is a fully human monoclonal antibody directed against receptor activator of nuclear factor-\u03baB ligand (RANKL), which interferes with the formation, activation, and survival of osteoclasts.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 207,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047",
                    "text": "Requiring claims for a bone or cartilage disorder or osteoporotic fracture after excluding claims for cancer prior to a denosumab-specific administration code gave the highest PPV (95.8%), followed by requiring a Prolia National Drug Code on the same claim as a denosumab-specific or nonspecific administration code (88.2%).",
                    "offsetInBeginSection": 717,
                    "offsetInEndSection": 1041,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25509894",
                    "text": "CONCLUSION The preliminary results of the open-label study of Prolia in postmenopausal OP suggest that the significantly lower BR activity determines the efficacy of this drug and its high safety.",
                    "offsetInBeginSection": 993,
                    "offsetInEndSection": 1189,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047",
                    "text": "CONCLUSIONS Prolia users are most accurately identified with administration code claims in conjunction with claims for Prolia National Drug Code and bone disorder treatment and diagnosis codes.",
                    "offsetInBeginSection": 1181,
                    "offsetInEndSection": 1374,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023901",
                    "text": "It is the first biologic antiresorptive therapy for osteoporosis, and the first osteoporosis therapy to show efficacy and safety in patients with renal impairment.",
                    "offsetInBeginSection": 502,
                    "offsetInEndSection": 665,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047",
                    "text": "PURPOSE The goal of this study is to develop and validate an algorithm to identify Prolia(\u00ae) users within a health insurance claims database.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22023901",
                    "text": "It was approved by the Food and Drug Administration in June 2010 as a new treatment for postmenopausal osteoporosis in women who are at high risk for fracture.",
                    "offsetInBeginSection": 208,
                    "offsetInEndSection": 367,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047",
                    "text": "METHODS Patients with a denosumab-specific or nonspecific administration claim during the early period of Prolia availability in the USA (June 1, 2010 to March 31, 2012) were classified as definite, probable, possible, and nonusers of Prolia using an algorithm consisting of nine different components based on claims patterns consistent with Prolia use.",
                    "offsetInBeginSection": 145,
                    "offsetInEndSection": 498,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a75df9483b0d9ea66000001",
            "body": "What is the mechanism of action of Tisagenlecleucel?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28887358",
                "http://www.ncbi.nlm.nih.gov/pubmed/28751490"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28751490",
                    "text": "An expert panel recommended approval of Novartis's experimental chimeric antigen T-cell therapy, tisagenlecleucel, for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28887358",
                    "text": "The first chimeric antigen receptor T-cell therapy, tisagenlecleucel, received FDA approval for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia who haven't responded to standard therapy or who have relapsed at least twice.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 273,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28751490",
                    "text": "The therapy would be the first of its kind approved for cancer and has the potential to transform standard of care for advanced blood cancers.",
                    "offsetInBeginSection": 210,
                    "offsetInEndSection": 352,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "id": "5a74e6eb0384be9551000009",
            "body": "What is Morgellons disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16489838",
                "http://www.ncbi.nlm.nih.gov/pubmed/21390982",
                "http://www.ncbi.nlm.nih.gov/pubmed/23326202",
                "http://www.ncbi.nlm.nih.gov/pubmed/19681520",
                "http://www.ncbi.nlm.nih.gov/pubmed/20489569",
                "http://www.ncbi.nlm.nih.gov/pubmed/21437061",
                "http://www.ncbi.nlm.nih.gov/pubmed/21110523",
                "http://www.ncbi.nlm.nih.gov/pubmed/19830222",
                "http://www.ncbi.nlm.nih.gov/pubmed/25192328",
                "http://www.ncbi.nlm.nih.gov/pubmed/21749875"
            ],
            "snippets": [
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326202",
                    "text": "Morgellons disease is an emerging skin disease characterized by formation of dermal filaments associated with multisystemic symptoms and tick-borne illness.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390982",
                    "text": "Morgellons Disease is a condition involving painful skin lesions, fibrous growths protruding from the skin, and subcutaneous stinging and burning sensations, along with symptoms of anxiety, depression, fatigue, and memory and attention deficits.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19830222",
                    "text": "CONCLUSIONS These data suggest Morgellons disease can be characterized as a physical human illness with an often-related delusional component in adults.",
                    "offsetInBeginSection": 1629,
                    "offsetInEndSection": 1781,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20489569",
                    "text": "Morgellons disease is a new emerging disease that is still controversial and believed to be, by some practitioners, as nothing more than delusional parasitosis.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390982",
                    "text": "Data from this case example suggest that hypnotherapy is a promising intervention for the physical and psychological symptoms associated with Morgellons Disease.",
                    "offsetInBeginSection": 548,
                    "offsetInEndSection": 709,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25192328",
                    "text": "Morgellons disease is well-known in the dermatology and psychiatry literature, where it is typically considered a subtype of delusional parasitosis, but it has not yet been described in the ophthalmology literature.",
                    "offsetInBeginSection": 134,
                    "offsetInEndSection": 349,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20489569",
                    "text": "A first case is reported of an oral lesion and symptoms consistent with Morgellons disease.",
                    "offsetInBeginSection": 305,
                    "offsetInEndSection": 396,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489838",
                    "text": "Morgellons disease is a mysterious skin disorder that was first described more than 300 years ago.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21110523",
                    "text": "Morgellons disease is a controversial and poorly defined symptom cluster of skin lesions and somatic symptoms, most notably 'fibers' in the skin.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                },
                {
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19681520",
                    "text": "Whether Morgellons disease is a delusional disorder or even a disease has been a mystery for more than 300 years.",
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "beginSection": "abstract",
                    "endSection": "abstract"
                }
            ]
        }
    ]
}